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ABSTRACT 
Christopher M. Grulke 
Development and Extension of Cheminformatics Techniques for 
Integration of Diverse Data to Enhance Drug Discovery 
 
The scientific community has fallen headlong into the age of data.  With the available crop of 
information available to scientists growing at an exponential pace, tools to harvest this data and 
process it into knowledge are needed.  This blanket statement is nowhere more true than in drug 
discovery today. 
The increasing quantities of bioactivity and protein crystallographic data provide key 
information capable of improving the state of virtual screening.  The CoLiBRI methodology 
attempts to learn from the large knowledge base of protein-ligand interactions to discover a 
comprehensive model capable of filtering large libraries very quickly using only a protein 
structure.  This modeling procedure has been greatly expanded to encompass a wide range of 
descriptor techniques and to use advanced statistical methods of multidimensional mapping.   
The growth of virtual screening methods (including CoLiBRI) has provided a plethora of 
options to cheminformaticians with little guidance on their strengths and weaknesses.  This 
oversight in methodology benchmarking should be addressed to reduce the time and effort 
wasted applying subpar screening protocols.  To attend to this issue, we developed a benchmark 
dataset that will enable a flood of methodology experimentation and validation. 
  
The recent generation of gene expression data and cancer cell growth inhibition data enable 
identification of signatures of cellular resistance.  These signatures can be used as validated 
prognostic markers to guide patient management thereby fueling the personalization of cancer 
treatment.  From the available data, we have derived hypothetical biomarkers of multidrug 
resistance and a flood of links between gene expression and chemical specific resistance that 
require experimental validation. 
The increasing capabilities of cheminformatics techniques require dissemination to the public 
to produce the greatest impact. We have therefore developed a web portal providing 
cheminformatics software and models to fuel public drug discovery efforts.  
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Chapter 1: Background and Significance 
1.1. Data and Drug Discovery 
Publicly available data in all forms of science is increasing at an exponential pace.
1
  This 
increase in data is nowhere more evident than in the field of drug discovery.  High-throughput 
technologies (e.g., parallel synthesis and high throughput screening) have become commonplace 
and bold publicly funded projects (e.g., the Molecular Libraries Initiative (MLI)
2
 and the Human 
Genome Project(HGP)) harness these technologies to create large amounts of publicly accessible 
data.  As a result, these large publicly available databases are ready to accelerate chemical 
biology and drug discovery. 
As an example, the availability of data linked to chemical compounds in the public domain 
has exploded.  Several databases have sprung up offering structural, biochemical, and phenotypic 
data in a chemocentric way.  The PubChem database
3
 (http://pubchem.ncbi.nlm.nih.gov/), 
developed as the central repository for chemical structure-activity data, is just a single instance 
of such databases.  In the short time since its introduction in 2005, PubChem has grown to 
contain nearly 31 million chemical compound records; over 1.5 million of these chemicals have 
been ―tested‖ in an assay with more than 300 thousand appearing active at least once.   Many 
similarly structured databases have emerged recently as well (e.g., ChemSpider,
4
 ChEMBL,
5
 
PDSP Ki,
6
 and others (cf. this recent review
7
)).  
2 
 
Additional resources are available with protein centric data (PDB, SCOP, UniProt), gene 
centric data (NCBI Genome, UniGene), and pathway/protein interaction centric data (KEGG, 
BioCyc, GeneNet). With the vast increase in the data related to the function of our bodies, one 
would expect that the rate of drug discovery would also have increased. 
Unfortunately, while available data to fuel drug discovery has drastically expanded, the 
number of new drugs introduced into the market has, in fact, remained stagnant.
8, 9
  With the 
increased output of ―me-too‖ drugs10, one could argue that the rate of drug discovery has 
decreased even as our knowledge has increased.  Also, the attrition of drug candidates entering 
clinical trials remains high.
11, 12
  The cost of drug discovery and development is continuing to 
grow,
13
 and the time to develop a drug remains roughly the same as it was 30 years ago.
12
   
The slow rate of drug discovery in the midst of an explosion of biomedical data is a 
conundrum that can be addressed by developing methods and studies that utilize the expanse of 
data to inform decisions related to the discovery of drugs.  In the last few years, the use of in 
silico methods to leverage data for drug discovery has become much more common.
14
 However, 
because the amount and breadth of the available data is constantly increasing, there is an 
abundance of unaddressed areas that require attention. 
To leverage the enormous amount and types of available data to address effectively the 
variety of questions in the field of drug discovery, specialized techniques are needed.  For many 
years, our group has been engaged in the development and application of innovative 
methodologies and approaches in the field of QSAR modeling.  This focus on conversion of 
statistical techniques to enable cheminformatics research, has given us a unique ability to select, 
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modify, and apply methods for analysis of data involving chemical structure.  The studies 
contained in this dissertation address only a few situations where developments have been made. 
1.2. Virtual Screening 
The contributions of virtual screening to drug discovery are many:
15
 cheminformatics 
techniques have aided in the discovery of such drugs as Dorxolamide for glaucoma
16
, Zanamavir 
for influenza
17
, and Raltegravir for HIV infection.
18
 The advancement of virtual screening could 
provide a steady stream of new hits to the drug discovery process, but such advancement requires 
both novel techniques and detailed comparisons of available tools. 
‗Virtual screening‘ has typically implied the use of protein structure to identify subsets of 
molecules in large chemical databases or virtual chemical libraries that are likely to bind to the 
target protein with appreciable affinity and specificity.  Structure-based virtual screening has 
become a fundamental part of modern computer-aided drug design
19, 20
.  It requires the posing 
and scoring of libraries of small molecules to find compounds that fit into the binding site and 
bind tightly to the receptor. Since the seminal publication by the Kuntz group in 1982
21
, this 
approach has been used successfully in numerous studies (such as that of HIV protease 
inhibitors) resulting in the design of approved drugs
22
. Numerous algorithms and programs have 
been introduced.  (For reviews, see Wong and McCammon
23
, Taylor et al.
24
, and Muegge
25
.) 
Examples of widely used docking programs include Autodock
26
, FlexE
27
, and Gold
28
. 
While the implication has been that virtual screening and structure-based virtual screening 
are synonymous, there has been an increase in the use of ligand-based techniques to identify hits 
from large chemical databases
29-32
.  Numerous algorithms have been introduced (cf. the recent 
reviews
33-35
).  Most recently, reviews
36, 37
 in the area of virtual screening have begun noting 
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studies comparing structure-based techniques to ligand-based techniques.  Use of 
cheminformatics techniques to cull large chemical databases to a size more conducive to 
application of slower docking methods is discussed frequently.  Novel scoring functions 
generated using methods typically applied in QSAR modeling
38
 or directly integrating ligand 
similarity
39
 have been reported.  This view of virtual screening as a field in which both ligand 
and structure-based techniques are applied to yield optimal results is good for drug discovery as 
a whole. 
Two chapters of this dissertation are focused on advancing the field of virtual screening.  
Chapter 2 details the efforts of the author to advance a novel method of structure-based virtual 
screening that uses techniques commonly applied in ligand-based virtual screening.  Chapter 3 
documents the creation of benchmark dataset intended to thoroughly assess various virtual 
screening methods and preliminary studies to verify its usefulness. 
1.3. Chemotherapeutic Resistance 
The resistance of cancer cells to chemotherapeutic treatment has been of interest for more 
than half a century.
40
  With chemotherapy being the preferred method of tumor treatment, the 
understanding of drug resistance is vital to provide quality care to cancer patients.  With the 
dawn of the genomic age, the investigation of chemotherapy resistance turned to analysis of 
genomic data to determine underlying factors and markers indicative of a tumor‘s resistance to 
chemical treatment. Even with the many new discoveries, our ability to accurately predict the 
response of a patient to a chemotherapeutic is limited.
41
 
The goal of personalizing treatments for patients to yield better clinical outcomes has been 
marked by both successes and disappointments.
42, 43
  It is hypothesized that a portion of the 
5 
 
difficulty in predicting patient outcomes is due to the large variety of mechanisms for drug 
resistance, while the remainder can be attributed to the lack of a single measurement type 
capable of capturing all types of resistance.  The use of gene expression signature to predict 
outcome only captures a portion of the potential causes of therapy failure.  
While the study described in Chapter 4 focused purely on the use of gene expression profiles 
to develop a series of markers of chemotherapeutic resistance, we recognize that to fully address 
the problems in personalization of medicine we need to include other data types such as SNP 
variations.  However, we believe that gene-expression profiles provide a great deal of insight in 
cellular resistance to drug agents and that treatment of this data (and others) to identify generic or 
multidrug biomarkers followed by analysis of single compound outcome biomarkers is most 
rational.  
1.4. Dissemination of Tools and Results 
A large portion of the results obtained by analysis of data is published, but not easily 
searchable, accessible, or usable.  The recently increased public availability of experimental data 
highlights the lack of a public repository to store tools to examine such data and the hypotheses 
generated by such examinations.  This deficiency is most evident in the field of cheminformatics. 
The field of bioinformatics may be considered the most closely related discipline to 
cheminformatics.  However, when we compare the two fields, the lack of publicly available 
cheminformatics tools is underscored.  In bioinformatics, tools are widely available to 
accomplish gene and protein sequence alignments
44, 45
 and classifications.
46-48
  Web interfaces 
are provided for several protein pocket identification schemes.
49-52
  The analysis of gene 
expression can be complete using software available through the web.
53
  This availability of tools 
6 
 
in the field of bioinformatics aids in the advancement of their field.  Access to some of this 
bioinformatics software was vital to complete portions of the studies discussed in this 
dissertation.  
Because the availability of tools enables research, the development of a web portal for 
cheminformatics investigation of data and dispersement of cheminformatics techniques was 
undertaken.  Chapter 5 provides information regarding the completion and impact of this portal, 
which we call Chembench. 
  
 
Chapter 2: Complementary Ligand Binding Receptor 
Interactions (CoLiBRI) 
2.1. Introduction 
Computer Aided Drug Design (CADD) can be defined as any method that uses 
computational power to analyze input information in order to enhance the drug discovery 
process.  Traditionally, these methods have been subcategorized into two classes based on the 
input that they require.  Structure based methods rely on the three-dimensional structure of the 
macromolecular target for which drugs are being designed while ligand-based methods analyze 
the chemical structures of compounds with known activity.  As such, each class of 
methodologies has its own domain of applicability and its own limitations. 
Structure based methods are often used to screen chemical databases for potential compound 
leads based on steric and electronic complementarity to a macromolecular target‘s binding 
pocket.  Several successes have been reported using a variety of popular software; however, 
accurate scoring and ranking of chemicals using structure-based methods is still difficult
54
 and 
being thoroughly researched
38, 55, 56
.  Additionally, since the docking technique relies on accurate 
3-D macromolecular structure, it is difficult to apply to several potential targets for which 
structures are rarely available (notably G-Protein Coupled Receptors (GPCRs) and ion channels).  
Finally, because of the complexity of conformational sampling and posing of chemicals, even the 
fastest methods take several seconds to screen a single compound.  
8 
 
Ligand-based methods, likely due to a longer history, cover a broader range of techniques; 
however, the most common approach is to represent compounds which have known target 
activity using chemical descriptors and subsequently apply statistical tools to discover 
correlations between the calculated descriptors and the target activity.  This activity need not be 
related to interaction with a single known macromolecular target.  This type of approach has 
been used successfully to screen chemical libraries to find new chemical leads
29, 57, 58
.  While 
screening with these methods is typically very fast, a drawback to this traditional Quantitative 
Structure-Activity Relationship (QSAR) approach is that it may be less likely to find active 
chemicals of different structural class from the set used to discern the SAR (though this is a point 
of contention among computational scientists).  Additionally, it requires a certain amount of 
bioactivity information that is often lacking in the early discovery process.  
In a recent publication from our lab, a traditional ligand-based method (SA-kNN) trained 
using publicly available 3-D macromolecular data was shown to be fast and effective for 
screening a large number of protein targets
59
.  This novel computational drug discovery strategy 
outlined in Figure 1 combines the strengths of both structure-based and ligand-based approaches 
while attempting to surpass their individual shortcomings.  The training of CoLiBRI models 
starts from a dataset of protein-ligand complexes.  From this dataset, the binding pocket of each 
protein is identified.  While the task of pocket selection has been well studied
60
, it is one that still 
lacks a complete solution.  Both ligands and the identified pockets are then transformed into 
multidimensional descriptors.  While description of ligands is often done in QSAR studies, there 
is little precedent for description of the chemical fragments that comprise a binding pocket.  
Based on best practices in analogous ensemble QSAR modeling workflows, modeling sets are 
separated into training and test sets.  Based on the hypothesis that the relative location of a novel 
9 
 
binding site with respect to other binding sites in multidimensional chemistry space could be 
used to predict the location of the ligand(s) complementary to this site in the ligand chemistry 
space, models that map the two multidimensional spaces are developed using the training sets.  
These models are used to rank the test set ligands within a large chemical library of putative 
inactives.  Models that appear to be predictive are then applied to the binding pocket of a protein 
of interest to generate a virtual ligand point that is used as a query in chemical similarity searches 
to identify putative ligands of the protein in available chemical databases. 
In the published approach testing of the CoLiBRI workflow was completed using 800 diverse 
protein-ligand complexes comprising the PDBBind dataset
61
.  The authors extracted the binding 
pocket from the protein using protein-ligand tessellation and then represented both the receptor 
 
 
Figure 1. The CoLiBRI workflow for model generation and virtual screening of an external compound database 
for a protein of interest. 
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active site and its corresponding ligand in the same universal, multidimensional chemical 
descriptor space (note that in principle, the descriptors used for receptors and ligands do not have 
to be the same, and we explored this aspect in the current project).  The authors reasoned that 
mapping of both binding pockets and corresponding ligands onto the same multidimensional 
chemistry space would preserve the complementary relationships between binding sites and their 
respective ligands. Thus, it is expected that ligands binding to similar active sites are also similar. 
Using a k nearest neighbor (kNN) pattern recognition approach and variable selection, it has 
been shown that knowledge of the binding pocket structure affords identification of its 
complimentary ligand among the top 1% of a large chemical database in over 90% of all test 
binding sites when a binding pocket of the same protein family was present in the training set.  
However, in a more realistic case where test receptors are highly dissimilar and not present 
among the receptor families in the training set, the prediction accuracy is decreased; still, 
CoLiBRI was able to quickly eliminate 75% of the chemical database as improbable ligands.  
The authors also showed that the method was highly computationally efficient allowing a user to 
process ca. 30K compounds per minute on a single Pentium 4 CPU 
59
.   
Unfortunately, the seminar work on CoLiBRI was relatively limited. Herein, we document 
our attempts to improve upon this method by examining and enhancing its key components: 
active site determination, active site and ligand descriptor generation, and model generation. 
2.2. Materials and Methods 
2.2.1. Dataset Preparation 
Coordinates for the protein-ligand complexes were obtained from multiple versions of the 
PDBBind Database
61
.  The PDBBind database provides an organized repository of protein ligand 
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complexes extracted from the PDB and annotated with binding constants extracted from 
literature.  From this compendium of protein-ligand complexes with affinities, a ―refined‖ set of 
complexes meeting the following criteria is pulled.  Complexes must have a resolution of greater 
than 2.5 angstrom; not contain covalent bonds between the protein and ligand; contain a ligand 
consisting only of C, N, O, S, P, H, and halogens with a molecular weight less than 1000; and 
have no unnatural amino acids in the binding pocket.  The ―refined‖ set is clustered using 
BLAST and a threshold of 90% similarity.  For each cluster containing 4 or more complexes, 3 
representatives are chosen—the one with the highest binding affinity, the one with the lowest 
binding affinity, and a one with the medium binding affinity—to form the ―core‖ set. 
In all cases, Sybyl
62
 was used to preprocess the proteins including the removal of 
crystallographic water, elimination of salts and metals, and addition of hydrogen atoms.  Ligands 
were ―washed‖ using the Wash Molecules application in MOE63. This application normalizes 
chemical structures by carrying out a number of operations including 2D depiction layout, 
hydrogen correction, salt and solvent removal, chirality and bond type normalization, adjustment 
and enumeration of protonation states, and expansion of fragment abbreviations. 
2.2.2. Active Site Determination 
The identification of the binding pocket is a crucial part of the CoLiBRI workflow.  In this 
study three methods of active site determination were investigated: protein-ligand tessellation, 
CastP, and SCREEN.   
2.2.2.1. Protein-Ligand Tessellation 
To appropriately calculate binding pocket descriptors, we are first required to identify 
individual atoms or amino acid fragments that are the pocket.  The first method we applied to 
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 Figure 2. Illustration of Voronoi/Delaunay 
tessellation in 2D space (Voronoi polyhedra are 
represented by dashed line, and Delaunay simplices by 
solid line). For the collection of points with 3D 
coordinates, such as atoms of the protein-ligand 
complex, Delaunay simplices are tetrahedra whose 
vertices correspond to the atoms. 
complete this task utilized a computational 
geometry technique known as Delaunay 
tessellation to isolate the protein atoms that 
made contacts with bound ligands. Applied 
to a collection of randomly distributed 
points, Delaunay tessellation partitions the 
space occupied by these points into an 
aggregate of space filling, irregular triangles 
(in 2D) or tetrahedra (in 3D) with the 
original points as vertices. Thus, this 
approach effectively identifies all nearest 
neighbor triplets (or quadruplets) of vertices.  An example of Delaunay tessellation in two 
dimensions is illustrated in Figure 2.  
Protein-ligand complexes are represented by the coordinates of their heavy atoms (i.e., in a 
hydrogen-depleted form). Delaunay tessellation of this representation uniquely defines all sets of 
nearest neighbor atom quadruplets, including three types of interfacial quadruplets: three 
receptor atoms and one ligand atom; two receptor and two ligand atoms; and one receptor and 
three ligand atoms. Thus, Delaunay tessellation affords an easy way of detecting all receptor 
atoms that directly contact the ligand.  These are then specified as the binding site. 
2.2.2.2. CastP 
The CastP method
64
 of identifying pockets also relies on the use of tessellation; however, this 
tessellation does not involve the bound ligand.  Instead, the protein is tessellated with all small 
molecules removed and cavities are detected using alpha shape theory.  Figure 3 and Figure 4 
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 Figure 3. Illustration of concepts in alpha theory (from Liang et al.
63
). A: A 
two-dimensional molecule consisting of disks of uniform radii. The dashed lines 
show the Voronoi diagram of the molecule. Arrows indicate 2 of the 10 Voronoi 
edges that are completely outside the molecule. B: The convex hull of the atom 
centers in Figure IA (all shaded area) with Delaunay triangulation (triangles 
defined by dark lines). C: The alpha shape of the molecule in A. The alpha shape. 
or dual complex, consists of the light-shaded triangles. the dark line segments, 
and the atom centers. There are 10 shaded line segments corresponding to the 10 
Voronoi edges that are completely outside the molecule. Any triangle with one or 
more shaded edges is an “empty triangle.” A void formed by three empty triangles 
can be seen at the bottom center. It encloses a molecular cavity. 
 
 Figure 4. Illustration of discrete flow for two-dimensional pockets (from Liang 
et al
 63
). A: Discrete flow of a pocket. Obtuse empty triangles ( I , 3. 4. and 5) flow 
to the acute triangle (2). Collectively, they form a pocket of the dual complex, 
which can he mapped to the molecular pocket. B: A depression for which obtuse 
triangles sequentially flow to the outside (to infinity). Depressions of this type are 
not identified as pockets. 
taken from Liang et al 
illustrate how the alpha 
shape theory can be 
applied in 2D space to 
identify protein 
pockets.  First the 
protein is tessellated 
(triangulated) and the 
Voronoi diagram is 
determined.  All 
Voronoi edges fully 
external to the protein are omitted.  Delaunay tetrahedra (triangles) that have edges crossing 
these fully external Voronoi edges are considered ―empty‖.  Empty tetrahedra (triangles) are 
merged together as long as they share a triangle (edge) into potential pockets.  Provided one of 
the tetrahedra 
(triangles) contained in 
a potential pocket is 
acute, the pocket is 
designated a protein 
pocket.  Pockets were 
identified in this 
manner for all proteins 
in our datasets using the CastP webserver
50, 65
 at http://sts.bioengr.uic.edu/castp/. The binding 
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pocket was identified by visual inspection of the identified pockets overlaid with the bound 
ligand. 
2.2.2.3.  SCREEN 
The Surface Cavity REcognition and EvaluatioN (SCREEN) method
49
 of pocket detection 
identifies the gap between a protein‘s molecular surface and a surface generated by rolling a 
intermediately sized sphere over the molecular surface.  Cavities were identified in this manner 
for all proteins in our datasets using the SCREEN2 webserver at 
http://luna.bioc.columbia.edu/honiglab/screen2/cgi-bin/screen2.cgi. The binding pocket was 
identified by visual inspection of the identified cavities overlaid with the bound ligand. 
2.2.3. Active Site Descriptor Calculation 
Descriptor generation for the set of chemical fragments is a significant difficulty in the 
CoLiBRI process.  Most molecular descriptors cannot be generated for chemical fragments.  As 
such, two newly developed methods of protein pocket description (feature point pairs and RDF) 
were added to the previously published TAE/RECON technique.   
2.2.3.1. TAE/RECON 
The generation of TAE/RECON descriptors relies on the concepts of Transferable Atom 
Equivalents (TAE) developed by Breneman and co-workers
66-68
.  The major advantage of these 
descriptors over other descriptor types is that they are derived from the electronic and shape 
properties of isolated atoms or chemical groups.  The additivity principle is used to calculate 
molecular descriptors by summing up the individual descriptor type values for all atoms in the 
molecule, using the RECON method.  In the case of ligands, this leads to the generation of 
molecular descriptors, similar to other approaches.  The same additivity principle can also be 
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used to derive pseudo-molecular descriptors for any group of atoms, e.g., binding site fragments, 
making the TAE descriptors exceptionally well suited for our approach. 
2.2.3.2. Feature Point Pairs 
While the application of atom pairs as a description of binding pockets is straightforward, the 
use of feature points overlaid on chemical structure rather than specific atom points provides an 
abstraction that could prove more biologically relevant.  Through collaboration with 
computational scientists in GlaxoSmithKline (GSK), a set of feature point representations of 
amino acids were implemented and used to transform binding pockets to a feature space.  This 
feature space first described by Yang
69
 provides a simple representation of amino acids based on 
their physicochemical properties.  Counts of feature pairs occurring within respective distance 
bins were used as a set of quantitative descriptors of the 3D characteristics of the binding pocket.  
The table of amino acid atom to feature transformations is contained in Appendix I. 
2.2.3.3. Radial Distribution Function 
Radial Distribution Function (RDF) descriptors were developed in 1999 by Hemmer, et al.
70
 
to better describe the three dimensional characteristics of small molecules.  Because other 
implementations of RDF descriptor generation could not be used to describe the disconnected 
chemical fragments that comprise our binding pockets, we implemented our own version of these 
descriptors.   
To start, a peptide containing each of the 20 standard amino acids bordered on its N- and C- 
termini by glycine was treated as a small molecule within the PETRA software from Molecular 
Networks
71
 to generate a table of atomic properties (including partial charge, electronegativity, 
and polarizability) for each atom type contained within proteins. The methods of property 
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calculation within the PETRA program have been shown to be quite accurate
72-76
. This table of 
properties along with the coordinates of the chemical fragments comprising the pocket was then 
processed using Equation 1.   In Equation 1, prop(atomi) is a predefined property of atom i;  
Distij is distance in 3D coordinate space between the atoms measured in Angstroms; and D and 
damp are bin and damping parameters.  RDF descriptors were calculated for binding pockets 
using values of D ranging from 0 to 20 with a step size of 0.2.  
     (1) 
2.2.4. Ligand Descriptor Calculation 
Ligand descriptors were generated using a variety of commercially available techniques.  
Specifically, TAE/RECON, Dragon, MOE2D, MolconnZ, and autocorrelation descriptors were 
all generated in the course of our study of the CoLiBRI methodology. 
2.2.5. Model Generation 
2.2.5.1. Simulated Annealing k-Nearest Neighbors  
While kNN is an excellent pattern recognition technique, it requires that the similarities to 
which it is applied be related to the property being modeled.  Because some descriptors 
generated for a ligand/binding pocket may be irrelevant to the binding interaction, these 
descriptors generate a level of inaccuracy within the resulting compound rankings. Variable 
selection—in particular simulated annealing (SA)—is a technique that has been successfully 
applied with the kNN principle to generate more robust and predictive models for traditional 
QSAR datasets
58, 77, 78
.  
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The first version of the CoLiBRI methodology is a SA-kNN model generation tool which 
optimizes the 
predicted mean 
rank (PMR) of 
the true ligand 
of a binding 
pocket using 
Leave-One-
Out(LOO) 
cross validation 
(outlined in Figure 5) where PMR is calculated by averaging the ranks at which a pocket‘s true 
bind ligand is retrieved across all pockets.   This generates a model that in theory should be more 
accurate in virtual screening than the kNN principle applied to distances calculated in the whole 
descriptor space. Additional details of this method are described in the original CoLiBRI 
publication
59
. 
2.2.5.2. CCA and kCCA 
The SA-kNN method attempts to select a descriptor subspace where similar proteins bind 
similar chemicals; however, when dealing with two multi-dimensional spaces the optimization 
becomes more complex.   Fortunately, Canonical Correlation Analysis (CCA) originally 
developed by Hotelling
79
 is specifically formulated to correlate multidimensional spaces.  
Therefore, its application in this situation is ideal.   
Considering two multidimensional spaces X and Y, if we limit ourselves to bilinear mapping 
of the multidimensional spaces, the optimization problem can be written as Equation 2 where wx 
 
 
Figure 5. SA-kNN model generation workflow. 
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and wy are the corresponding mapping matrices.  The problem defined in Equation 2 is that of 
the well-known canonical correlation analysis that can be rearranged into a generalized eigen 
problem and subsequently solved.  This provides a mapping of the two multidimensional spaces 
such that corresponding proteins and chemicals should be located near each other in their 
projected spaces. 
  (2) 
Additionally, CCA can be extended using kernel methods.  Although there are a multitude of 
potential kernels which could be applied, in this study we applied a newly developed spectral 
kernel
80
.  Because the datasets are diverse and the similarity principle is only applicable in a 
local sense, the spectral kernel defined in Equation 3 and 4 provides a logical extension to the 
CCA method for this application.   
                         (3) 
                                                                       (4) 
  where:  xi = descriptor vector for observation i 
N(xi) = the k nearest neighbors of observation i 
    n = number of observations 
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Once CCA is completed, the similarity in the projected spaces allows prediction of the point 
in chemical space using a more advanced method than weighted averaging of the ligand 
descriptors for the neighboring proteins.  Ridge regression
81
 is used to build two models.  Both 
models are generated using the binding site descriptors of the active site being predicted as the 
independent variables; however, one uses ligand descriptors of the k nearest neighbors as 
independent variables and the other uses the binding site descriptors of the k nearest neighbors as 
independent variables. The weights generated by this modeling are averaged and then applied to 
the ligand descriptors of the k nearest neighbors to predict the ligand point in the projected 
chemical space.  This ligand point is then used to rank the chemical library. 
2.3. Results and Discussion 
2.3.1. External Validation of the CoLiBRI Workflow 
The previously published work by our lab indicated that the CoLiBRI methodology may 
have potential as a fast and accurate structure–based virtual screening methodology; however, 
the experiment in 
the published work 
focus on extraction 
from a large 
chemical database 
of a single co-
crystallized 
binding partner.  
While similar, this 
 
Figure 6. Recall of HIV protease ligands dissolved in World Drug Index using 
consensus prediction by CoLiBRI models. 
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is not the same experiment as attempting to find all known chemicals that bind to a protein.  
Additionally, the accuracies reported were for the test set, not a fully external validation set.   
Since, we have expanded the training set using more recent versions of the PDBBind dataset.  
We have also applied the models generated from these sets to fully external test cases in order to 
more accurately determine the validity of this modeling technique.  Figure 6 contains the results 
of a sample virtual screen for HIV protease inhibitors dissolved in the World Drug Index (WDI) 
using SA-kNN CoLiBRI models.  Models trained using three versions of the PDBBind database 
with all HIV protease complexes removed recalled more than half the active ligands in 1% of the 
database.  These results are comparable to those found in literature for virtual screening by 
conventional 3-D docking methods
82
.  However, while docking typically takes over second for 
each screened ligand, the entire library of over 50,000 compounds were screened in less than 100 
seconds The success of this pilot study indicates that the CoLiBRI method can filter large 
chemical databases to recall cognate ligands much more quickly than traditional methods.   
2.3.2. Preliminary CCA Testing 
The limitations of using only a single method of multidimensional optimization to build 
CoLiBRI models led to the desire to integrate additional methods.  In particular, research into 
CCA and kCCA being conducted in the Department of Statistics at UNC provided access to a 
deterministic method of multidimensional optimization that is significantly faster than the 
stochastic SA-kNN method applied previously.  To ascertain the capabilities of this technique, 
CCA was applied to the 800 protein-ligand complexes contained in PDBBind.  Figure 7 
demonstrates that when the multidimensional binding pocket and ligand points are projected onto 
their respective CCA vectors generated from combined analysis of the respective TAE 
21 
 
multidimensional spaces, they correlate very well.  Figure 8 is a scatter plot of projection on 
these same variates of the 800 binding sites (in red) and ligands (in blue) represented using their 
 internal ids.  The subfigure contains a magnified view of a portion of the project space.  Visual 
inspection indicates that although the overlay is not perfect, it can be noted that ligands from a 
complex are near to their corresponding binding site and the neighborhood distributions are quite 
similar.  For example, when inspecting the region surrounding pocket 666, it is clear that ligand 
666 is located near it in space.  Additionally, the pocket neighbors of pocket 666 (pockets 96, 
135, 657, 658, 659, and 686) match the ligand neighbors of ligand 666.   
2.3.3. Integration of CCA in the CoLiBRI Workflow 
Because CCA provides a telling visual correlation between these two spaces, we believed 
that applying this method during the model development process could greatly improve our 
prediction accuracy.  Therefore, we initiated a direct study comparing the SA-kNN, linear CCA, 
and kCCA.  This study relied on the 1300 complexes of the refined set of the 2007 version of 
 
Figure 7.  Correlation of the (a) first and (b) second canonical variates from ligands and proteins 
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PDBBind.  In addition, 210 of these complexes belonged to the core set, which is selected based 
on clustering of the 1300 complexes using protein sequence similarity and retaining only 3 
complexes from each cluster.   
From this data, we selected three different separations of the data by applying different 
methods for extracting the external validation set.  For the first separation, an external validation 
set of 135 complexes was selected randomly from the 1300 complex refined set.  For the second 
separation, an external validation set of 4 proteins (132 complexes) was extracted from the 1300 
complex refined set based on the protein names stored in PDBBind for these complexes.    For 
the third separation, an external validation set of 7 clusters (21 complexes) was taken randomly 
from the 70 cluster (210 complexes) core set.  The remaining complexes which were not to be 
 
Figure 8. Projection of binding sites and their cognate ligands from PDBBind V2003 onto the first two 
canonical vectors 
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used for external validation were then split using the Sphere Exclusion Algorithm
83
 yielding 
training and test sets of size 966 and 169 complexes for the first separation, 1006 and 162 
complexes for the second separation, 153 and 36 complexes for the third separation. 
The first separation was referred to as the ―standard set‖ since it closely mimics the normal 
method of 3-way data splitting applied by our lab to generate traditional QSAR models
84
.   The 
second separation is referred to as the ―name set‖ intended to have completely virgin proteins in 
the external set, and therefore, provide a more robust test of the modeling methods.  The third 
separation is referred to as the ―cluster set‖ and while containing the least amount of data, 
guarantees that the external set proteins are not exceedingly similar to proteins used during 
model development.   
 
Figure 9. Comparison of external prediction accuracies of different methods of CoLiBRI model generation. 
“Best”, “average”, and “random-best” refer to single model prediction by the model that did best on the test set, 
average prediction of all generated models, and single model prediction by the best model generated using 
randomized pocket-ligand associations. 
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Both training and test sets were used to optimize the models for prediction of the external set 
though only the training set is used as a knowledge-base for the kNN predictions.  In order to 
more closely replicate the act of virtual screening, the World Drug Index (WDI) compound 
database
85
 was added to the test and external sets.  To verify accuracies were not based on 
chance correlations, an additional set of models were generated where the training set ligand-
pocket associations were randomly shuffled.  
To assess the necessity of optimization procedures, both sequence similarity based (as 
determined using ClustalW
45
) and pocket similarity based kNN methods were also applied to all 
data splits with varied k values. TAE/RECON descriptors were used for both binding pockets 
(identified using protein-ligand tessellation) and ligands. 
   The PMRs for prediction of the external sets are shown in Figure 9.  While SA-kNN 
provided only a very minor improvement over non-variable selected kNN techniques, CCA and 
kCCA performance was clearly superior.  However, the results of linear CCA appear to be for 
both the cluster and standard sets indistinguishable from the results with randomized pocket-
ligand associations.  On the other hand, kCCA provided the best predictions for every external 
set and for what could be considered the most difficult case (the cluster set) predicted the true 
ligand on average in the top 10 compounds of the nearly 54000 contained in the screening 
database.  This results indicates that CoLiBRI is capable of re-identifying the ―true ligand‖ for a 
pocket in less than 0.1% of the database. 
2.3.4. RDF descriptors 
Through collaboration with Molecular Networks
71
, software capable of developing RDF 
descriptors for binding pockets was developed.  The effect of this method of descriptor 
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calculation was compared to the TAE/RECON method of binding pocket description on 
modeling of a regeneration of the cluster set described above from the 2008 version of PDBBind.  
Figure 10 displays the distribution of retrieved ranks for true ligands when screened with 
CoLiBRI for both the test and external sets.  Based on the test set results, it appears as though 
neither TAE nor RDF descriptors of active sites provide superior predictive power.  However, 
when applying the best model for each descriptor type, RDF descriptors and autocorrelation 
descriptors for pockets and ligands respectively showed clearly improved prediction over using 
TAE descriptors.  This indicates that similar to traditional QSAR modeling, a ―combi‖ approach 
may lead to more predictive results. 
2.3.5. True Ligand Identification or Virtual Screening 
Generally speaking, CoLiBRI models have been developed and validated using the retrieval 
of the ―true ligand‖ for a binding pocket.  While similar, this is not the goal of virtual screening 
which attempts to identify all (or at least most) of the ligands that will bind to a pocket.  This 
distinction required a reprocessing of the PDBBind core set in order to properly test it.   
In the 2009 version of PDBBind, the core set consists of 219 protein-ligand complexes 
organized into 73 clusters.  For each cluster, its 3 members were aligned using ClustalX
45
 to 
determine whether the proteins contained therein were actually the same protein.  A protein was 
considered to be the same as another if there was no more than 1 point mutation or insertion in 
the body of the protein.  5% of the protein‘s residues at the head and tail of the protein were 
omitted from consideration when examining the protein sequence since alterations at the head or 
tail are common to aid protein purification and crystallization.  49 of the 73 clusters proved to 
meet the above criteria and the three complexes‘ ligands for each cluster were considered to be 
―true 
26 
 
 
 
 
Figure 10. Comparison of (a) test and (b) external predictive power for different methods of CoLiBRI binding pocket/ligand 
description. 
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ligands‖ for that protein target.  This set was used for all further analysis of the CoLiBRI 
technique and its members are recorded in Appendix II. 
2.3.5.1. Pocket Consistency 
A key difficulty that must be addressed when examining the three protein-ligand complexes as a 
whole is the definition of a pocket.  The protein-ligand tessellation method of pocket 
identification provides a unique pocket for each protein-ligand complex.  These pocket 
definitions can have a wide variability in their level of overlap.  Figure 11 contains example 
Venn diagrams of the atoms selected as pocket members for different PDB entries for the same 
protein. (Additional diagrams are provided in Appendix III.)  While there is a large degree of 
overlap in pockets, the difference of on average more than 15% of a pocket‘s atoms is alarming.  
 
 
 
Figure 11. Venn diagrams exhibiting atom overlap between pockets defined using protein-ligand 
tessellation.  
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The level of 
uncertainty in 
descriptor values 
caused by this 
difference in a 
pocket‘s 
constitution for 
the same protein 
often leads to 
being unable to determine if two proteins are the same based on their pocket representations in 
multidimensional space.  Figure 12 shows the distributions of distances in TAE/RECON space 
between pockets selected using protein-ligand tessellation.  While distances between 
representations of the same protein are skewed toward zero, nearly 50% of the distances between 
the same protein are larger than the smallest of distances between different proteins. We 
hypothesized that a portion of this difference in pocket definition could be rectified by training 
CCA with connections between all three of a protein‘s pockets and all three ligands rather than a 
single connection between each complex‘s pocket and ligand.  To obtain a better grasp of the 
feasibility of this approach, PCA and CCA were applied to the dataset and the co-localization of 
pockets and ligands of the same protein were visually inspected.  An example of this analysis 
with representatives of acetyl-cholinesterase marked in red is displayed in Figures 13-15.  It was 
visually apparent that while correspondence between pockets and ligands in their respective 
spaces is high after CCA analysis, the multiple representatives for a single protein still have other 
pockets interspersed. Thus, modeling alone was insufficient for dealing with pocket differences.  
 
Figure 12. Histogram of distances between pockets selected with protein-ligand 
tessellation in TAE/RECON space  
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Figure 13. PCA projections of (a) protein pockets and (b) ligands in TAE/RECON space. 
a) 
 
b) 
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Figure 14. CCA projections of (a) protein pockets and (b) ligands in TAE/RECON space when only a single 
connection between complex’s pocket and ligand was modeled. 
a) 
 
b) 
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Figure 15. CCA projections of (a) protein pockets and (b) ligands in TAE/RECON space when connection between 
all three representatives of a protein pocket and all three ligands were modeled. 
a) 
 
b) 
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Protein-ligand tessellation to determine the pocket for each protein was convenient; however, 
some (including me) would claim that use of the crystallized ligand to map the specific atoms of 
a protein pocket might imprint ligand information not inherent to protein onto the defined 
pocket.  Therefore we had great interest in converting to a method of pocket identification that 
was ligand insensitive.   We applied 2 protein-only methods of pocket detection: CastP and 
SCREEN.  However, analysis of the pockets identified with both methods indicated that the 
consistency of pockets identified with these methods was no better than that of pockets identified 
with protein-ligand tessellation.   
Figure 16 displays exemplar Venn diagrams for pockets defined using CastP and SCREEN 
(with additional examples in Appendix III).  It is important to note that for many protein-ligand 
complexes, CastP and SCREEN were unable to identify the pocket of interest. While many more 
methods of pocket identification exist, a broad survey of such methods was outside the scope of 
this study.  To discover the achievability of identifying multiple ligands that bind to a single 
protein, a union of the 3 representative pockets defined using protein-ligand tessellation was 
considered as the ―true‖ pocket that would be defined by an accurate and consistent pocket 
identification scheme. 
 
Figure 16. Example Venn diagram for (a) CastP and (b)SCREEN pockets. 
b) 
 
a) 
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2.3.5.2. Combi-CoLiBRI Modeling 
While temporarily setting aside the issue of pocket consistency, generation of CoLiBRI 
models was realized for the union pockets defined using protein-ligand tessellation.  Models 
were generated with CCA and kCCA modeling methodology using ProFeat
86
 descriptors of 
proteins; TAE/RECON, Feature Pairs, and 3 variants of RDF descriptors for pockets; and 
Dragon with hydrogens, Dragon without hydrogens, MACCS keys, and MOE2D descriptors for 
ligands.  5-fold external validation was used to ensure statistical robustness.  External folds were 
dissolved into DrugBank
87
 rather than WDI to reduce computational cost.  Figure 17 reports the 
calculated predictive capability using PMRR.  PMRR is the average across the 49 proteins of the 
PMR for the ligands of that protein.  Even in the contrived case of ―true‖ pocket definition, 
prediction accuracy was mediocre.  Being that the DrugBank database contains only includes 
roughly 4500 compounds, the retrieval rates were rough on the order of 10% of the database.  
Surprisingly, linear CCA performed better than kCCA on prediction of the external sets which 
directly contradicts the results obtained previously.  In addition, it is unexpected that MOE2D 
descriptors would perform better than dragon descriptors, which are more comprehensive. The 
ranks of ligands that bind to a pocket  (shown in  
Figure 18 for one descriptor type and method ) by applying kCCA to RDF pocket 
descriptors calculated using partial charge and polarizability and MOE2D ligand descriptors 
shows that prediction accuracy for individual proteins covers a braod range.  To extract at least 
one active for 98% of external set proteins at least 250 compounds (around 5% of the database) 
would have to be screened. If retrieval of all three ligands for a protein was desired, for 80% of 
the proteins in the database 500 compounds (roughly 10% of the database) would have to be 
screened.  
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Figure 17. PMRRs for “Combi-CoLiBRI” analysis  
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2.3.5.3. Ligand Consistency 
An additional difficulty 
unconsidered prior to modeling is 
that of ligand consistency.  Figure 
19 displays a PCA projection of 
ligands in Dragon space with those 
of the same protein connected by a 
line.  This plot realized with the 
ADDRAGRA software written in 
our lab shows the variation in ligand 
structure that is inherent in our 
dataset.   
 
Figure 19. ADDAGRA plot of ligands in Dragon space with 
ligands of the same protein connected.  
 
 
Figure 18. Retrieval ranks for ligands when modeled by CCA CoLiBRI using rdf_q_pol and MOE2D descriptors.  
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This variation of ligand structure is likely directly related to the method by which 
representative ligands were chosen in PDBBind.  For each cluster, the complexes in which the 
ligands had the highest, lowest and median activities were chosen.  This means that in several 
cases the difference between the measured binding affinities for the representative ligands of a 
protein can be quite large (average of 2.76 log units, maximum of 8.57 log units).  This 
corresponds well to the large differences in ligand structure for the same protein and may explain 
a portion of the difficulty in prediction.    Figure 20 shows the binding modes and affinities for 
two different ligands of FBKP.  
2.4. Conclusions and Future Work 
During the course of research into the CoLiBRI workflow for virtual screening of large 
compound libraries, I have carried out the following tasks: 
1. Performed external validation of the original CoLiBRI methodology in screening HIV-
protease (Section 2.3.1) 
2. Integrated into the CoLiBRI workflow a novel method for optimizing multiple 
multidimensional spaces (Sections 2.3.2 and 2.3.3) 
3. Assessed the capabilities of two additional techniques for protein pocket designation 
(Sections 2.3.5.1) 
4. Implemented two new methods of protein pocket description (Sections 2.2.3.2 and 
2.2.3.3) 
5. Performed ―Combi-CoLiBRI‖ using available methods of pocket and ligand description 
(Section 2.3.5.2) 
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Figure 20. Binding modes and affinities of 2 ligands of FKBP  
Rapamycin 
Ki = 0.2nM 
4-hydroxy-2-butanone  
Ki = 500µM 
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The CoLiBRI workflow exhibits excellent results when ―re-docking‖ ligands with the protein 
pocket extracted from the same complex.  Additionally, when applied in a situation more akin to 
virtual screening (i.e. the extraction of multiple ligands using a single pocket), CoLiBRI allows 
the elimination of a large portion of the chemical library and does so with a rate of screening 
several orders of magnitude faster than typical structure-based methods.  Pockets in the database 
for which this wasn‘t the case typically had diverse ligands with a broad range of binding 
affinities.  The primary limitation to the use of CoLiBRI in general structure-based studies is that 
the identification of a protein‘s pocket reproducibly across the PDB entries of a single protein 
was unattainable by the tested pocket definition software.  This causes an unacceptable level of 
uncertainty in the description of the protein pocket and subsequently in ligand ranking. For this 
reason, a more extensive analysis of the consistency of pocket prediction should be completed; 
perhaps even the development of a technique for pocket detection that will provide consistently 
defined boundaries should be included.   
There is additional refinement required in the analysis of CoLiBRI as a virtual screening 
technique.  While the retrieval of all three representative ligands for a protein is more similar to 
virtual screening than the identification of just one, a thorough benchmarking of CoLiBRI using 
the benchmark developed in Chapter 2 is required. Also, the variation in prediction accuracy for 
different protein members should be examined in greater detail to determine if there is a rational 
way to form an applicability domain for CoLiBRI models.  Finally, CoLiBRI should be built and  
using a more extensive set of protein crystal structures and known binders.  
  
 
Chapter 3: Benchmarking of Virtual Screening 
Techniques 
3.1. Introduction 
Virtual screening methodologies all have unique advantages and disadvantages.  As such, it 
is generally accepted that no method is unilaterally better than every other method of virtual 
screening.  While typically new methods are tested and shown to be useful on a small number of 
well documented sets
88, 89
, this type of investigation provides little statistical validation of the 
usefulness of the tool and no understanding of the proper situation for application of the 
technique.   
While comparison within the fields of structure-based and ligand-based techniques are often 
undertaken
54, 82, 90, 91
, there has only been a minimal amount of study across the two fields.  
Theoretically, if enough active compounds are known for a particular target, ligand-based 
methods should provide better predictions than structure-based methods; however, the amount of 
binding data required to a make the application of a ligand-based technique more advantageous 
is still unknown.  Therefore, a thorough comparison between structure-based and ligand-based 
methods for virtual screening must be carried out on several targets that have a sufficient amount 
of known binding data.   
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Though there are already benchmarks for docking (Directory of Useful Decoys (DUD)
92
) and 
QSAR (Mittal et al.
93
), there is not a benchmark intended to be utilized by both methods.  The 
importance of such a benchmark can be noted by the attempts of some to benchmark ligand-
based tools
94, 95
 with the DUD database even though it was designed so that decoys could easily 
be separated from binders with topological indices. This study‘s intent was to define a set of 
targets with available binding data to be used as a benchmark for virtual screening in the public 
domain.  After generation of this set, preliminary testing of QSAR methods, similarity searching, 
and docking were carried out to demonstrate the utility of such a set. 
3.2. Materials and Methods 
3.2.1. Databases 
The benchmark datasets were drawn from extensive databases containing large amounts of 
biological activity data.  The databases (ChEMBL, WOMBAT, and MDDR) used in this study 
are described infra. 
3.2.1.1. ChEMBL 
The ChEMBL 
database
5
 is a publicly 
available repository of 
―drug-like‖ small 
molecules linked with 
biological assay data.  This 
biological assay data is 
 
     Figure 21. Distribution of ChEMBL targets. 
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extracted from peer reviewed scientific literature and curated by members of EMBL-EBI.  The 
ChEMBL database contains nearly 600K compounds, 450K assays, and 7.5k targets.  The 
distribution of ChEMBL‘s targets over the proteome can be seen in Figure 21. 
3.2.1.2. WOMBAT 
WOMBAT
96
 is a commercial product of Sunset Molecular.  The database is also populated 
with data from scientific 
literature, but the data is 
specifically taken from 
selected articles within 
medicinal chemistry 
journals.  In total, the 
wombat team has 
indexed more than 
15,000 articles and annoted over 300,000 entries of biological activity.  The distribution of 
activities in WOMBAT is shown in Figure 22.  
3.2.1.3. MDDR 
The MDL Drug Data Report
97
 has long been an industry standard database covering patent 
literature and journal submissions.  The database was jointly produced by Symyx and Prous 
Science and is currently being marketed by Accelrys.  The database contains over 150K 
biologically relevant compounds with biological activities classified using the Prous 
classification system.  The compounds are also annotated with trade names, company codes, 
generic names, originating company, and its current phase of development. 
 
Figure 22. Distribution of WOMBAT activities. 
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3.2.2. Dataset Extraction 
Based on preliminary searching of the available data, a subset of biological targets was 
selected to form the benchmark set.  Compounds and their associated activities were compiled to 
create datasets for both modeling and validation from the ChEMBL database with the one 
exception being the Ack1 dataset, which was compiled from 3 patents.  For each target, an 
additional search of WOMBAT and MDDR was completed to extract fully external sets. 
Each compound set was cleaned thoroughly.  All molecules were processed with Pipeline 
Pilot
98
 to remove salts and solvents, normalize protonation states, standardize chiral definitions, 
and aromatize the molecules.   Activities for the ligands of each target were categorized as either 
active or inactive using an upper and lower threshold that provided roughly balanced sets for 
each target and eliminated compounds with uncertain activities. Subsequently, duplicate 
structures were identified and an inspection of the activities of duplicates was carried out.  
Duplicates for which binned activity disagreed were removed while duplicates for which binned 
activity agreed had a single representative retained.  A detailed description of processing of 
ligands for each target is contained in Appendix IV.   
3.2.3. Dataset Splitting and Screening 
To properly assess the effect of modeling set size on modeling statistics and virtual screening 
the data splitting scheme show in Figure 23 was applied for each target.   
In all cases, the dataset of chemicals for a target drawn from ChEMBL was split into 
modeling and validation sets using the 5-fold method.  While the definition of a modeling set is 
unnecessary in the case of docking, defining external sets that are the same across all methods is 
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ideal for comparison purposes.  The external sets were then dissolved into the compendium of 
ligands from other targets to provide a larger number of decoys in our screening sets. 
Subsets were generated from each modeling set to preserve the integrity of the validation 
sets.  For each modeling set, five subsets were selected of size 26, 50, 100, 250, and 500 for 
analysis with QSAR and similarity searching yielding 25 total subsets.  These subsets were 
randomly selected with 
an equal number of 
representatives from 
each class. For some 
datasets, subsets of 
size 250 and 500 were 
omitted due to a lack 
of data.  An additional 
five subsets were 
selected of size 1 and 5 
from each modeling 
set yielding 10 more 
sets for similarity 
searching.   The smaller sets selected for similarity searching were drawn only from the active 
class.  In total, at most 130 ensemble QSAR models were developed (25 subsets * 5 modeling 
sets + 5 modeling sets).  Each model was used to predict the appropriate screening library.  A 
total of 180 similarity searches using probes drawn from the modeling sets were completed on 
the appropriate screening library.  In addition, each screening library was ranked by docking and 
 
 
 
 
 
 
 
 
 
Figure 23. Splitting protocol for generation of modeling, validation, subset, and 
screening databases. 
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by a similarity search with the ligand contained in the PDB entry. Thus at most 320 differently 
ranked screening libraries were generated for each target. 
3.2.4. Docking 
To prepare the protein structures for docking, all the water molecules and ions associated 
with the structure were removed. eHiTS was used to preprocess the protein by extracting the 
ligand from the PDB complex files and generating a native eHiTS file format. A radius of 7.5Ǻ 
to 10Ǻ was used to define the active site and calculate steric grids and feature descriptions. 
The ligand database for docking was prepared using LigPrep Module as implemented in 
Schrodinger 9.2. LigPrep provides an efficient way to prepare all-atom 3D structures, starting 
from 2D or 3D structures. Low energy 3D structures of ligands were generated from canonical 
SMILES strings using OPLS 2005 force field. Calculation of possible states at pH 7±2 resulted 
in generation of the correct ionization state. Specified chiralities were retained from the 
canonical SMILES and the lowest energy conformation of rings was retained for each ligand. 
Hydrogen atoms were added to complete valences as necessary. Ligands just comprising ions or 
molecule fragments having 4 atoms or less were removed. Structures that caused processing 
failures in the energy minimization of the structures were also removed. In the end one unique 
conformation per ligand was retained for docking. 
eHiTS v2009.1 (www.symbiosys.com), an automated docking software, was used for virtual 
screening. The eHiTS software package
99
 is a flexible ligand docking program that utilizes 
exhaustive fragment based search algorithm to dock and then energetically optimizes the 3D 
coordinates of docked poses within the active site of target. One of the critical steps in a 
successful docking approach is to correctly position each ligand in the binding site based on the 
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defined constraints. This step involves exploration of the configurational and conformational 
space for the interaction between target and ligand. This step attempts to correctly identify the 
most favorable binding mode of the ligand in the target active site.  
The eHiTS docking algorithm docks rigid fragments generated from a ligand independently 
within a binding pocket. The binding pocket is represented using Geometric Shape and Chemical 
Feature graph (GSCF), where nodes of the GSCF graph represent a rigid shape by a simplified 
geometric hull generated from regular polyhedra where each vertex of a polyhedron is encoded 
with its chemical properties. The ligand is broken down into rigid fragments and flexible 
chain/linker atoms/fragments. Each fragment is also represented using a GSCF graph made up of 
regular polyhedra with chemical properties associated with each vertex of the polyhedron. Each 
rigid ligand fragment is docked in each cavity polyhedron during the rigid docking phase by 
matching and exploring each cavity-ligand fragment orientation. Thousands to millions of 
fragment poses are generated within the binding cavity depending on the size and fragmentation 
pattern of original ligand.  
Poses are then selected using a fast graph matching algorithm and rigid fragments are 
reconnected through their flexible linker atoms that comprise the matching pose set. Flexible 
chains are tweaked and optimized such that its end matches the rigid fragment precisely without 
violating any energetic and steric constraints. The final binding poses are refined by a local 
energy minimization in the active site of the receptor, driven by eHiTS scoring function. The 
binding energy of each pose is calculated and reported as eHiTS score.  
The eHiTS scoring function is based on a combination of novel scoring term (local surface 
point contact evaluation) plus a hybrid scoring term based on traditional empirical and 
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knowledge based scoring functions. The interaction score between fragment surface points and 
receptor surface points are computed from the interaction statistics collected separately for 
distinct types of surface point pairs. Surface points are classified into 23 types and interactions 
between ligand and receptor surface points are recorded. The random probability of interaction is 
used to convert to interactions into an energy term using energy scaling factors.  Besides this 
energy term the final scoring also includes terms for steric clash, depth value, conformational 
strain energy of the ligand, entropy, intra-molecular interaction, receptor surface coverage, and 
family coverage. The terms of the scoring function are combined using adjustable weights for 
each protein family.  To train these weights, interaction statistics were collected for all pairs of 
atoms within 5.6 Å of each other for a set of ~1420 high resolution protein-ligand complex. The 
complexes were clustered into 71 clusters or families and family specific weight sets were 
generated. In addition to the family optimized scoring function, eHiTS allows new scoring 
weight sets to be generated by training the scoring function with addition protein-ligand complex 
data or with known active and inactive ligands.  
While the scoring function of eHiTS program can be trained using known actives and 
inactives to bias the function toward finding ligands that are more similar to known actives.  
However, in our benchmarking study we carried out an unbiased docking based on default 
eHiTS parameters.  Compounds were ranked based on the returned eHiTS score. 
3.2.5. Similarity Searching 
Similarity searching is the simplest form of ligand-based virtual screening.  The method 
typically involves generating a set of multidimensional descriptors for both the known ligand(s) 
and the chemical database, then ranking all compounds in the chemical database based on their 
similarity to the ligand.  There are many different types of descriptors that can be applied and 
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several different ways to assess similarity.  In this study, similarity searching was carried out 
using both the ligand contained within the protein-ligand complex obtained from the PDB and 
the actives in the modeling sets defined supra.  Similarity was assessed using the Tanimoto 
coefficient and FCFP4 from Pipeline Pilot.  Compounds were ranked based on their similarity to 
the nearest probe. 
3.2.6. QSAR 
The generation of all QSAR models was accomplished through use of the Chembench web 
portal.  Only random forest modeling was applied as the number of modeling set to be analyzed 
was large. In all cases, the random forest modeling procedure Chembench was applied to Dragon 
descriptors
100
 of chemical structure with the following selections: range scaling of descriptors 
and elimination of descriptors with perfect correlation, 50 random divisions of training/test set 
containing between 20% and 30% of the dataset, and 50 trees generated for each split using 50 
descriptors.  Further discussion of the random forest procedure implemented in Chembench is 
contained in section 5.2.2.  During screening, each compound was scored and ranked using the 
percentage of models within the ensemble that predicted it to be active.  
3.3. Results and Discussion 
3.3.1. Preliminary Error Analysis 
Prior to defining datasets for each target, it was necessary to assess the level of noise that 
appears in the numeric activity values contained in the bioactivity databases.  Since these 
databases are extracted from peer reviewed literature, we expected the data to be of high quality.  
To verify this hypothesis, activity values were extracted for all 22 targets of interest from the 
ChEMBL database.  Of the 43319 entries returned, 6917 were identified as duplicates (the same 
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ChEMBL ID had multiple listed activity values for a target and an activity type).  Figure 24 
contains the histogram of the maximal difference in activity values for each duplicate.  The 
cumulative histogram indicates that the majority (70%) of duplicates have a maximal difference 
between reported activities of less than one log unit.  90% of duplicates have a maximal 
difference of less than two log units.  Based on this information, we decided that the 
inconsistency of reported values within ChEMBL made modeling them problematic.  We 
decided to categorize the continuous values into active and inactive classes.  To reduce the error 
in labeling, the threshold to be considered active was two log units greater than the threshold to 
be considered inactive.    
An interesting side note concerning maximal error measurements is that there are distinctive 
increases in the number of duplicates with errors of three and six in the histogram.  These 
increases are likely due to errors in interpretation of units when data is being extracted from 
literature sources. 
 
Figure 24. Maximal difference in activity reported for duplicates in ChEMBL. 
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3.3.2. Selected Datasets 
In total, datasets were extracted for 22 targets.  These targets cover multiple protein classes whose 
activities can be modulated by small compounds.  This set includes GPCRs, nuclear hormone receptors, 
and several enzyme families such as kinases and proteases.  High resolution protein structures for all 
targets were identified within the PDB and ligands for each target were extracted from the three 
bioactivity databases: ChEMBL, WOMBAT, and MDDR.  Information regarding the data extracted for each 
target is contained in  
Table 1.    
3.3.3. Ranking with Docking 
The ranking of screening sets was completed for all targets with eHiTS, a commonly used 
fast flexible docking solution.  For each of the resultant ordered screening sets two Receiver 
Operating Characteristic (ROC) curves were generated.  The first ROC curve is generated 
considering decoy compounds in the screening set coming from the other targets to be inactives.  
The second is generated considering only the compounds in the screening set belonging to that 
target‘s dataset.  Figure 25 contains examples of the former while Figure 26 contains examples 
of the latter.  All ROC curves are available in Appendix V. 
While docking did an excellent job in selecting true actives from the full screening sets in the 
majority of cases, in some cases it was indistinguishable from random prediction.  These cases 
correspond to the lack of a family based scoring function of certain proteins.  In order for optimal 
performance, eHiTS requires that a family be known for a protein.  This limitation makes 
identification of binders of proteins under-populated in the PDB difficult.  
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Table 1. Summary of results for benchmark dataset generation 
Abbreviation Target PDB ID 
Active 
Threshhold 
(nM) 
Inactive 
Threshold 
(nM) 
# Compounds 
in modeling/ 
validation set 
# Compounds 
in WOMBAT 
external set 
# Compounds 
in MDDR 
external set 
ACK1 
Activated Cdc42-
associated Kinase 
3EQR ≤ 100 ≥ 10000 172 NA NA 
ACHE Acetylcholinesterase 1EVE ≤ 100 ≥ 10000 887 652 860 
AR Androgen Receptor 2AM9 ≤ 100 ≥ 10000 422 258 NA 
B2AR 
Beta-2 Adrenergic 
Receptor 
2RH1 ≤ 100 ≥ 10000 248 137 238 
CA2 
Carbonic Anhydrase 
II 
3K34 ≤ 10 ≥ 1000 1073 778 267 
CDK2 
Cyclin Dependent 
Kinase 2 
2R3I ≤ 100 ≥ 10000 1360 756 NA 
COX2 Cyclooxygenase 2 3PGH ≤ 100 ≥ 10000 1429 811 1168 
DHFR 
Dihydrofolate 
Reductase 
2W3A ≤ 100 ≥ 10000 463 240 250 
ESR1 
Estrogen Receptor 
Alpha 
2OUZ ≤ 10 ≥ 1000 878 799 311 
ESR2 
Estrogen Receptor 
Beta 
2NV7 ≤ 10 ≥ 1000 703 681 NA 
F10 Coagulation Factor X 2XBV ≤ 10 ≥ 1000 999 2050 1648 
GR 
Glucocorticoid 
Receptor 
3K22 ≤ 10 ≥ 1000 385 387 NA 
HIV-Int HIV Integrase 1QS4 ≤ 1000 ≥ 50000 749 954 475 
HIV-Pr HIV Protease 1G35 ≤ 10 ≥ 1000 1526 2691 1140 
HIV-RT 
HIV Reverse 
Transcriptase 
2ZD1, 
3KK1 
≤ 100 ≥ 10000 1133 1411 NA 
PARP1 
Poly [ADP-ribose] 
Polymerase-1 
3GJW ≤ 10 ≥ 1000 299 293 377 
PDE5 
Phosphodiesterase 
5A 
1TBF ≤ 10 ≥ 1000 687 499 660 
PNP 
Purine Nucleoside 
Phosphorylase 
1VHW ≤ 10 ≥ 1000 173 81 82 
PPARG 
Peroxisome 
Proliferator-
Activated Receptor 
Gamma 
3ET3 ≤ 100 ≥ 10000 376 340 NA 
REN Renin 3K1W ≤ 10 ≥ 1000 1235 536 1529 
SRC 
Tyrosine Protein 
Kinase SRC 
3G5D ≤ 100 ≥ 10000 1443 689 NA 
F2 Thrombin 2BVR ≤ 100 ≥ 10000 1150 1933 1373 
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The usefulness of ranking when only known active and inactive compounds were considered 
was much lower.  The ability to select true binders from known non-binders using only eHiTS 
scoring appears to be quite limited.  
3.3.4. Ranking with Similarity Searches 
Similarity searching using Tanimoto score and FCFP-4 fingerprints was completed using 
Pipeline Pilot.    Results were obtained using either the ligand from the PDB entry or the actives 
from a selected modeling set as probes.  ROC curves are provided only for the cases of the PDB 
ligand and full modeling sets. (ROCS using probes extracted from subsets were not generated.)  
Example ROC curves of type I are displayed in Figure 27 and Figure 28 while those of type II 
are shown in Figure 29 and Figure 30. All ROC curves are available in Appendix V. 
3.3.5. Ranking with QSAR models 
The ranking of all screening sets was completed using random forest models developed on 
Chembench.  Models were obtained for all 130 modeling sets (including subsets).   The 
predictive power of all these sets was assessed using their validation sets.  Graphics 
exemplifying the effects of modeling set size on the predictive power of the resultant models are 
shown in Figure 31.  The stability of the resultant models (measured with the standard deviation 
in CCR) is displayed in Figure 32 for select targets.  Appendix VI holds additional examples of 
these plots. 
Examination of Figure 31 confirms that as a modeling set size increases, its predictive power 
increases.  Additionally, Figure 32 shows that generally the stability of a model increased as 
more compounds are modeled.  These results completely agree with what would be expected as 
set sampling increases. 
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Figure 25. Example ROC curves resulting from the docking the full screening library using eHiTS. 
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Figure 26. Example ROC curves resulting from the docking of compounds with known activity using eHiTS. 
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Figure 27. Example ROC curves resulting from searching the full screening library using the PDB ligand and Tanimoto similarity with FCFP-4. 
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Figure 28. Example ROC curves resulting from searching compound with known activity using the PDB ligand and Tanimoto similarity with FCFP-4. 
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Figure 29. Example ROC curves resulting from searching the screening library using the modeling set actives and Tanimoto similarity with FCFP-4. 
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Figure 30. Example ROC curves resulting from searching compounds with known activity using the modeling set actives and Tanimoto similarity with FCFP-4. 
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ROC curves were generated only for models developed using the entire modeling set (not 
subsets).  ROC curves for the entire screening set are available in Figure 33 while those for 
compounds with known target activity are displayed in Figure 34.  
QSAR models were able to effectively rank both the screening library and the compounds with 
known activities.  Being that QSAR models are specifically trained to make separations between 
actives and inactives in the modeling set, they can be insensitive when predicting compounds not 
similar to the modeling set; however this is not readily apparent in ROC curves generated when 
using the entire modeling set.  In typical applications of QSAR for virtual screening, a global 
applicability domain filter is used to guarantee that selected compounds are similar to the 
modeling set.  However, an applicability domain filter was not applied in this case as its most 
tradition implementation is a similarity search using all modeling set members as probes.  The 
use of multiple modeling methods in concert to obtain superior predictive power was beyond the 
scope of this study‘s focus of ascertaining the usefulness of the benchmark set.   
3.3.6. Method Comparison 
Being that different virtual screening methods require different inputs, it is hard to compare 
them in an unbiased way.  QSAR modeling using 1000 modeling compounds cannot be fairly 
compared to docking results that rely on single protein structure.  However, there are two fair 
comparisons that can be made.  Similarity searching using the ligand contained within the PDB 
entry as a probe and docking both use only a single protein-ligand complex to rank a chemical 
database.  Also similarity searching using all actives from a modeling set as probes uses the base 
of knowledge as a QSAR model. 
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Figure 31. Prediction accuracy as measured using mean CCR for selected targets. 
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Figure 32. Prediction stability as measured using the standard deviation in validation set CCR for selected targets. 
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Figure 33. Example ROC curves resulting from prediction of the screening library using QSAR models. 
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Figure 34. Example ROC curves resulting from prediction of compounds with known activity using QSAR models. 
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Figure 35 demonstrates that in there is no clear pattern in whether similarity searching or 
docking will provide better ranking of a screening library.  While docking certainly fails in some 
cases, there are also examples of similarity searching proving mediocre in recall of actives.   
When examining the capacity of the two methods to properly classify only compounds with 
known activities, it is apparent (see Figure 36) that often neither method proves successful.   
Figure 37 and Figure 38 display the ROC curves for similarity searching and QSAR 
modeling using each of the modeling sets.  While similarity searching appears to be much better 
at extracting active compounds from a large chemical library, QSAR does a superior job of 
separating the known actives from the known inactives.  This sensitivity of QSAR to fine 
differences in chemical structure while similarity searching provides coarse separation of actives 
from a large set of putative inactives speaks to the complementary of the two methods in virtual 
screening.   
While different methods use different sets of knowledge to rank chemical libraries, all 
methods are united in that their goal is enrichment of known actives in a subset of a database.  
Therefore, it is reasonable to compare all methods and their respective knowledge bases on the 
criteria of enrichment. For each target, enrichments were calculated at 0.5%, 1%, 5%, and 10% 
of the database.  An example of the resulting enrichment comparison is contained in Figure 39.   
Enrichment comparisons for additional targets are available in Appendix VII. 
Based on the generated figures, enrichment appears to usually increase as ligand information 
is added to the model system.  In terms of raw enrichment of active compounds, similarity 
searching appears to be the best method for utilizing this information.   
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Figure 35. Comparison of ROC curves between docking and similarity searching on the full screening library. 
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Figure 36. Comparison of ROC curves between docking and similarity searching on compounds with known activity. 
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 Figure 37. Comparison of ROC Curves from QSAR modeling and similarity searching using full modeling sets on screening library. 
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Figure 38. Comparison of ROC Curves from QSAR modeling and similarity searching using full modeling sets on compounds with known activity. 
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Figure 39. Enrichment on the screening library for DHFR.  
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3.3.7. CCR or Enrichment for Model Characterization 
Questions often arise regarding how to select QSAR models that will yield superior virtual 
screening results.  While our lab primarily relies on CCR as a measurement of a model‘s 
usefulness, for the goal of virtual screening one would expect that metrics more commonly 
applied within the fields such as enrichment would provide a better assessment of a model‘s 
capabilities.  While the experimental design of this study was specifically focused on the 
evaluation of the effect of modeling set size on QSAR in relation to both docking and similarity 
searching, the abundance of derived data allows us to examine the relationship between CCR and 
enrichment.    
Figure 40 contains a scatter plot of CCR vs. enrichment for two selected targets.  Additional 
figures of this type are contained in Appendix VIII.  While the relationship between CCR and 
enrichment does appear to have slight correlation, that correlation appears to be inconsistent and 
in many cases weak.   
3.4. Conclusions and Future Directions 
During the generation and assessment of a benchmark dataset for assessment of virtual 
screening techniques, the following goals have been achieved  
1. Extraction and curation of ligand datasets for 22 targets from three (one public and 
two commercial) bioactivity databases (Section 3.3.2) 
2. Docking of a library of nearly 17,000 compounds to 22 different protein targets 
(Section 3.3.3 
3. Similarity searching using nearly 4000 different probe sets (Section 3.3.4) 
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Figure 40. The lack of correlation between CCR and enrichment. 
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4. Generation of more than 2500 ensemble QSAR models including 22 externally 
validated predictors of biological activity (Section 3.3.5) 
Using the data generated from assessment of the benchmark datasets, we have determined 
that the selected docking and similarity searching protocols perform very poorly in separating 
tested actives from tested inactives.  We have validated the importance of being able to classify a 
target in the family based scoring scheme promoted by eHiTS.  We have determined that in 
terms of ability to identify hits from a chemical library, similarity searching and docking perform 
nearly equivalently. 
While assessing the selected QSAR method, it was apparent that QSAR alone is poor in 
comparison to similarity searching at enriching a large chemical library; however, QSAR models 
significantly outperform docking  and similarity searching in their ability to separate the known 
actives from the known inactives.  The inability of QSAR models to effectively separate the most 
interesting compounds from a chemical database is easily rectified with the use of a global 
applicability domain (an assessment of whether a compound in the chemical library is similar 
enough to members of modeling set to make a prediction).  The results of this study show that 
the use of a global applicability domain as is often done when performing a virtual screen with 
QSAR is vital to achieve optimal selection of hypothetical binders. 
The performance of QSAR models in classification and virtual screening as measured using 
CCR and enrichment respectively often correlate, but are not equivalent.  Optimizing enrichment 
rather than CCR could generate models better suited to virtual screening of large chemical 
libraries. 
 72 
 
Clearly this study is limited in the number of methods applied to analyze these datasets.  To 
gain a better understanding of the capability of cheminformatics in the task of virtual screening, a 
larger study involving more cheminformatics specialists must be initiated.  By encouraging a 
collaborative study, a better assessment of cheminformatics tools will be obtained since experts 
will use the tools with which they are most familiar and comfortable.  This will lead to 
comparison of tools when applied in the best manner. 
The metrics of virtual screening success should be improved.  Rather than assessing the 
number of compounds returned, a better measure of success is the number of new chemical 
classes identified.  Clustering the dataseta then manually defining the boundaries between the 
different classes of actives could achieve this goal.  Then the recall of active classes could be 
measured when virtually screening the library. 
The above consideration highlights a limitation in our strategy for determining the effects of 
knowledge base size on similarity searching and QSAR.  In realistic applications, the knowledge 
base often contains only a subset of the known active classes for a target whereas with random 
sampling no attempt to control the diversity of modeling set was made.  It is expected that if a 
compound‘s target class were considered when selecting compounds for modeling sets, a more 
distinct drop would be seen in predictive power as modeling set size was decreased.  This 
hypothesis surely bears testing as the usefulness of ligand-based methods should be assessed in 
the most realistic manner so the method comparison can inform application scientists. 
Finally, while sets were generated from both WOMBAT and MDDR, they have not been 
utilized in benchmarking screening tools.  The commercial restrictions on the extracted sets are 
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surely a strike against them, but studies should be completed verifying that virtual screening on 
these sets and the ChEMBL set are similar. 
  
 
Chapter 4: Chemical Sensitivity of Cancer Cell Lines  
4.1. Introduction 
Over the past decade there has been increased interest in shifting the treatment of cancer 
from a tissue or organ specific approach to a more personalized approach
43
.  Personalized 
medicine relies on the measurement of biomarkers that indicate how an individual will respond 
to a particular treatment.  However, a comprehensive set of biomarkers is still unavailable.  This 
is disappointing as there has been a decided increase in our capacity for genetic screening. 
 Biomarkers can be defined using a variety of techniques in the fields of genomics, 
proteomics, or metabolomics.  Herein, we focus on the use of gene expression profiles to predict 
the resistance or sensitivity of a cell line to a chemotherapeutic or several chemotherapeutics.  
The NCI-60 dataset provides an excellent resource to mine to identify gene expression 
biomarkers as it provides a measure of drug-induced cytotoxicity for a large number of 
chemicals in a panel of 60 cell lines.  These cell lines also have their gene expressions profiled. 
While many have mined this data to identify biomarkers of resistance, most works focus on 
analysis of single compounds at a time
101
.  At most a small set of compounds are examined
102
.  
This lack of comprehensive analysis of the NCI-60 dataset likely obscures markers that are 
relevant to large set of compounds (i.e. multidrug resistance genes).  Therefore, we have 
completed a study of the entirety of the NCI-60 dataset looking to identify both multidrug 
resistance biomarkers and drug specific resistance biomarkers.   
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4.2. Materials and Methods 
4.2.1. NCI-60 dataset  
The In Vitro Cell Line Screening Project (IVCLSP) has been fully operational since April of 
1990.  This project, tasked with the direct support of the Development Therapeutics Program 
(DTP) anticancer drug discovery effort, is designed to screen up to 3,000 compounds per year for 
growth inhibition of 60 different human tumor cell lines representing a variety of tissue types.  
Portions of the results of this screening are made available to the public.  Our data was taken 
from the following locations: GI50 values were taken from the archive file available from 
http://dtp.nci.nih.gov/docs/cancer/cancer_data.html, chemical data was drawn from both the 
structural file contained within the bioactivity data archive file and the 2D structural file 
available at http://dtp.nci.nih.gov/docs/3d_database/structural_information/structural_data.html, 
and Affymetrix HG-U133(A-B) raw data
103
 were extracted with use of Cellminer
104
. 
4.2.2. Dataset Curation 
Being that the dataset contains chemical, screening, and gene expression data, the first step of 
curation was to ensure consistency of representatives across data types.  When examining the 
chemical and screening data, we determined that 585 identifiers in the screening data had no 
stored chemical data.  Of the 60 cell lines commonly screened in the IVCLSP, only 59 had 
recorded gene expression data.  The 585 identifiers that did not have chemical data and the cell 
line without gene expression data were eliminated from further analysis. 
The chemical structures for the remaining 47039 compounds were then standardized and 
compared using Pipeline Pilot to determine if duplicates were present.  532 duplicate structures 
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were identified linked to 1114 nsc_ids.  The screening results for duplicate structures were 
treated as having been submitted with the same identifier (see process of curation infra).   
The screening data provided via download often contained multiple pGI50 values for the 
same identifier-cell line pair.  Additionally, the data was occasionally reported in more than one 
type of unit.  To deal with this multiplicity of values, unless the pGI50 was equal to maximum 
concentration tested, we weighted the pGI50 measurements (in M units) by the number of tests 
from which that measurement was obtained and then averaged them. When the reported pGI50 
was equal to the maximum concentration tested, it was only included in the averaging if it was 
less than minimum pGI50 reported for other instances of the identifier-cell line pair.  While 
inclusion of any data where the reported pGI50 is equal to the maximum concentration tested may 
be considered questionable, elimination of all such instances significantly reduces the amount of 
available data and obscures the chemical sensitivity trends across cell lines.  All data not reported 
in M units was ignored. 
After coalescing duplicative pGI50 values, only the 4614 compounds for which all 59 cell 
lines had pGI50 values were retained.  Additionally, compounds that did not have a difference of 
greater than one order of magnitude between their most active GI50 and their least active GI50 
were removed leaving 3555 compounds.   
In order to apply QSAR techniques, additional curation was required prior to generation of 
chemical descriptors.  As the descriptor techniques being employed were insensitive to chirality, 
all chirality was removed using Pipeline Pilot prior to QSAR modeling and duplicates were again 
analyzed leaving 3524 compounds.  Additionally, the Dragon descriptor generation software was 
unable to process chemicals that contained certain atoms eliminating another 11 compounds. 
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4.2.3. Computation Study Design 
The simultaneous analysis of chemical, bioactivity, and gene expression data is quite 
difficult.  Therefore, we decided to progressively segment the data to analyze individual portions 
at a time.  In short, we hypothesize that the GI50 values contained within our dataset can be 
estimated by adding a wholly chemical component and a wholly cellular component to an 
interaction component as described in Equation 5.   
                (5) 
This description of activity values allows us to eliminate the wholly chemical component by 
normalizing each compound‘s GI50 values using the average and standard deviation in the 
activity of that compound across the cell lines. This normalized GI50 value becomes our measure 
of a cell‘s resistance or sensitivity to the drug (see Equation 6).  
                     (6) 
Our separation of the data into parts leads to a cellular resistance that while certainly a 
function of both cellular composition and chemical structure can be analyzed as a multidrug 
resistance (an estimate of the hardiness of a cell when treated by a spectrum of chemicals) and 
specific cellular resistance (the specific interaction between a cell and chemical that is separate 
from the mechanisms for generic resistance).   
4.2.4. Multidrug Resistance 
Multidrug resistance can be described as the hardiness of a cell line against a broad spectrum 
of chemical stimuli.  The resistance of a cell line to a chemical probe is only apparent in relation 
to the effects of the same stimulus on other cell lines.  This being the case, the pGI50 values 
across the cell lines for each compound were centered and scaled using the mean and standard 
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deviation for that compound as an estimate of each cell line‘s resistance to that compound.  The 
resulting matrix of 59 cell lines with resistance estimates for 3555 compounds was then 
subjected to Singular Value Decomposition (SVD)
105
 to select a single vector that represented 
the general resistance (or multidrug resistance) of the cell lines.   
4.2.5. Gene Identification 
After definition of a response variable (either generic cellular resistance as above or a 
particular compound‘s GI50 spectrum as below), selection of significant genes was carried out 
using Significance Analysis of Microarrays (SAM)
106
.  Specifically, we applied the SAMR 
package available from http://www-stat.stanford.edu/~tibs/SAM/ using 1000 permutations.  The 
delta parameter was altered to obtain an appropriate level of significance based on each case. 
4.2.6. Pathway Analysis 
Analysis of the networks and pathways populated and formed by the identified genes was 
accomplished using Ingenuity Pathways Analysis (Ingenuity® Systems, www.ingenuity.com).  
In our case, a core analysis was conducted using a maximum network size of 35 members. The 
core analysis includes network analysis, functional analysis, and canonical pathway analysis. 
 Network analysis was carried out by first mapping each identifier to its corresponding object 
in Ingenuity's Knowledge Base. These molecules, called Network Eligible molecules, were 
overlaid onto a global molecular network developed from information contained in Ingenuity‘s 
Knowledge Base. Networks of Network Eligible Molecules were then algorithmically generated 
based on their connectivity. 
The Functional Analysis identified the biological functions and/or diseases that were most 
significant to the set of genes. The identified markers associated with biological functions and/or 
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diseases in Ingenuity‘s Knowledge Base were considered for the analysis. Right-tailed Fisher‘s 
exact test was used to calculate a p-value determining the probability that each biological 
function and/or disease assigned to that data set is due to chance alone. 
Canonical pathways analysis identified the pathways from the Ingenuity Pathways Analysis 
library of canonical pathways that were most represented by the identified genes. The 
significance of the association between the data set and the canonical pathway was measured in 2 
ways: 1) A ratio of the number of molecules from the data set that map to the pathway divided 
by the total number of molecules that map to the canonical pathway is displayed. 2) Fisher‘s 
exact test was used to calculate the probability that the association between the genes in the 
dataset and the canonical pathway is explained by chance alone. 
4.2.7. QSAR modeling of expected/aberrant behavior 
  The apparent of nature of compounds belonging to one of two classes based on the 
hierarchical clustering of correlation value (see Section 4.3.3) was used as a response variable to 
build a QSAR model.  Compounds were loaded into Chembench and standardized.  Five-fold 
external validation was used to ensure model robustness.  The random forest procedure 
implemented in Chembench was applied to Dragon descriptors
100
 of chemical structure with the 
following selections: range scaling of descriptors and elimination of descriptors with perfect 
correlation, 50 random divisions of training/test set containing between 20% and 30% of the 
dataset, and 50 trees generated for each split using 50 descriptors.  Further discussion of the 
random forest procedure implemented in Chembench is contained in section 5.2.2. 
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4.2.8. Nearest Neighbor Analysis 
The aberrant compounds identified via hierarchical clustering were treated to individual 
SAM analysis to identify the genes most significantly related to their pGI50 profile.  For each 
compound, the nearest neighbor compound in FCFP4 space was identified and the overlap of 
significant genes between neighbors was assessed.     
4.3. Results and Discussion 
4.3.1. Gene Expression Markers of Multidrug Resistance 
To visualize the amount of multidrug resistance evident within the cells contained within the 
NCI-60 panel, the centered and scaled pGI50 values indicative of the level of resistance were 
separated into resistant, sensitive, and neutral groupings where any normalized pGI50 < -1 was 
considered resistant, any normalized pGI50 > 1 was considered sensitive, and the remainder were 
considered neutral.  Figure 41 contains a bar graph of the number of chemicals to which a cell 
line was sensitive or resistant.  These results indicate that not only are some cell lines resistant to 
multiple drugs, but some cell lines are sensitive to multiple drugs.  
With the knowledge that a large portion of the measured cellular resistance and sensitivity 
appears to be caused by multidrug effects, we quantized the multidrug resistance of a cell using 
SVD projection of the normalized pGI50 matrix into a single vector.  The application of SAM to 
this quantized multidrug resistance identified 361 genes (121 linked to sensitivity and 240 linked 
to resistance) with less than a 0.1% 90
th
 percentile FDR.  A listing of these hypothetical markers 
of multidrug resistance is contained in Appendix IX. 
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4.3.2. Pathways of Multidrug Resistance 
Following identification with SAM of markers of multidrug resistance, the 361 markers were 
subjected to Ingenuity Pathway Analysis.  When loaded, a total of 11 probe set ids failed to map 
to genes.  The resulting gene list was subjected to IPA core analysis.  This analysis resulted in 
the identification of several protein networks that have a high degree of connection amongst the 
identified markers.  One such network is shown in Figure 42.  Additional networks and table of 
the networks and their linked functions are displayed in Appendix X. 
When examining the network, it is interesting to note that a large number of the markers 
identified have previously been linked to cancer.  c-Myc (MYC) is a transcription factor that has 
been identified in several cases to be linked to cancer and which is currently being investigated 
as a cancer target.  c-Myc has been previously linked to the sensitization of melanoma cells to 
radiotherapy
107
.  DNA Fragmentation Factor Beta (DFFB) is a protein that when activated 
initiates DNA fragmentation and chromosome condensation
108
.  Lowered DFFB expression has  
 
Figure 41. Multidrug resistance profile of cell lines.  
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been linked with Oligodendrogliomas.
109
  Increased expression of alpha-actinins (including 
ACTN1 and ACTN4) has been identified in hepatocellular carcinomas.
110
  Profilin is an actin 
binding protein that has previously been shown to decrease cancer cell motility
111
 and suppress 
tumors.
112
  Ajuba (JUB) is a protein that is known to be essential to enter into mitosis.
113
  It has 
been found to interact with protein 14-3-3σ, a protein commonly silenced in cancers114. These 
are just a subset of links that can be made between this network (which contains a large number 
of motility effecting genes) and cancer. 
Additionally, IPA detected both the canonical pathways and cellular functions that were 
highly represented by the hypothetic markers.  These pathways and function are documented in 
Figure 43.  Several of these pathways and functions are linked to cancer.  With respect to 
pathways, the similarity of leukocyte extravasation to tumor cell extravasation has been 
 
Figure 42. Network of identified gene expression markers of multidrug resistance. (Red nodes are resistance 
genes and Green nodes are Sensitizing genes. 
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previously noted and reviewed.
115
  Agrin interaction and neuromuscular signaling have been 
shown to be affected by the mouse tumor suppressor protein Adenomatous Polyposis Coli 
(APC).
116
  Integrin signaling is known to be required for development and metastasis of 
cancer.
117
  With respect to the functions, cellular movement is needed for cancer spread, and 
cellular assembly and organization is required for any proliferating cell line. 
The high degree of linkage between the identified markers, their pathways, and their 
 
Figure 43. (a) Canonical pathways and (b) functions enriched with markers of multidrug resistance 
a) 
 
b) 
 
 84 
 
functions and cancer lend credence to the hypothesis that the identified genes are in fact related 
to multidrug resistance.   
4.3.3. Correlation of GI50s and Marker Expression 
Based on our separation of resistance into a multidrug component and a drug specific 
component, we expected that several chemicals contained within the dataset would behave 
differently than projected by multidrug markers. To detect these compounds, we correlated the 
gene expression for the selected multidrug resistance and sensitizing genes to the pGI50 values 
for compounds across the 59 cell lines.  Using these correlation values, the compounds were 
clustered using Partek Genomics Suite‘s118 hierarchical clustering with Euclidean distance and 
average linkage. (See Figure 44a.) 
Chemicals are clearly segregated into two clusters: one comprised of 2933 compounds whose 
pGI50 values correlate as expected with the expression of selected generic resistance and 
sensitivity genes and one comprised of 622 compounds whose pGI50 values in general do not 
correlate as expected.  While these two classes were apparent when clustering was done on the 
correlation values, they were not evident when the chemicals were clustered using the 
normalized pGI50 values (Figure 44b) or two sets of chemical descriptors (Figure 44c,d). 
While the two noted classes are the most glaring result of the clustering, the heatmap also 
indicated that there is still variation within the 2933 compounds that generally have expected 
behavior.  These variations could also be related to gene expression effects.  Unfortunately, these 
deviations were not addressed in this study. 
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Figure 44.  Clustering results of the NCI-60 compounds based on (a) correlation of pGI50 values and gene expression 
of multidrug resistance markers, (b) Normalized pGI50 values, (c) MACCS keys, and (d) MOE2D descriptors 
b) 
 
c) 
 
d) 
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4.3.4. Prediction of Aberrant Behavior  
While it can be expected that the resistance of a cell line to a chemical can usually be 
understood by an estimate of a cell line‘s generic hardiness, it is not surprising that some 
compounds may have specific interactions that allow them to exhibit cellular growth inhibition 
profiles that are uncommon.  As global similarity in chemical descriptor spaces appeared to be 
insufficient for predicting which compounds would elicit abnormal growth inhibition profiles, 
we built a QSAR to aid in this task.   
The imbalance in the dataset provided a significant complication to the modeling.  To 
address this imbalance, three methods for down-sampling the overrepresented class patterned 
after those used in a recent unpublished study of anti-malarial compounds were applied: random 
selection of five folds of the overrepresented class, selection of compounds from the 
overrepresented class most similar to underrepresented class, and selection of two neighbors 
from the overrepresented class for each member of the underrepresented class.  These down 
sampling techniques were applied after five-fold extraction of validation sets to ensure 
accuracies would be comparable.   
 Since we were applying Random Forests, our QSAR modeling was consensus in nature.  
This being the case, each compound was predicted with a numeric value between 0.0 and 1.0 
with 0.0 representing high consensus that a compound was normal, 1.0 representing high 
consensus that a compound was aberrant, and 0.5 indicating that there was no consensus amongst 
models.  While typically a threshold at 0.5 is used to separate active and inactive predictions, 
there are times where compounds with numeric values near 0.5 are thrown out.  To define the 
level of agreement required, an agreement threshold was defined such that if the agreement 
threshold were 0.1, only compounds with numeric values above 0.6 would be considered 
a) 
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aberrant while compounds with numeric value below 0.4 would be considered normal.  
Compounds with predicted numeric value between 0.4 and 0.6 are eliminated.   
 Figure 45 presents the prediction accuracy in terms of CCR and the coverage when 
predicting the validation sets as a function of the agreement threshold.  As expected the 
prediction accuracy increases as the compounds with lower levels of consensus are removed.  No 
method of down-sampling appears to be definitively superior to another.  Additionally, only a 
small number of the compounds (roughly 10%) can be accurately identified as being aberrant 
using only information from their chemical structure.  This is understandable considering there 
are likely a large number of ways for a compound to elicit a resistance profile that cannot be 
predicted based on the selected markers of multidrug resistance.  As such, it is likely that the 622 
 
Figure 45. Validation set prediction accuracy and coverage for QSAR prediction of aberrant compounds. 
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compounds identified as having aberrant behavior in this study only sparsely populate the 
pathways that modulate resistance in a chemical specific manner. 
4.3.5. Genetic Markers of Aberrant Compounds   
As the causes of compound specific resistance remain unknown, SAM analysis was applied 
to the resistance profile of each compound in the aberrant set.  Genes with less than a 1% median 
FDR were identified as potential biomarkers for a chemical‘s specific resistance profile.  While 
no genes were found for nearly half of the chemicals at this cutoff, 58000 gene-compound pairs 
were identified.  The amount of overlap of genes between chemicals was measured.  Figure 46 
shows the distribution of overlap in gene expression markers for chemicals.   
Figure 46 clearly shows that very little overlap occurs between potential biomarkers of 
specific chemical resistance within the aberrant set and this plot omits the nearly 130 thousand 
 
Figure 46. Infrequency of overlap in resistance genes of aberrant compounds. 
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pairs for which there were zero gene overlaps.  To determine if chemical similarity would be 
capable of predicting which chemicals would overlap in the resistance genes, we plotted for the 
three nearest 
neighbors of 
each compound 
the Tanimoto 
similarity of 
compound 
pairs in FCFP-
4 space against 
the count of 
their 
overlapping resistance genes.  This plot (displayed in Figure 47) clearly shows that the 
correlation between similarity and overlap is very weak.  
4.4. Conclusions and Future Directions 
During analysis of the NCI-60 dataset to identify gene expression markers of resistance, 
multiple tasks were completed. 
1. An unbiased method was defined for quantifying the multidrug resistance potential of 
a cell line. (Section 4.3.1) 
2. SAM was used to identify 361 genes whose expression appears linked to multidrug 
resistance (Section 4.3.1) 
 
Figure 47. Scatterplot of the number of overlapping genes vs the chemical similarity for 
pairs of neighbor compounds 
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3.  These potential biomarkers were analyzed for their biological significance and 
connections to one another thereby implicating several functions in the conference of 
resistance. (Section 4.3.2) 
4. Compounds having drastically different responses than expected based on expression 
of multidrug resistance markers were identified. (Section 4.3.3) 
5. QSAR analysis was completed indicating that only a small portion of aberrantly 
behaving compounds can be predicted based on structure. (Section 4.3.4) 
6. 58000 chemical-genes resistances were hypothesized. (Section 4.3.5) 
These results provide the basis for a great deal of experimental validation.  In addition to 
experimental validation of the hypothetical genes that were identified in this study, there are 
computational studies that could be carried out to refine the selection of markers.  In particular, 
the treatment of genes as individual entities during identification of markers ignored knowledge 
of how the genes work as a network.  While the identified genes appear to be highly connected in 
networks, by quantifying the differences in these networks between cells rather than the 
expression of individual genes, greater insight may be possible.  Instead of selecting genes that 
appear linked to resistance phenomenon and building the networks with these blocks, it would be 
more logical to directly link alterations in networks to resistance.  Difficulties in appropriately 
quantifying the fluctuations in a network prevented us from carrying out this study. 
Ability to predict compounds for which there would be specific resistance effects eluded us 
for a large portion of our dataset.  This appears to be a limitation in either the dataset or in the 
methods applied to it.  It may be that a local approach to modeling of this data would lead to 
more predictive models since we consider the causes of specific chemical resistance to be very 
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local in nature.  Inclusion of compounds eliminated because they were not tested against every 
cell line could expand the dataset and increase understanding of different resistance profiles. 
  
 
Chapter 5: Chembench 
5.1. Introduction 
Thanks in large part to publicly funded efforts, there has been an accumulation of bioactivity 
data in the public domain. The size and complexity of databases containing this data rivals that 
of the large biological datasets that established the need for bioinformatics. However, the rapidly 
growing data about interactions of small-molecule probes with biological systems remain largely 
underexplored because of the absence of appropriate public domain tools for their analysis. This 
is particularly distressful given the significance of chemical biology for understanding the 
functions of living organisms. 
Within the last decade, cheminformatics has emerged as a burgeoning discipline combining 
computational, statistical, and informational methodologies with some of the key concepts in 
chemistry and biology.
119-121
 We describe modern cheminformatics broadly as a chemocentric 
scientific discipline encompassing the creation, retrieval, management, visualization, modeling, 
discovery, and dissemination of chemical knowledge.  Cheminformatics plays a critical role in 
understanding the fundamental problem of structure-property relationships and therefore applies 
to almost any area of chemical and biological research.  Similar to the role that bioinformatics 
has played in transforming modern biomedical research, cheminformatics is poised to 
revolutionize all areas of research in chemical genomics and drug discovery.  
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While cheminformatics 
has been recognized as a 
distinct, impactful scientific 
discipline, there is a painful 
absence of cheminformatics 
tools in the public domain.  
While some advancement 
was stimulated by the NIH 
cheminformatics planning 
grants awarded to six 
research groups nationally in 
2006, the majority of 
attainable cheminformatics 
tools (see Table 2) can 
perform only rudimentary 
functions; even the most 
advanced of the accessible 
tools lack thorough 
validation protocols, are 
poorly integrated with each 
other, or require specialized 
knowledge to apply them.  Therefore, we chose to develop Chembench, a web portal providing 
access to several techniques used within the field of cheminformatics.  
Table 2. Limited cheminformatics resources available online or for 
download (mostly free to academia) 
Repository Website Cheminformatics Capabilities 
RECCR http://reccr.chem.rpi.edu  
Multiple Modeling Methods 
Descriptor Generation (paid) 
PowerMV 
http://nisla05.niss.org/Po
werMV/  
Multiple Modeling Methods 
Descriptor Generation 
Calculation of Drug-like 
Properties 
Cheminfor-
matics.org 
http://www.cheminform
atics.org/  
Similarity Search 
Diversity Estimation 
Molinspira-
tion 
http://molinspiration.co
m/  
Calculation of Drug-like 
Properties 
Prediction of Drug Class 
Indiana 
http://sites.google.com/si
te/davidjwild/home  
Similarity Search/ 
Data Extraction 
PubChem 
http://pubchem.ncbi.nlm
.nih.gov/  
Heatmap Generation  
Similarity Search/Clustering 
ChemSpider 
http://www.chemspider.
com/  
Prediction  of Properties 
(ACD/Labs) Similarity Search 
VCCLab http://www.vcclab.org/  
Prediction of a Property 
Descriptor Calculation 
Multiple Modeling Methods 
Laboratoire 
d'Infochimie 
http://infochim.u-
strasbg.fr/recherche/Do
wnload/Download.php  
Fragment Generation 
MLR modeling 
Prediction of Biological Activity 
SEA http://sea.bkslab.org/  Prediction of Biological Activity 
Mold2 
http://www.fda.gov/Scie
nceResearch/Bioinforma
ticsTools/Mold2/default.
htm  
Descriptor Generation 
Chemistry 
Developmen
t Kit (CDK) 
http://sourceforge.net/ap
ps/mediawiki/cdk/index.
php?title=Main_Page  
Descriptor Generation 
Multiple Modeling Methods 
QSAR appli- 
cation 
Toolbox 
http://www.oecd.org/doc
ument/23/0,3343,en_264
9_34379_33957015_1_1
_1_1,00.html  
Prediction of Biological Activity 
Similarity Search 
Data-Gap Filling 
Chemaxon 
http://www.chemaxon.c
om/free-software/  
Calculation of Drug-like 
Properties 
Similarity Searching (Free) 
Clustering (paid) 
Pipeline 
Pilot 
Student 
http://accelrys.com/solut
ions/industry/academic/s
tudent-edition.html  
Calculation of Drug-like 
Properties 
Clustering 
Fingerprint Generation 
Multiple Modeling Methods 
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5.2. Materials and Methods 
5.2.1. Chembench Architecture 
The Chembench 
system is quite 
complicated.  Figure 48 
contains a simplified 
representation of the 
Chembench system 
detailing general 
structure and 
component interaction.  
A brief summary 
follows.  
The front end is comprised primarily of JavaServer Pages (JSPs) with the occasional 
inclusion of an embedded java applet.  Information displayed by the JSPs typically is provided 
via session variables set by the stateful java classes.    User-provided input is processed via 
servlets and passed to stateful java classes when an action within the JSP is executed. 
Stateful java classes hold all the data with which a user interacts.  The majority of logic 
within Chembench is carried out within this part of the system.  Contained within is the job 
queuing system. 
Accessory classes manage the mundane tasks of the Chembench system.  The classes control 
all global constant definition, I/O operations, and error logging.  
 
Figure 48. Overview of Chembench architecture. 
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Workflows are a set of java functions that interface between the Chembench system and 
external programs.    Several external programs are needed to properly carry out 
cheminformatics analysis.  The workflows portion of code also contains standalone functions 
that carry out necessary functions of cheminformatics analysis that are not handled by external 
programs such as data format transformation. 
External programs perform the primary actions of cheminformatics analysis of data. Many of 
these programs are commercial and provided through the generous support of software 
contributors.  External software generates chemical images, calculates descriptors, splits datasets, 
and develops models.   
Information about the users, datasets, models, predictors, predictions, and tasks are all stored 
within a MySQL database.  Stateful java classes access this database is accessed through 
Hibernate.   
5.2.2. Integrated Methods 
A large number of external programs have been integrated into the Chembench system.  This 
allows users to perform a series of cheminformatics analyses.  The general workflow of data 
analysis implemented within the system can be seen in Figure 49 taken from Tropsha‘s recent 
review of QSAR best practices. 
84
   
The key steps of the QSAR modeling process are outlined in Figure 49.  In Chembench, we 
have integrated software to standardize structures, split datasets, calculate descriptors, perform y-
randomization, build models, and enforce applicability domains.  Generally, these tasks are 
implemented in a modular manner, allowing users to mix and match techniques in each category 
with members of other categories.  As such, Chembench users can undertake a large number of 
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varying QSAR analyses, and variables in the process can be analyzed individually for their effect 
on modeling accuracy. Below is described in more detail the techniques that have been 
integrated into the system. 
5.2.2.1. Structure Curation 
The importance of structure curation and harmonization has been recently documented
122
.  
The accuracy of chemical structure representation may have a profound effect on the outcome of 
cheminformatics studies.  Therefore, we have devised a standardized chemical data curation 
strategy that should be followed at the onset of any molecular modeling investigation.    Figure 
50 illustrates major steps of this strategy enabled by several publicly available and free-for–
academic-use tools. The simple, but important, steps for cleaning chemical records in a database 
include the removal of a fraction of the data that cannot be appropriately handled by 
 
 
Figure 49. Flow of data in QSAR analysis as implemented in Chembench (taken from Tropsha
45
) 
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Figure 50. General dataset curation workflow. 
conventional 
cheminformatics techniques, 
e.g., inorganic and 
organometallic compounds, 
counterions, salts and 
mixtures; structure validation; 
ring aromatization; 
normalization of specific 
chemotypes; curation of 
tautomeric forms; and the deletion of duplicates.  It is also critical to visualize and manually 
inspect at least a fraction of chemical data that go into model development.   
The current version of Chembench does not have a fully integrated data curation procedure; 
however, portions have been integrated.  The Standardizer component from ChemAxon‘s 
Suite
123
 of cheminformatics products is used to perform normalization of chemical structures 
upon user request.  Structures can then be manually inspected once a dataset is uploaded. 
5.2.2.2. Data Splitting and Validation 
As detailed in the dataflow overview in Figure 49, the Chembench website relies on the three 
way split of datasets into training, test, and external sets.  Training sets are used for model 
generation.  Test sets are used for model analysis and selection.  External sets are used to 
validate the predictive power of the ensemble models.   
Currently, there are two methods of dataset splitting available in Chembench.  The most 
intuitive is the random split technique that randomly divides the dataset into two subsets whose 
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proportions are determined by the user.  This random split technique can be tempered by use of 
activity binning to ensure that both subsets have similar activity profiles.   
The second technique is that of Sphere Exclusion
83
 originated in our lab.  This algorithm 
considers each compound as a point in the multidimensional descriptor space. The procedure 
starts with the calculation of the distance matrix D between representative points in the 
descriptor space.  Let Dmin and Dmax be the minimum and maximum elements of D, respectively.  
N sphere radii are defined by the following formulas,  Rmin=R1=Dmin, Rmax=RN=Dmax/4, Ri=R1+(i-
1)*(RN-R1)/(N-1), where i=2,…,N-1.  Each sphere radius corresponds to one division of the set 
in training and test set.  A sphere-exclusion algorithm consists of the following steps.   
1. Select randomly a compound.    
2. Include it in the training set.   
3. Construct a sphere around this compound.   
4. Select compounds from this sphere and include them alternatively into test and 
training sets.   
5. Exclude all compounds from within this sphere for further consideration.   
6. If no more compounds left, stop.  Otherwise let m be the number of spheres 
constructed and n be the number of remaining compounds. Let dij (i=1,…,m; 
j=1,…,n) be the distances between the remaining compounds and sphere centers. 
Select a compound corresponding to a user defined rule. 
To properly assess the robustness of generated models, models are also always generated for 
y-randomized data.  Statistics of y-randomized models can then be directly compared to those 
generated on the true data and the significance of generated models can be determined. 
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5.2.2.3. Descriptor Generation 
The generation of Combi-QSAR models requires the calculation of multiple descriptor 
types in addition to multiple modeling methods.  Chembench provides the methods of descriptor 
generation detailed below.  After generation, the descriptors can be normalized either by range-
scaling (so that their values are distributed within the interval 0-1) or auto-scaling (subtraction of 
the mean and then division by the standard deviation).  Additionally highly correlated descriptors 
can be removed. 
DRAGON Descriptors. The DragonX software
124
 is used to calculate all 2D Dragon 
descriptors. These included topological descriptors, constitutional descriptors, walk and path 
counts, connectivity indices, information indices, 2D autocorrelations, edge adjacency indices, 
Burden eigenvalues, topological charge indices, eigenvalue-based indices, functional group 
counts, atom-centered fragments and molecular properties. DragonX can calculate descriptors for 
either hydrogen depleted or hydrogen containing representations of a compound. 
MolconnZ Descriptors. The MolconnZ software
125
 available from EduSoft affords the 
computation of a wide range of topological indices of molecular structure. These indices include, 
but are not limited to, the following descriptors: valence, path, cluster, path/cluster and chain 
molecular connectivity indices
126-128
, kappa molecular shape indices
129, 130
, topological
131
 and 
electrotopological state indices
132-135
, differential connectivity indices
126, 136, graph‘s radius and 
diameter
137
, Wiener
138
 and Platt
139
 indices, Shannon 
140
 and Bonchev-Trinajstić141 information 
indices, counts of different vertices, counts of paths and edges between different types of vertices 
(http://www.edusoft-lc.com/molconn/manuals/400).  
 100 
 
MOE2D Descriptors. MOE software
142
 is used to generate MOE2D descriptors. These 
included physical properties, subdivided surface areas, atom and bond counts, Kier and Hall 
connectivity
126-128
 and kappa shape indices
130, 143
, adjacency and distance matrix descriptors
138, 
144-146
, pharmacophore feature descriptors, and partial charge descriptors
147
.  
MACCS keys.  MOE software
148
 is used to generate MACCS keys.  MACCS keys consist of 
a set of 166 chemical rules commonly associated with biological activity.  This fingerprint was 
first developed by MDL.   
5.2.2.4. Model Development 
Three methods of model generation are currently available in Chembench.  Of these three 
techniques, one has been fully developed and its effectiveness has been validated in our lab.  
Two of these techniques are modifications upon techniques developed elsewhere and modified to 
enable integration into the Chembench system. 
Variable Selected kNN.  The first method implemented in Chembench was the variable 
selected kNN procedure first introduced in the field of cheminformatics in 2000 .
149
  This method 
has been applied in many situations to develop predictive models. 
The first version of kNN implemented in the system employed the leave-one-out (LOO) 
cross-validation (CV) procedure and a simulated-annealing algorithm
150, 151
 to optimize variable 
selection. The procedure starts with the random selection of a predefined number of descriptors 
from all descriptors. If the number of nearest neighbors k is higher than one, the estimated 
activities ŷi of compounds excluded by the LOO procedure are calculated using the following 
formula: 
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where yj is the activity of the j-th compound. Weights wij are defined as: 
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and dij is Euclidean distances between compound i and its j-th nearest neighbor. However, if 
the number of nearest neighbors k is equal to one, then the estimated activity ŷi of the compound 
will be equal to the activity of this one nearest neighbor. 
For classification kNN, the predicted iyˆ  values (see Equation 7) are rounded to the closest 
whole numbers (which are, in fact, the class numbers), and the prediction accuracy (correct 
classification rate, CCRtrain) is calculated as follows: 
total
corr
total
corr
N
N
N
N
CCR
2
2
1
15.0      (9) 
where 
corr
jN and 
total
jN are the number of correctly classified and total number of compounds 
of class j (j=1, 2). Then, a predefined small number of descriptors are randomly replaced by 
other descriptors from the original pool, and the new value of CCRtrain is obtained. If CCRtrain 
(new) > CCRtrain (old), the new set of descriptors is accepted. If CCRtrain (new) ≤ CCRtrain (old), 
the new set of descriptors is accepted with probability p = exp (CCR (new) - CCR (old))/T, or 
rejected with probability (1-p), where T is a simulated annealing (SA) ―temperature‖ parameter. 
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During this process, T is decreasing until a predefined threshold. Thus, the optimal (highest) 
CCRtrain is achieved. For the prediction, the final set of selected descriptors is used, and Equation 
7 and 8 are applied to predict activities of compounds of the test sets. Then the activities are 
rounded to the closest whole numbers, and the correct classification rate for the test set is 
calculated using Equation 9. 
For continuous kNN, this procedure is maintained, but the optimization function is changed 
from CCR to q
2
.  q
2
 is calculated according to Equation 10.   
     (10) 
In addition to the simulated annealing procedure for variable selected, we have recently 
added the genetic algorithm (GA)
152
 method of optimization.  Rather than starting with a single 
randomly selected set of descriptors, the genetic algorithm is initiated with a population of 
different randomly selected descriptors.  Similar to SA, the fitness of member of the population 
is calculated using Equation 9 or 10 for classification or continuous modeling respectively based 
on predicted values determined using a LOO-CV procedure and Equations 7 and 8.  A second 
generation of the population is spawned through breeding (crossover) of parents selected based 
on their fitness.  Generation will continue to be spawned until a predefined number of 
generations have been created or none of the members of the population have become more fit in 
a set number of generations.   
Support Vector Machine. A common learning technique applied in the field of data 
classification is that of Support Vector Machines (SVM).  SVM was developed by Vapnik
153
 as a 
general data modeling methodology where both the training set error and the model complexity 
are incorporated into a special loss function that is minimized during model development.  SVM 
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has been extended to afford the development of SVM regression models for datasets with 
continuous activities.  It has been used in several QSAR applications.
154, 155
 
To provide access to SVM learning, we have integrated the LIBSVM package
156
 in 
Chembench.  LIBSVM provides several SVM variants including traditional SVM (C-SVC), 
Regression SVM (epsilon-SVR), and nu-SVM implementation for both classification and 
regression.  LIBSVM also provides several kernels for transformation of the descriptor space.  
Our own grid modeling technique was implemented on top of LIBSVM to generate ensembles of 
SVM models. 
Random Forest.  Random forest is a technique developed by Breiman
157
 that builds series of 
decision trees based on a dataset and then uses them as an ensemble predictor.  Typically, the 
optimal decision tree is generated for a randomly selected subset of a dataset and a randomly 
select subset of descriptors.  This typical implementation of random forests is unfortunately not 
modular as it requires a specific implementation of dataset splitting.  Therefore, a variant of 
random forests with alterations to internal training and test set selection was done to maintain the 
modular nature of modeling within Chembench so splitting techniques can be altered without 
variation of learning methods.   
The modified random forest procedure in Chembench is quite similar to the traditional 
application of random forest but varies in the way that modeling set selection is done.  Rather 
than a new training set being selected for each new tree grown, a manageable number of internal 
training sets are defined and then multiple trees (a grove) grown for each of these sets.  
Additionally, these sets are selected without replacement.  The generation of groves is done 
using the randomForest package for R available from http://stat-
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www.berkeley.edu/users/breiman/RandomForests. The original implementation of random 
forests can be mimicked by performing a large number of data splits and generating only a single 
tree for each split. 
5.3. Results and Discussion 
The Chembench web portal was officially released to the public in April of 2010 at 
http://chembench.mml.unc.edu.  Users upon entering the site can choose to either register or to 
use the system as a guest.  Guest users have all the capabilities of registered users, but their data 
objects are subject to periodic deletion and their data is accessible by any other guest user.   
The capabilities of the website consist of functions organized around 3 key components of 
the QSAR workflow: Datasets, Modeling, and Prediction.  These three components become the 
objects generated within the portal upon use of three tabs containing forms controlling their 
generation.  An additional tab (My Bench) allows management and further analysis of these 
three types of objects.  
5.3.1. Datasets 
Datasets are generally the entrance point for users to a cheminformatics analysis.  A dataset 
is required for a user to develop a model or make predictions (though the inclusion of public 
datasets and models allows Chembench users to bypass this step).   
5.3.1.1. Dataset Creation 
The Chembench interface for dataset uploading allows many options for users inputting their 
data.  The primary option is the type of dataset a user would like to upload.  Users can choose to 
upload modeling and prediction sets either with or without pre-calculated descriptors.  Modeling 
sets require the inclusion of an activity value for each compound, allowing the generation of 
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models.  Users are required to designate whether activity values are continuous or categorical in 
nature. Prediction sets can consist of purely structural data meant to be annotated by previously 
generated predictors.  The inclusion of pre-calculated descriptors allows users to compare their 
own descriptor generation packages to those integrated in the Chembench framework.  If for 
confidentiality reason, a user wishes to use the site without uploading chemical structures, they 
can upload a set with no structure file, but pre-calculated descriptors.  However, this precludes 
the use of the integrated descriptor generation techniques and the use of the system for 
commercial calculations is prohibited.  Upload format standards are defined in the help 
documentation. 
 When uploading the dataset, users are expected to define an external set.  This external 
set will be extracted from the uploaded set by random selection.  For users that have already 
defined an external set outside the Chembench site, input of a list of identifiers is provided to 
ensure comparability of Chembench results to those of nonintegrated methods. 
 Once a dataset is named and the form is submitted, a series of data checks are done to 
ensure that formatting of the uploaded data files is correct.  Additionally, identifiers are checked 
for uniqueness and are matched across all uploaded files to verify their capability to be used as a 
key.  Once data compatibility with the Chembench system has been validated, the dataset is 
created; the external set is defined; descriptors are calculated; and 2D chemical images are 
generated. 
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5.3.1.2. Dataset Inspection 
Once a dataset has been created in Chembench, it can be accessed via the My Bench page.  
Also, it will be populated in lists of datasets on the Modeling and Prediction pages where 
relevant.   
Selection of a dataset on the My Bench page will allow user to inspect several aspects of 
their dataset.  All compounds are contained in a table so users can manually ascertain the 
correctness of interpretation of their upload structures.  The selected external set can be viewed.  
A histogram of the activity values uploaded for the dataset is provided.  A heatmap of 
Mahalanobis distance or Tanimoto similarity between compounds in MACCS key space is 
available.  Finally, any warnings or errors in descriptor generation are provided to the user for 
consideration prior to modeling. 
5.3.2. Modeling 
The modeling step is considered the primary contribution of Chembench to the public.  
Modeling is complex and option rich.  It depends on the consistency and accuracy of the 
uploaded dataset and is required for identification of compounds of interest from chemical 
library.  To better distinguish the difference between individual models generated and the 
ensemble models (i.e. the consensus of individual models), with in Chembench the latter is 
referred to as a ―predictor‖. 
5.3.2.1. Model Generation   
The initiation of model generation depends on the selection of a dataset.  Modeling datasets 
are segregated into two groups, continuous sets and category sets, because the applicability of 
modeling techniques and parameters of the modeling techniques are dependent on that 
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designation.  All datasets available for modeling are provided in a drop-down list for selection 
with user uploaded datasets being listed first.   
Once a user has selected a dataset, they can choose the descriptor type that they would like to 
use for model generation.   Descriptor types for which at least one compound in the dataset could 
not be generated are grayed out and not selectable.  If a user desires to apply a grayed out 
descriptor type, they must address the issues identified in the ―Descriptor Warnings‖ section 
when they view that dataset.  The descriptors selected for model development can be additionally 
processed by eliminating highly correlated descriptors and by normalizing descriptors using 
either range-scaling or autoscaling. 
The internal splitting of the dataset can be accomplished using either random splitting or 
sphere exclusion.  Both methods allow the user to specify the number of splits to generate and 
the approximate size of the test sets.  Additional parameters of the sphere exclusion method are 
made available to users on its tab. 
The modeling method section of the page allows users to select from the currently supported 
methods of model generation.  Each method has its own tab which when selected provides access 
to the many parameters necessary to control the model development algorithm.  Default values 
for all these parameters are provided based on the modeling experience of the site developers and 
parameter limitations are enforced to prevent improper parameter inputs.   
5.3.2.2. Predictor Review 
Once a predictor name is defined and the job is submitted, it will be sent to the queue and 
modeled will be completed either locally or on the emerald computing cluster depending on the 
modeling type.  Job progress can be tracked on the My Bench page.  Upon job completion, it can 
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be accessed through the My Bench page and users will be notified via email (if requested on 
submission).  It will also be made available to that user as a predictor on the Prediction page. 
Accessing a predictor from My Bench allows users to see several aspects of the modeling 
results.  Of most interest is the prediction accuracy of the predictor on the external set.  A table is 
provided containing the predicted value, actual value, residual, and number of models applicable 
for each compound of the external set.  A summary of this information is contained either in a 
confusion matrix for categorical modeling or a plot of predicted vs. actual values for continuous 
modeling.  The correct statistic (either CCR or R
2
) is calculated to provide a quantitative 
assessment of the predictor‘s accuracy.  In addition to external results, internal modeling 
information is recorded in the models or trees tab.  Herein, the statistics of the individual models 
that compose the ensemble are provided.  Also, the results of model generation using Y-
randomized activities are provided so the user can validate that the models generated using the 
correct data are significantly better than those using y-randomized activities.  Finally, the model 
generation parameters are displayed to remind the user of the protocol applied.  
5.3.3. Prediction 
While modeling is the expertise of the authors of the Chembench web portal, the most 
publicly beneficial portion of the site may be the Prediction tab.  Here, users can quickly and 
easily identify compounds that are expected to have properties of interest.   
Prediction is a two-step process.  First a user must select the predictors they would like to 
use.  These predictors are separated into private (the predictors that user has generated) and 
public (the predictors provided by the authors).  Public predictors are categorized by the type of 
activity (specific target interaction, toxicity, or ADME related properties) that they predict. 
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Multiple predictors can be selected for a single prediction allowing users the ability to see a 
spectrum of predicted activities if they desire.  Once a user has selected the predictor(s) that they 
wish to apply, they then are given the opportunity to predict either a previously uploaded dataset 
or a single compound defined by a SMILES string or drawn in MarvinSketch applet. All 
prediction jobs are submitted to the queue and can be accessed on completion from the My 
Bench page.  Prediction results are paginated and can be sorted on any of the predicted values.   
5.3.4. Additional Features 
The Chembench web portal has several components and aspects that are vital for its function 
but not directly related to cheminformatics analysis of data.   
One of the most important aspects of the website is that it is user specific.  User sessions are 
created upon login.  All objects within Chembench are linked to a user.  This allows the website 
to protect the private data of individual users.  It also enables the customization of interfaces for 
users depending on their level of expertise.  Several parameters available for tuning of model 
building are only of interest to experts in the field of cheminformatics.  Display of these 
parameters can be turned on and off under a user‘s profile.  The amount of public data a user 
wishes to access can also be modified.  Also, the definition of users allows the ability to provide 
special access to data for some.  In particular, the ability to download descriptors can be enabled 
for users with the appropriate software licenses.  The user system also provides interface for 
administrative actions within Chembench.  Users defined as administrators can view and control 
many aspects of the system including canceling of other user‘s jobs.  However, the most 
important aspect of the user oriented aspect of Chembench is that it allows users to submit jobs 
and easily retrieve them at a later time. 
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The queue component of the system enables the efficient use of computational power.  
Chembench is hosted on an 8 processor system managed by ITS research computing at UNC.  It 
is linked to the Emerald computing cluster, which has more than 800 processors.  While the 
available computing power is large, shorter jobs are much more efficiently handled by the local 
system whereas larger jobs typically are better treated on the cluster.  As such, the queue in 
Chembench has been designed to handle different types of jobs in different ways.  It has also 
been structured to allow the easy addition of other computational resources. The design of the 
queue provides users with fast and efficient generation of their models and prevents jobs from 
overrunning the host server and causing portal usability issues.   
The most important piece of the Chembench portal is that it has developed a user base.  
There are now over 200 registered users of the Chembench site and frequently multiple users are 
logged on at once.  In total the site has run over 9000 jobs and provided nearly 11.5 years of 
compute time to the public. 
5.3.5. Public Datasets and Models 
Chembench was originally intended as a way to provide access to the results of work within 
the Tropsha lab to the public.  As such, the site is populated with many datasets generated or 
used within our lab as well as several validated and published predictors.  Table 3 and Table 4 
list the datasets and predictors currently available via Chembench.   
The lack of availability of the datasets and predictors generated as part of the development of 
a benchmark for virtual screening detailed in Chapter 3 is an omission caused by the fact that we 
are in the process of upgrading the site to handle datasets with multifold external sets.  As such, 
these datasets and predictors will be available shortly.  Also, the addition of the random forest 
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and SVM modeling algorithms to the site has been recent.  Several predictors reliant on these 
methods are currently waiting reformatting for input into the Chembench framework. 
5.4. Conclusions and Future Directions 
We have completed the following key steps in the generation of web portal to allow the 
application of cheminformatics techniques by worldwide users.   
1. Integration of cheminformatics software for structure standardization, descriptor 
generation, model development, and prediction (Sections 5.3.1-5.3.3) 
2. Development of a queuing system to manage cluster and local job (Section 5.3.4) 
3. Creation of an easy-to-use interface allowing experts and non-experts in 
cheminformatics access to needed tools (Section 5.3.4) 
4. Publication through the portal of more than 50 datasets and 7 validated predictors 
(Section 5.3.5) 
Table 3. Selected datasets made available through Chembench 
Dataset Name 
Number of 
Compounds 
Reference Description 
HDAC_59 59 
J Chem Inf Model. 
2009 Feb;49(2):461-
76. 
A set of 59 hdac inhibitors used to generate models as 
discussed in the above referenced article. 
Ames_Mutagenicity 6542 Pending 
A set of 6452 compounds with a binary assessment of 
the mutagenic liability. 
T.Pyriformis_Mod 983 
http://dx.doi.org/10.1
021/ci700443v 
The set of 983 compound with measured values of 
toxicity against T.Pyriformis used for modeling in the 
above reference. 
T.Pyriformis_Ext2 110 
http://dx.doi.org/10.1
021/ci700443v 
The set of 110 compounds with measured values of 
toxicity against T.Pyriformis used as a second validation 
set in the above reference. 
Drugbank 4494 
http://www.drugbank
.ca 
A set of 4494 compounds retrived from Drugbank after 
standardization, cleaning, and de-duplication. 
P-Glycoprotein 195 
http://dx.doi.org/10.1
021/ci0504317 
A set of 195 substrate/non-substrates for P-Glycoprotein 
used as a modeling set in the linked reference. 
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This site provides access to methods commonly used in the field of cheminformatics through 
a simple user interface that can be tailored to allow more advanced usage.  Additionally, the site 
contains several predictors of biological properties that could be used by non-experts in the field 
of cheminformatics to assess compounds of interest prior to synthesis or experimental testing.    
Table 4. Predictors made available through Chembench 
Predictor Name 
Modeling 
Method 
Descriptor 
Type 
Predictor Class Description 
48_ 
ANTICONV 
KNN 
MOLCONN
Z 
DrugDiscovery 
This predictor is a regeneration of the SA-kNN models 
developed by M Shen; et al in 
http://dx.doi.org/10.1021/jm030584q.  These models 
built using 48 Functionalized Amino Acids (FAAs) 
predict the log(ED50 Âµmol/kg) of chemicals in the 
mice Maximal Electroshock Seizure (MES) test. 
T.Pyriformis KNN 
MOLCONN
Z 
Toxicity 
This predictor contains the kNN-MolconnZ models 
generated by H Zhu; et al in 
http://dx.doi.org/10.1021/ci700443v.  These models 
built using 983 compounds (644 training/339 external 
test) predict aquatic toxicity (pIGC50) against 
Tetrahymena Pyriformis. 
P-Glycoprotein 
_DragonkNN 
KNN DRAGONH ADME 
This predictor is the regeneration of models developed 
by P de Cerqueira Lima; et al in 
http://dx.doi.org/10.1021/ci0504317 using DRAGON 
descriptors with SA-kNN .  These binary models built 
using 195 compounds predict whether a compound will 
be a substrate for P-Glycoprotein (1) or will be a non-
substrate (0).  
Blood_Brain_Bar
rier_MZkNN 
KNN 
MOLCONN
Z 
ADME 
This predictor contains the  kNN-MolconnZ models 
generated by L Zhang; et al in 
http://dx.doi.org/10.1007/s11095-008-9609-0.  These 
models built using 159 compounds (144 training/15 
external test) predict the log(BB) in rats. . 
Anti-
Malarial_Dragon
kNN 
KNN DRAGONH DrugDiscovery 
This predictor is a collection of models generated in the 
Tropsha lab on a set of 3133 compounds screened for 
their antimalarial activities in St. Jude Children's 
Research Hospital. These binary models predict 
whether a compound will inhibit growth of the P. 
falciparum 3D7 strain (1) or not (0). 
5HT2B_Binder_
DragonkNN 
KNN DRAGONH Toxicity 
This predictor contains models generated using Dragon 
and kNN by R Hajjo; etal in 
http://dx.doi.org/10.1021/jm100600y.  These models 
built and validated using 304 compounds with 
binder/non-binder classification defined based on 
functional assays. 
RAT-ACUTE-
LD50_DragonkN
N 
KNN DRAGONH Toxicity 
This predictor contains models generated using Dragon 
and kNN by H Zhu; etal in 
http://dx.doi.org/10.1021/tx900189p.  These models 
built and validated using 3472 compounds predict 
Acute Toxicity (pLD50(mol/kg)) in Rats. 
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The creation of Chembench was completed in a multidisciplinary team headed by Dr. Diane 
Pozefsky.  The writing of the software was primarily completed by hiring of developers with a 
computer science background.  As the scientific lead on the team my primary contribution was in 
communication of the workflows used by cheminformaticians, training developers in 
cheminformatics software, and definition of user interface requirements.  In addition, I wrote the 
original version of the underlying MySQL database and was tasked with collection of public 
datasets and predictors.    
Development of the site is an ongoing project.  There are additional methods and techniques 
to be added to the site, in particular the integration of molecular descriptors that are not bound by 
license.  While we are grateful to software contributors for providing their tools for descriptor 
use within the site, allowing users to download descriptors would increase the usefulness of the 
web portal within the cheminformatics community. 
The integration of the website with repositories for biological data is undergoing 
development.  Creation of web service protocols allowing efficient transfer of data between 
ChemSpider and Chembench has been completed, but integration of the protocols into the user 
interface is still ongoing.  Completion of integration with ChemSpider will provide a proof of 
concept to aid the integration of Chembench with PubChem and other public databasing efforts.   
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Appendix I: Amino Acid to Feature Transformations 
Contained in this appendix is a table of the transformations used to generate features from 
amino acids.  For each amino acid fragment, the atoms selected as part of the binding pocket 
were transformed to features.  Seeing as some features contain more than one atom from an 
amino acid, as long as a portion of the atoms of that feature were contained in the defined pocket, 
the feature was included.  The location of the feature was calculated as the average of the atomic 
coordinates of atoms defined as being a part of the binding pocket which comprise that feature. 
Feature 
ID 
Residue 
Pharmacophore 
Feature 
Atom 1 Atom 2 Atom 3 Atom 4 Atom 5 Atom 6 
1 GLU - CD OE1 OE2 
   
2 ALA A OXT 
     
3 ALA H CB 
     
4 ALA D N 
     
5 ALA A O 
     
6 ARG A OXT 
     
7 ASN A OXT 
     
8 ARG H CB CG 
    
9 ASP A OXT 
     
10 CYS A OXT 
     
11 ARG + CZ NE NH1 NH2 
  
12 ARG D N 
     
13 ARG D NE 
     
14 ARG D NH1 
     
15 ARG D NH2 
     
16 ARG A O 
     
17 GLN A OXT 
     
18 HIS A OXT 
     
19 ASN H CB 
     
20 LYS A OXT 
     
21 ASN D N 
     
22 ASN A ND2 
     
23 ASN A O 
     
24 ASN A OD1 
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Feature 
ID 
Residue 
Pharmacophore 
Feature 
Atom 1 Atom 2 Atom 3 Atom 4 Atom 5 Atom 6 
25 MET A OXT 
     
26 PRO A OXT 
     
27 ASP H CB 
     
28 ASP - CG OD1 OD2 
   
29 ASP D N 
     
30 ASP A O 
     
31 ASP A OD1 
     
32 ASP A OD2 
     
33 SER A OXT 
     
34 TRP A OXT 
     
35 CYS H CB 
     
36 CYS D N 
     
37 CYS A O 
     
38 CYS A SG 
     
39 TYR A OXT 
     
40 ALA - C O OXT 
   
41 GLN H CB CG 
    
42 ARG - C O OXT 
   
43 ASN - C O OXT 
   
44 GLN D N 
     
45 GLN A NE2 
     
46 GLN A O 
     
47 GLN A OE1 
     
48 ASP - C O OXT 
   
49 CYS - C O OXT 
   
50 GLU H CB CG 
    
51 GLN - C O OXT 
   
52 GLU - C O OXT 
   
53 GLU D N 
     
54 GLU A O 
     
55 GLU A OE1 
     
56 GLU A OE2 
     
57 GLU A OXT 
     
58 GLY - C O OXT 
   
59 HIS - C O OXT 
   
60 GLY D N 
     
61 GLY A O 
     
62 GLY A OXT 
     
63 ILE - C O OXT 
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Feature 
ID 
Residue 
Pharmacophore 
Feature 
Atom 1 Atom 2 Atom 3 Atom 4 Atom 5 Atom 6 
64 LEU - C O OXT 
   
65 HIS H CB 
     
66 LYS - C O OXT 
   
67 MET - C O OXT 
   
68 HIS R CG CD2 NE2 CE1 ND1 
 
69 HIS D N 
     
70 HIS + ND1 
     
71 HIS + NE2 
     
72 HIS A O 
     
73 PHE - C O OXT 
   
74 PRO - C O OXT 
   
75 ILE H CB CG1 CD1 CG2 
  
76 SER - C O OXT 
   
77 THR - C O OXT 
   
78 TRP - C O OXT 
   
79 ILE D N 
     
80 ILE A O 
     
81 ILE A OXT 
     
82 TYR - C O OXT 
   
83 VAL - C O OXT 
   
84 LEU H CB CG CD1 CD2 
  
85 ASN D ND2 
     
86 ASN D OD1 
     
87 CYS D SG 
     
88 LEU D N 
     
89 LEU A O 
     
90 LEU A OXT 
     
91 GLN D NE2 
     
92 GLN D OE1 
     
93 LYS H CB CG CD 
   
94 HIS D ND1 
     
95 HIS D NE2 
     
96 LYS D NZ 
     
97 LYS D N 
     
98 LYS + NZ 
     
99 LYS A O 
     
100 SER D OG 
     
101 THR D OG1 
     
102 MET H CB CG 
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Feature 
ID 
Residue 
Pharmacophore 
Feature 
Atom 1 Atom 2 Atom 3 Atom 4 Atom 5 Atom 6 
103 MET H CE SD 
    
104 TYR D OH 
     
105 MET D N 
     
106 MET A O 
     
107 PHE H CB 
     
108 PHE H CG CD1 CE1 CZ CDE2 CD2 
109 PHE R CG CD1 CE1 CZ CE2 CD2 
110 PHE D N 
     
111 PHE A O 
     
112 PHE A OXT 
     
113 PRO H CB CG 
    
114 PRO A O 
     
115 SER D N 
     
116 SER A O 
     
117 SER A OG 
     
118 THR H CG2 
     
119 THR D N 
     
120 THR A O 
     
121 THR A OG1 
     
122 THR A OXT 
     
123 TRP H CB CG 
    
124 TRP R CG CD1 NE1 CE2 CD2 
 
125 TRP R CD2 CE2 CZ2 CH2 CZ3 CE3 
126 TRP H CD2 CE2 CZ2 CH2 CZ3 CE3 
127 TRP D N 
     
128 TRP D NE1 
     
129 TRP A O 
     
130 TYR H CB 
     
131 TYR R CG CD1 CE1 CE2 CD2 CZ 
132 TYR H CG CD1 CE1 CE2 CD2 
 
133 TYR D N 
     
134 TYR A O 
     
135 TYR A OH 
     
136 VAL H CB CG1 CG2 
   
137 VAL D N 
     
138 VAL A O 
     
139 VAL A OXT 
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Appendix II: Selected Clusters from the PDBBind Core 
Set 
Contained in this appendix is the list of PDBBind cluseters defined as containing a single 
protein using the criteria described in Section 2.3.5.  These proteins formed the dataset for a 
more accurate test of CoLiBRI‘s virtual screening capabilities. 
CLUSTER_ID PDB_ID NAME 
1 
1ps3 
3d4z 
2f7o 
ALPHA-MANNOSIDASE II 
2 
1amw 
1bgq 
2iwx 
HEAT SHOCK PROTEIN 90 
HEAT SHOCK PROTEIN 82 
5 
3cj2 
1nhu 
2d3u 
RNA-DEPENDENT RNA POLYMERASE 
7 
1ajp 
1ai5 
1ajq 
PENICILLIN AMIDOHYDROLASE 
8 
1gpk 
1h23 
1e66 
ACETYLCHOLINESTERASE 
9 
2rkm 
1b9j 
1b7h 
OLIGO-PEPTIDE BINDING PROTEIN 
10 
2qv4 
1u33 
1xd1 
ALPHA-AMYLASE 
11 
1uwt 
2ceq 
2cer 
BETA-GALACTOSIDASE 
12 
2qwb 
2qwd 
2qwe 
NEURAMINIDASE 
13 
2j77 
2j78 
2cet 
BETA-GLUCOSIDASE A 
14 
3ccw 
3cdb 
3cd5 
3-HYDROXY-3-METHYLGLUTARYL-COENZYME A 
REDUCTASE 
15 
3bra 
3ckp 
2g94 
BETA-SECRETASE 1 
16 
2qfu 
1x8r 
2pq9 
3-PHOSPHOSHIKIMATE 1-
CARBOXYVINYLTRANSFERASE 
18 
1n2v 
1k4g 
1s39 
QUEUINE TRNA-RIBOSYLTRANSFERASE 
TRNA GUANINE TRANSGLYCOSYLASE 
19 
1kv1 
2bak 
3e93 
MITOGEN-ACTIVATED PROTEIN KINASE P38  
MITOGEN-ACTIVATED PROTEIN KINASE 14 
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CLUSTER_ID PDB_ID NAME 
20 
2hu6 
3f19 
3f17 
MACROPHAGE METALLOELASTASE (MMP-12) 
21 
1ndw 
1ndy 
1ndz 
ADENOSINE DEAMINASE 
22 
1m2q 
1zoe 
2pvk 
CASEIN KINASE II 
24 
2v00 
5er2 
4er2 
ENDOTHIAPEPSIN 
25 
2qbp 
1nl9 
2azr 
PROTEIN-TYROSINE PHOSPHATASE 
PROTEIN-TYROSINE PHOSPHATASE 1B 
26 
2wec 
1bxq 
1bxo 
PENICILLOPEPSIN 
27 
2brb 
2c3j 
1nvq 
SERINE/THREONINE-PROTEIN KINASE CHK1 
28 
4tln 
1tmn 
4tmn 
THERMOLYSIN 
31 
2exm 
1b38 
1pxo 
CELL DIVISION PROTEIN KINASE 2 
33 
1qi0 
1w3k 
1w3l 
ENDOGLUCANASE B 
ENDOGLUCANASE 5A 
34 
1bcu 
1c1v 
1sl3 
THROMBIN 
37 
1jqd 
1jqe 
2aou 
HISTAMINE N-METHYLTRANSFERASE 
38 
1y1z 
1pb8 
1pbq 
N-METHYL-D-ASPARTATE RECEPTOR SUBUNIT 1 
39 
2obf 
1hnn 
2g71 
PHENYLETHANOLAMINE N-
METHYLTRANSFERASE 
41 
1p1q 
1syh 
1ftm 
GLUTAMATE RECEPTOR 2 
43 
1fcx 
1fd0 
1fcz 
RETINOIC ACID RECEPTOR GAMMA-1 
44 
1f4e 
1f4f 
1f4g 
THYMIDYLATE SYNTHASE 
45 
1yc1 
3ekr 
2uwd 
HEAT SHOCK PROTEIN HSP90-ALPHA 
46 
2osf 
2pow 
1if7 
CARBONIC ANHYDRASE II 
47 
2bok 
1mq6 
1nfy 
COAGULATION FACTOR X 
COAGULATION FACTOR XA 
48 
2usn 
2d1o 
1hfs 
STROMELYSIN-1 
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CLUSTER_ID PDB_ID NAME 
49 
2flr 
2b7d 
2bz6 
COAGULATION FACTOR VII 
COAGULATION FACTOR VIIA 
50 
1loq 
1lol 
1x1z 
OROTIDINE 5'-MONOPHOSPHATE 
DECARBOXYLASE 
52 
1uto 
1g3e 
1o3f 
TRYPSINOGEN 
TRYPSIN BETA 
53 
1jys 
1nc1 
1y6q 
MTA/SAH NUCLEOSIDASE 
54 
1bma 
1ela 
1elb 
ELASTASE 
55 
1pr5 
1a69 
1k9s 
PURINE NUCLEOSIDE PHOSPHORYLASE 
56 
3pce 
3pcn 
3pcj 
PROTOCATECHUATE 3 
57 
2pgz 
3c84 
2bys 
ACETYLCHOLINE-BINDING PROTEIN 
61 
6std 
2std 
3std 
SCYTALONE DEHYDRATASE 
62 
1jaq 
1zs0 
1zvx 
NEUTROPHIL COLLAGENASE (MMP-8) 
64 
2g8r 
1o0h 
1u1b 
RIBONUCLEASE PANCREATIC 
65 
1sv3 
1jq8 
2arm 
PHOSPHOLIPASE A2 
68 
1d7j 
1fki 
1fkb 
FK506 BINDING PROTEIN (FKBP) 
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Appendix III: Venn Diagrams of Pocket Overlap 
Contained in this appendix is the compendium of venn diagrams (as exemplified in Figure 11 
and 16) generated while assessing the consistency of pockets defined for different protein-ligand 
complexes of the same protein.  The figures are separated based on the technique used to identify 
the pocket.  There are 49 diagrams for protein-ligand tessellated pockets, 11 for CastP pockets, 
and 24 for SCREEN.  The reduced number of examples for the two latter methods is due to those 
methods not identifying the binding pocket for at least one of the protein-ligand complexes for a 
protein.  Overall the venn diagrams display that pocket detection with these methods is 
inadequate for consistent identification of the same protein pocket for the multiple 
representatives of a protein. 
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Appendix IV: Virtual Screening Dataset Selection Details 
Contained in this appendix is the detailed descriptions of how datasets were extracted, 
curated, and categorized for the ChEMBL and WOMBAT databases.  These descriptions are 
organized by target with ChEMBL extraction being discussed as the modeling/validation set and 
WOMBAT as the external set. 
ACHE (Acetylcholinesterase) 
Modeling/Validation Set 
All activities with a standard_type of IC50 were extracted from ChEMBLdb using assay_ids 
that corresponded to tid 93.  These activities were then filtered into active and inactive classes 
using thresholds of <= 100nM and >=10000nM respectively yielding 445 active molregnos and 
472 inactive molregnos.  A total of 8 molregnos occurred in both the active and inactive classes.  
These were excluded from the set leaving 901 (437 active and 464 inactive) molregnos.  For 
each of these molregnos, the compound‘s smiles were extracted from ChEMBLdb.  After 
removing salts, standardizing charges, and normalizing stereo information, 13 compounds were 
found to occur more than once in the dataset.  Activities were analyzed for each of these 
compounds.  All duplicates were found to fall in the same activity class, so one example was 
retained while the others were deleted.  This resulted in a final dataset of 887 compounds (424 
active and 463 inactive).   
When preparing the dataset for QSAR modeling, chirality of compounds was removed.  This 
caused the identification of several more ―duplicates‖.  When the activity class of each 
representative of these ―duplicates‖ was investigated, one replicate was kept for each duplicate 
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where the activity classes were in agreement (removed 22 structures) and no duplicates were 
found where the activity classes were in disagreement.    
External Set 
From WOMBAT, all activities with an act_type of IC50 and Ki were extracted using 
target_fullname AChE.  The activities were filtered using Pipeline Pilot. For each of the MIREG, 
the compound‘s smiles were extracted from WOMBAT. 29 of the MIREG could not be 
converted from SMILES. The remaining compounds were separated into active and inactive 
classes using thresholds of <= 100nM and >=10000nM respectively yielding 405 active MIREG 
and 344 inactive MIREG. After removing salts, standardizing charges, and normalizing stereo 
information, 84 active and 6 inactive compounds were found to occur more than once in the 
dataset. Activities were analyzed for each of these compounds.  All duplicates were found to fall 
in the same activity class, so one example was retained while the others were deleted.  This 
resulted in a final dataset of 659 compounds (321 active and 338 inactive). No MIREG occurred 
in both the active and inactive classes.  7 compounds overlap with ChEMBL, leaving a final 
dataset of 652 compounds (321 active and 331 inactive). 
 
ACK1 (Activated Cdc42-associated Kinase) 
Modeling/Validation Set 
The Ack1 dataset was curated from patented data from Amgen (US patent 2006- 0040965, 
US patent US 2007 - 0072851), OSI Pharmaceuticals (US patent 2009 - 0286768) and other 
sources published in literature.  In total, 487 activities were collected.  These were separated into 
active and inactive classes using thresholds of <= 100nM and >=10000nM respectively yielding 
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124 actives and 68 inactives. After removing salts, standardizing charges, and normalizing stereo 
information,  16 active and 4 inactive compounds were found to occur more than once in the 
dataset. Activities were analyzed for each of these compounds.  All duplicates were found to fall 
in the same activity class, so one example was retained while the others were deleted.  This 
resulted in a final dataset of 172 compounds (108 active and 64 inactive). 
External Set 
A lack of known ligands for this protein prevented the generation of additional external sets. 
 
AR (Androgen Receptor) 
Modeling/Validation Set 
All activities with a standard_type of IC50 were extracted from ChEMBLdb using assay_ids 
that corresponded to tid 56.  These activities were then filtered into active and inactive classes 
using thresholds of <= 100nM and >=10000nM respectively yielding 305 active molregnos and 
149 inactive molregnos.  A total of 16 molregnos occurred in both the active and inactive classes.  
These were excluded from the set leaving 422 (289 active and 133 inactive) molregnos.  For 
each of these molregnos, the compound‘s smiles were extracted from ChEMBLdb.  After 
removing salts, standardizing charges, and normalizing stereo information, no compounds were 
found to occur more than once in the dataset.  Therefore the final dataset consists of 422 
compounds (289 active and 133 inactive).   
When preparing the dataset for QSAR modeling, chirality of compounds was removed.  This 
caused the identification of several more ―duplicates‖.  When the activity class of each 
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representative of these ―duplicates‖ was investigated, one replicate was kept for each duplicate 
where the activity classes were in agreement (removed 19 structures) and all replicates were 
removed for duplicates where the activity classes were in disagreement (removed 9 structures).  
External Set 
From WOMBAT, all activities with an act_type of IC50 and Ki were extracted using 
target_fullname AR.  The activities were filtered using Pipeline Pilot. For each of the MIREG, 
the compound‘s smiles were extracted from WOMBAT.  MIREG were separated into active and 
inactive classes using thresholds of <= 100nM and >=10000nM respectively yielding 449 active 
MIREG and 68 inactive MIREG. After removing salts, standardizing charges, and normalizing 
stereo information, 161 active and 7 inactive compounds were found to occur more than once in 
the dataset. Activities were analyzed for each of these compounds.  All duplicates were found to 
fall in the same activity class, so one example was retained while the others were deleted.  This 
resulted in a dataset of 349 compounds (288 active and 61 inactive).  A total of 80 MIREG 
occurred in both the active and inactive classes leaving a final dataset of 269 compounds (248 
active and 21 inactive). 11 compounds overlap with ChEMBL, leaving a final dataset of 258 
compounds (237 active and 21 inactive). 
 
B2AR (Beta-2 Adrenergic Receptor) 
Modeling/Validation Set 
All activities with a standard_type of IC50 or Ki were extracted from ChEMBLdb using 
assay_ids that corresponded to tid 43.  These activities were then filtered into active and inactive 
classes using thresholds of <= 100nM and >=10000nM respectively yielding 94 active 
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molregnos and 157 inactive molregnos.  No molregnos occurred in both the active and inactive 
classes.  For each molregno, the compound‘s smiles were extracted from ChEMBLdb.  After 
removing salts, standardizing charges, and normalizing stereo information, 3 compounds were 
found to occur more than once in the dataset.  Activities were analyzed for each of these 
compounds.  All duplicates were found to fall in the same activity class, so one example was 
retained while the others were deleted.  This resulted in a final dataset of 248 compounds (94 
active and 154 inactive).   
When preparing the dataset for QSAR modeling, chirality of compounds was removed.  This 
caused the identification of several more ―duplicates‖.  When the activity class of each 
representative of these ―duplicates‖ was investigated, one replicate was kept for each duplicate 
where the activity classes were in agreement (removed 10 structures) and all replicates were 
removed for duplicates where the activity classes were in disagreement (removed 3 structures).  
External Set 
From WOMBAT, all activities with an act_type of IC50, pKi and Ki were extracted using 
target_fullname ‗beta2 adrenergic‘.  The activities were filtered using Pipeline Pilot. For each of 
the MIREG, the compound‘s smiles were extracted from WOMBAT. Compounds were 
separated into active and inactive classes using thresholds of <= 100nM and >=10000nM 
respectively yielding 60 active MIREG and 88 inactive MIREG. After removing salts, 
standardizing charges, and normalizing stereo information, 9 active and 2 inactive compounds 
were found to occur more than once in the dataset. Activities were analyzed for each of these 
compounds.  All duplicates were found to fall in the same activity class, so one example was 
retained while the others were deleted.  This resulted in a final dataset of 137 compounds (51 
active and 86 inactive). No MIREG occurred in both the active and inactive classes.   
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CA2 (Carbonic Anhydrase II) 
Modeling/Validation Set 
All activities with a standard_type of Ki were extracted from ChEMBLdb using assay_ids 
that corresponded to tid 15.  These activities were then filtered into active and inactive classes 
using thresholds of <= 10nM and >=1000nM respectively yielding 726 active molregnos and 382 
inactive molregnos.  A total of 15 molregnos occurred in both the active and inactive classes.  
These were excluded from the set leaving 1078 (711 active and 367 inactive) molregnos.  For 
each of these molregnos, the compound‘s smiles were extracted from ChEMBLdb.  After 
removing salts, standardizing charges, and normalizing stereo information, 5 compounds were 
found to occur more than once in the dataset.  Activities were analyzed for each of these 
compounds.  All duplicates were found to fall in the same activity class, so one example was 
retained while the others were deleted.  This resulted in a final dataset of 1073 compounds (709 
active and 364 inactive).   
When preparing the dataset for QSAR modeling, chirality of compounds was removed.  This 
caused the identification of several more ―duplicates‖.  When the activity class of each 
representative of these ―duplicates‖ was investigated, one replicate was kept for each duplicate 
where the activity classes were in agreement (removed 43 structures) and all replicates were 
removed for duplicates where the activity classes were in disagreement (removed 2 structures). 
Errors in descriptor calculation identified compounds with carboranes as problematic and 12 
compounds were removed. 
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External Set 
From WOMBAT, all activities with an act_type of IC50 and Ki were extracted using 
target_fullname ‗CA-II‘.  The activities were filtered using Pipeline Pilot. For each of the 
MIREG, the compound‘s smiles were extracted from WOMBAT.  16 of the MIREG could not 
be converted from SMILES. The remaining MIREG were separated into active and inactive 
classes using thresholds of <= 10nM and >=1000nM respectively yielding 953 active MIREG 
and 251 inactive MIREG. After removing salts, standardizing charges, and normalizing stereo 
information, 270 active and 61 inactive compounds were found to occur more than once in the 
dataset. Activities were analyzed for each of these compounds.  All duplicates were found to fall 
in the same activity class, so one example was retained while the others were deleted.  This 
resulted in a dataset of 873 compounds (683 active and 190 inactive).  A total of 30 MIREG 
occurred in both the active and inactive classes leaving a final dataset of 843 compounds (668 
active and 175 inactive). 65 compounds overlap with ChEMBL, leaving a final dataset of 778 
compounds (662 active and 116 inactive). 
CDK2 (Cyclin Dependent Kinase 2) 
Modeling/Validation Set 
All activities with a standard_type of IC50 were extracted from ChEMBLdb using assay_ids 
that corresponded to tid 11678.  These activities were then filtered into active and inactive 
classes using thresholds of <= 100nM and >=10000nM respectively yielding 739 active 
molregnos and 633 inactive molregnos.  A total of 6 molregnos occurred in both the active and 
inactive classes.  These were excluded from the set leaving  1360 (733 active and 627 inactive) 
molregnos.  For each of these molregnos, the compound‘s smiles were extracted from 
ChEMBLdb.  After removing salts, standardizing charges, and normalizing stereo information, 
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no compounds were found to occur more than once in the dataset.  Therefore the final dataset 
consists of 1360 compounds (733 active and 627 inactive).   
When preparing the dataset for QSAR modeling, chirality of compounds was removed.  This 
caused the identification of several more ―duplicates‖.  When the activity class of each 
representative of these ―duplicates‖ was investigated, one replicate was kept for each duplicate 
where the activity classes were in agreement (removed 21 structures) and all replicates were 
removed for duplicates where the activity classes were in disagreement (removed 2 structures).  
External Set 
From WOMBAT, all activities with an act_type of IC50 and Ki were extracted using 
target_fullname ‗CDK2‘.  The activities were filtered using Pipeline Pilot. For each of the 
MIREG, the compound‘s smiles were extracted from WOMBAT.  MIREG were separated into 
active and inactive classes using thresholds of <= 100nM and >=10000nM respectively yielding 
501 active MIREG and 289 inactive MIREG. After removing salts, standardizing charges, and 
normalizing stereo information, 20 active and 6 inactive compounds were found to occur more 
than once in the dataset. Activities were analyzed for each of these compounds.  All duplicates 
were found to fall in the same activity class, so one example was retained while the others were 
deleted.  This resulted in a dataset of 758 compounds (481 active and 277 inactive).  A total of 2 
MIREG occurred in both the active and inactive classes leaving a final dataset of 756 compounds 
(480 active and 276 inactive). 
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COX2 (Cyclooxygenase-2) 
Modeling/Validation Set 
All activities with a standard_type of IC50 were extracted from ChEMBLdb using assay_ids 
that corresponded to tid 126.  These activities were then filtered into active and inactive classes 
using thresholds of <= 100nM and >=10000nM respectively yielding 699 active molregnos and 
759 inactive molregnos.  A total of 14 molregnos occurred in both the active and inactive classes.  
These were excluded from the set leaving 1430 (685 active and 745 inactive) molregnos.  For 
each of these molregnos, the compound‘s smiles were extracted from ChEMBLdb.  After 
removing salts, standardizing charges, and normalizing stereo information, 1 compound was 
found to occur more than once in the dataset.  Activities were analyzed for each of this 
compound.  The duplicates were found to fall in the same activity class, so one example was 
retained while the other was deleted.  This resulted in a final dataset of 1429 compounds (685 
active and 744 inactive).   
When preparing the dataset for QSAR modeling, chirality of compounds was removed.  This 
caused the identification of several more ―duplicates‖.  When the activity class of each 
representative of these ―duplicates‖ was investigated, one replicate was kept for each duplicate 
where the activity classes were in agreement (removed 9 structures) and all replicates were 
removed for duplicates where the activity classes were in disagreement (removed 2 structures).  
External Set 
From WOMBAT, all activities with an act_type of IC50 and Ki were extracted using 
target_fullname ‗COX-2‘.  The activities were filtered using Pipeline Pilot. For each of the 
MIREG, the compound‘s smiles were extracted from WOMBAT.  MIREG were separated into 
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active and inactive classes using thresholds of <= 100nM and >=10000nM respectively yielding 
514 active MIREG and 406 inactive MIREG. After removing salts, standardizing charges, and 
normalizing stereo information, 84 active and 19 inactive compounds were found to occur more 
than once in the dataset. Activities were analyzed for each of these compounds.  All duplicates 
were found to fall in the same activity class, so one example was retained while the others were 
deleted.  This resulted in a dataset of 817 compounds (430 active and 387 inactive).  A total of 6 
MIREG occurred in both the active and inactive classes leaving a final dataset of 811 compounds 
(427 active and 384 inactive).  
DHFR (Dihydrofolate Reductase) 
Modeling/Validation Set 
All activities with a standard_type of IC50 were extracted from ChEMBLdb using assay_ids 
that corresponded to tid 6.  These activities were then filtered into active and inactive classes 
using thresholds of <= 100nM and >=10000nM respectively yielding 232 active molregnos and 
251 inactive molregnos.  A total of 10 molregnos occurred in both the active and inactive classes.  
These were excluded from the set leaving 463 (222 active and 241 inactive) molregnos.  For 
each of these molregnos, the compound‘s smiles were extracted from ChEMBLdb.  After 
removing salts, standardizing charges, and normalizing stereo information, no compounds were 
found to occur more than once in the dataset.  Therefore the final dataset consists of 463 
compounds (222 active and 241 inactive).   
When preparing the dataset for QSAR modeling, chirality of compounds was removed.  This 
caused the identification of several more ―duplicates‖.  When the activity class of each 
representative of these ―duplicates‖ was investigated, one replicate was kept for each duplicate 
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where the activity classes were in agreement (removed 4 structures) and no duplicates were 
found where the activity classes were in disagreement.  
External Set 
From WOMBAT, all activities with an act_type of IC50 and Ki were extracted using 
target_fullname ‗DHFR‘.  The activities were filtered using Pipeline Pilot. For each of the 
MIREG, the compound‘s smiles were extracted from WOMBAT.  MIREG were separated into 
active and inactive classes using thresholds of <= 10nM and >=1000nM respectively yielding 93 
active MIREG and 210 inactive MIREG. After removing salts, standardizing charges, and 
normalizing stereo information, 29 active and 30 inactive compounds were found to occur more 
than once in the dataset. Activities were analyzed for each of these compounds.  All duplicates 
were found to fall in the same activity class, so one example was retained while the others were 
deleted.  This resulted in a dataset of 244 compounds (64 active and 180 inactive).  A total of 2 
MIREG occurred in both the active and inactive classes leaving a final dataset of 240 compounds 
(62 active and 178 inactive).  
ESR1 (Estrogen Receptor Alpha) 
Modeling/Validation Set 
All activities with a standard_type of IC50 were extracted from ChEMBLdb using assay_ids 
that corresponded to tid 19.  These activities were then filtered into active and inactive classes 
using thresholds of <= 10nM and >=1000nM respectively yielding 316 active molregnos and 571 
inactive molregnos.  A total of 3 molregnos occurred in both the active and inactive classes.  
These were excluded from the set leaving 881 (313 active and 568 inactive) molregnos.  For 
each of these molregnos, the compound‘s smiles were extracted from ChEMBLdb.  After 
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removing salts, standardizing charges, and normalizing stereo information, 2 compounds were 
found to occur more than once in the dataset.  Activities were analyzed for each of these 
compounds.  All duplicates were found to fall in the same activity class, so one example was 
retained while the others were deleted.  This resulted in a final dataset of 878 compounds (312 
active and 566 inactive).   
When preparing the dataset for QSAR modeling, chirality of compounds was removed.  This 
caused the identification of several more ―duplicates‖.  When the activity class of each 
representative of these ―duplicates‖ was investigated, one replicate was kept for each duplicate 
where the activity classes were in agreement (removed 50 structures) and no duplicates were 
found where the activity classes were in disagreement.   Errors in descriptor calculation 
identified compounds with carboranes as problematic and 6 compounds were removed. 
External Set 
From WOMBAT, all activities with an act_type of IC50 and Ki were extracted using 
target_fullname ‗ERalpha‘.  The activities were filtered using Pipeline Pilot. For each of the 
MIREG, the compound‘s smiles were extracted from WOMBAT.  MIREG were separated into 
active and inactive classes using thresholds of <= 100nM and >=10000nM respectively yielding 
972 active MIREG and 176 inactive MIREG. After removing salts, standardizing charges, and 
normalizing stereo information, 335 active and 3 inactive compounds were found to occur more 
than once in the dataset. Activities were analyzed for each of these compounds.  All duplicates 
were found to fall in the same activity class, so one example was retained while the others were 
deleted.  This resulted in a dataset of 810 compounds (637 active and 173 inactive).  A total of 8 
MIREG occurred in both the active and inactive classes leaving a final dataset of 802 compounds 
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(633 active and 169 inactive). 3 compounds overlap with ChEMBL, leaving a final dataset of 
799 compounds (633 active and 166 inactive). 
ESR2 (Estrogen Receptor Beta) 
Modeling/Validation Set 
All activities with a standard_type of IC50 were extracted from ChEMBLdb using assay_ids 
that corresponded to tid 174.  These activities were then filtered into active and inactive classes 
using thresholds of <= 10nM and >=1000nM respectively yielding 356 active molregnos and 352 
inactive molregnos.  A total of 2 molregnos occurred in both the active and inactive classes.  
These were excluded from the set leaving 704 (354 active and 350 inactive) molregnos.  For 
each of these molregnos, the compound‘s smiles were extracted from ChEMBLdb.  After 
removing salts, standardizing charges, and normalizing stereo information, 1 compound was 
found to occur more than once in the dataset.  Activities were analyzed for this compound.  The 
duplicates were found to fall in the same activity class, so one example was retained while the 
other was deleted.  This resulted in a final dataset of 703 compounds (353 active and 350 
inactive).   
When preparing the dataset for QSAR modeling, chirality of compounds was removed.  This 
caused the identification of several more ―duplicates‖.  When the activity class of each 
representative of these ―duplicates‖ was investigated, one replicate was kept for each duplicate 
where the activity classes were in agreement (removed 32 structures) and all replicates were 
removed for duplicates where the activity classes were in disagreement (removed 9 structures). 
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External Set 
From WOMBAT, all activities with an act_type of IC50 and Ki were extracted using 
target_fullname ‗ERbeta‘.  The activities were filtered using Pipeline Pilot. For each of the 
MIREG, the compound‘s smiles were extracted from WOMBAT.  MIREG were separated into 
active and inactive classes using thresholds of <= 10nM and >=1000nM respectively yielding 
338 active MIREG and 335 inactive MIREG. After removing salts, standardizing charges, and 
normalizing stereo information, 70 active and 16 inactive compounds were found to occur more 
than once in the dataset. Activities were analyzed for each of these compounds.  All duplicates 
were found to fall in the same activity class, so one example was retained while the others were 
deleted.  This resulted in a dataset of 587 compounds (268 active and 319 inactive).  A total of 2 
MIREG occurred in both the active and inactive classes leaving a final dataset of 583 compounds 
(266 active and 317 inactive). 4 compounds overlap with ChEMBL, leaving a final dataset of 
579 compounds (266 active and 313 inactive). 
F10 (Coagulation Factor X) 
Modeling/Validation Set 
All activities with a standard_type of IC50 were extracted from ChEMBLdb using assay_ids 
that corresponded to tid 194.  These activities were then filtered into active and inactive classes 
using thresholds of <= 10nM and >=1000nM respectively yielding 510 active molregnos and 494 
inactive molregnos.  A total of 2 molregnos occurred in both the active and inactive classes.  
These were excluded from the set leaving 1000 (508 active and 492 inactive) molregnos.  For 
each of these molregnos, the compound‘s smiles were extracted from ChEMBLdb.  After 
removing salts, standardizing charges, and normalizing stereo information, 1 compound was 
found to occur more than once in the dataset.  Activities were analyzed for this compound.  The 
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duplicates were found to fall in the same activity class, so one example was retained while the 
other was deleted.  This resulted in a final dataset of 999 compounds (508 active and 491 
inactive).   
When preparing the dataset for QSAR modeling, chirality of compounds was removed.  This 
caused the identification of several more ―duplicates‖.  When the activity class of each 
representative of these ―duplicates‖ was investigated, one replicate was kept for each duplicate 
where the activity classes were in agreement (removed 32 structures) and all replicates were 
removed for duplicates where the activity classes were in disagreement (removed 2 structures). 
External Set 
From WOMBAT, all activities with an act_type of IC50 and Ki were extracted using 
target_fullname ‗%fXa%‘.  The activities were filtered using Pipeline Pilot. For each of the 
MIREG, the compound‘s smiles were extracted from WOMBAT.  5 of the MIREG could not be 
converted from SMILES. The remaining MIREG were separated into active and inactive classes 
using thresholds of <= 100nM and >=10000nM respectively yielding 1870 active MIREG and 
445 inactive MIREG. After removing salts, standardizing charges, and normalizing stereo 
information, 236 active and 15 inactive compounds were found to occur more than once in the 
dataset. Activities were analyzed for each of these compounds.  All duplicates were found to fall 
in the same activity class, so one example was retained while the others were deleted.  This 
resulted in a dataset of 2064 compounds (1634 active and 430 inactive).  A total of 14 MIREG 
occurred in both the active and inactive classes leaving a final dataset of 2050 compounds (1627 
active and 423 inactive). 
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GR (Glucocorticoid Receptor) 
Modeling/Validation Set 
All activities with a standard_type of IC50 were extracted from ChEMBLdb using assay_ids 
that corresponded to tid 25.  These activities were then filtered into active and inactive classes 
using thresholds of <= 10nM and >=1000nM respectively yielding 210 active molregnos and 206 
inactive molregnos.  A total of 15 molregnos occurred in both the active and inactive classes.  
These were excluded from the set leaving 386 (195 active and 191 inactive) molregnos.  For 
each of these molregnos, the compound‘s smiles were extracted from ChEMBLdb.  After 
removing salts, standardizing charges, and normalizing stereo information, 1 compound was 
found to occur more than once in the dataset.  Activities were analyzed for this compound.  The 
duplicates were found to fall in the same activity class, so one example was retained while the 
other was deleted.  This resulted in a final dataset of 385 compounds (194 active and 191 
inactive).   
When preparing the dataset for QSAR modeling, chirality of compounds was removed.  This 
caused the identification of several more ―duplicates‖.  When the activity class of each 
representative of these ―duplicates‖ was investigated, one replicate was kept for each duplicate 
where the activity classes were in agreement (removed 9 structures) and all replicates were 
removed for duplicates where the activity classes were in disagreement (removed 3 structures). 
External Set 
From WOMBAT, all activities with an act_type of IC50 and Ki were extracted using 
target_fullname ‗%Glucocorticoid receptor%‘.  The activities were filtered using Pipeline Pilot. 
For each of the MIREG, the compound‘s smiles were extracted from WOMBAT.  MIREG were 
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separated into active and inactive classes using thresholds of <= 100nM and >=10000nM 
respectively yielding 677 active MIREG and 30 inactive MIREG. After removing salts, 
standardizing charges, and normalizing stereo information, 295 active and 3 inactive compounds 
were found to occur more than once in the dataset. Activities were analyzed for each of these 
compounds.  All duplicates were found to fall in the same activity class, so one example was 
retained while the others were deleted.  This resulted in a dataset of 409 compounds (382 active 
and 27 inactive).  A total of 18 MIREG occurred in both the active and inactive classes leaving a 
final dataset of 391 compounds (611 active and 71 inactive). 4 compounds overlap with ChemBl, 
leaving a final dataset of 387 compounds (370 active and 17 inactive). 
HIV-Int (HIV Integrase) 
Modeling/Validation Set 
All activities with a standard_type of IC50 were extracted from ChEMBLdb using assay_ids 
that corresponded to tid 12456.  These activities were then filtered into active and inactive 
classes using thresholds of <= 1000nM and >=50000nM respectively yielding 213 active 
molregnos and 567 inactive molregnos.  A total of 15 molregnos occurred in both the active and 
inactive classes.  These were excluded from the set leaving 750 (198 active and 552 inactive) 
molregnos.  For each of these molregnos, the compound‘s smiles were extracted from 
ChEMBLdb.  After removing salts, standardizing charges, and normalizing stereo information, 1 
compound was found to occur more than once in the dataset.  Activities were analyzed for this 
compound.  The duplicates were found to fall in the same activity class, so one example was 
retained while the other was deleted.  This resulted in a final dataset of 749 compounds (197 
active and 552 inactive).   
 162 
 
When preparing the dataset for QSAR modeling, chirality of compounds was removed.  This 
caused the identification of several more ―duplicates‖.  When the activity class of each 
representative of these ―duplicates‖ was investigated, one replicate was kept for each duplicate 
where the activity classes were in agreement (removed 10 structures) and no duplicates were 
found where the activity classes were in disagreement. Errors in descriptor calculation identified 
compounds with carboranes as problematic and 1 compound was removed. 
External Set 
From WOMBAT, all activities with an act_type of IC50 and Ki were extracted using 
target_fullname ‗%HIV%‘ and ‗%IN%‘.  The activities were filtered using Pipeline Pilot. For 
each of the MIREG, the compound‘s smiles were extracted from WOMBAT.  MIREG were 
separated into active and inactive classes using thresholds of <= 100nM and >=10000nM 
respectively yielding 150 active MIREG and 1631 inactive MIREG. After removing salts, 
standardizing charges, and normalizing stereo information, 35 active and 766 inactive 
compounds were found to occur more than once in the dataset. Activities were analyzed for each 
of these compounds.  All duplicates were found to fall in the same activity class, so one example 
was retained while the others were deleted.  This resulted in a dataset of 980 compounds (115 
active and 865 inactive).  A total of 14 MIREG occurred in both the active and inactive classes 
leaving a final dataset of 966 compounds (108 active and 858 inactive). 12 compounds overlap 
with ChemBl, leaving a final dataset of 954 compounds (108 active and 846 inactive). 
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HIV-Pr (HIV Protease) 
Modeling/Validation Set 
All activities with a standard_type of IC50 were extracted from ChEMBLdb using assay_ids 
that corresponded to tid 191.  These activities were then filtered into active and inactive classes 
using thresholds of <= 10nM and >=1000nM respectively yielding 912 active molregnos and 633 
inactive molregnos.  A total of 9 molregnos occurred in both the active and inactive classes.  
These were excluded from the set leaving 1527 (903 active and 624 inactive) molregnos.  For 
each of these molregnos, the compound‘s smiles were extracted from ChEMBLdb.  After 
removing salts, standardizing charges, and normalizing stereo information, 1 compound was 
found to occur more than once in the dataset.  Activities were analyzed for this compound.  The 
duplicates were found to fall in the same activity class, so one example was retained while the 
other was deleted.  This resulted in a final dataset of 1526 compounds (903 active and 623 
inactive).   
When preparing the dataset for QSAR modeling, chirality of compounds was removed.  This 
caused the identification of several more ―duplicates‖.  When the activity class of each 
representative of these ―duplicates‖ was investigated, one replicate was kept for each duplicate 
where the activity classes were in agreement (removed 116 structures) and all replicates were 
removed for duplicates where the activity classes were in disagreement (removed 20 structures). 
External Set 
From WOMBAT, all activities with an act_type of IC50 and Ki were extracted using 
target_fullname ‗%HIV%‘ and ‗%P%‘.  The activities were filtered using Pipeline Pilot. For 
each of the MIREG, the compound‘s smiles were extracted from WOMBAT.  4 of the MIREG 
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could not be converted from SMILES. The remaining MIREG were separated into active and 
inactive classes using thresholds of <= 100nM and >=10000nM respectively yielding 3519 
active MIREG and 330 inactive MIREG. After removing salts, standardizing charges, and 
normalizing stereo information, 1113 active and 32 inactive compounds were found to occur 
more than once in the dataset. Activities were analyzed for each of these compounds.  All 
duplicates were found to fall in the same activity class, so one example was retained while the 
others were deleted.  This resulted in a dataset of 2704 compounds (2406 active and 298 
inactive).  A total of 10 MIREG occurred in both the active and inactive classes leaving a final 
dataset of 2694 compounds (2401 active and 293 inactive). 3 compounds overlap with ChemBl, 
leaving a final dataset of 2691 compounds (2400 active and 291 inactive). 
HIV-RT (HIV Reverse Transcriptase) 
Modeling/Validation Set 
All activities with a standard_type of IC50 were extracted from ChEMBLdb using assay_ids 
that corresponded to tid 228.  These activities were then filtered into active and inactive classes 
using thresholds of <= 100nM and >=10000nM respectively yielding 513 active molregnos and 
664 inactive molregnos.  A total of 21 molregnos occurred in both the active and inactive classes.  
These were excluded from the set leaving 1135 (492 active and 643 inactive) molregnos.  For 
each of these molregnos, the compound‘s smiles were extracted from ChEMBLdb.  After 
removing salts, standardizing charges, and normalizing stereo information, 1 compound was 
found to occur more than once in the dataset.  Activities were analyzed for this compound.  The 
duplicates were found to fall in opposing activity classes, so both deleted.  This resulted in a final 
dataset of 1133 compounds (491 active and 642 inactive).   
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When preparing the dataset for QSAR modeling, chirality of compounds was removed.  This 
caused the identification of several more ―duplicates‖.  When the activity class of each 
representative of these ―duplicates‖ was investigated, one replicate was kept for each duplicate 
where the activity classes were in agreement (removed 32 structures) and all replicates were 
removed for duplicates where the activity classes were in disagreement (removed 5 structures). 
Errors in descriptor calculation identified compounds with carboranes as problematic and 1 
compound was removed. 
External Set 
From WOMBAT, all activities with an act_type of IC50 and Ki were extracted using 
target_fullname ‗%HIV%‘ and ‗%RT%‘.  The activities were filtered using Pipeline Pilot. For 
each of the MIREG, the compound‘s smiles were extracted from WOMBAT.  20 of the MIREG 
could not be converted from SMILES. The remaining MIREG were separated into active and 
inactive classes using thresholds of <= 100nM and >=10000nM respectively yielding 1381 
active MIREG and 1053 inactive MIREG. After removing salts, standardizing charges, and 
normalizing stereo information, 629 active and 273 inactive compounds were found to occur 
more than once in the dataset. Activities were analyzed for each of these compounds.  All 
duplicates were found to fall in the same activity class, so one example was retained while the 
others were deleted.  This resulted in a dataset of 1532 compounds (752 active and 780 inactive).  
A total of 120 MIREG occurred in both the active and inactive classes leaving a final dataset of 
1412 compounds (692 active and 720 inactive). 1 compound overlaps with ChemBl, leaving a 
final dataset of 1411 compounds (692 active and 719 inactive). 
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PARP1 (Poly [ADP-ribose] Polymerase-1) 
Modeling/Validation Set 
All activities with a standard_type of IC50 were extracted from ChEMBLdb using assay_ids 
that corresponded to tid 11663.  These activities were then filtered into active and inactive 
classes using thresholds of <= 10nM and >=1000nM respectively yielding 176 active molregnos 
and 123 inactive molregnos.  No molregnos occurred in both the active and inactive classes and 
after removing salts, standardizing charges, and normalizing stereo information, no compounds 
were found to occur more than once in the dataset.  Therefore the final dataset consists of 299 
compounds (176 active and 123 inactive).   
When preparing the dataset for QSAR modeling, chirality of compounds was removed.  This 
caused the identification of several more ―duplicates‖.  When the activity class of each 
representative of these ―duplicates‖ was investigated, one replicate was kept for each duplicate 
where the activity classes were in agreement (removed 6 structures) and no duplicates were 
found where the activity classes were in disagreement.  
External Set 
From WOMBAT, all activities with an act_type of IC50 and Ki were extracted using 
target_fullname ‗%PARP1%‘.  The activities were filtered using Pipeline Pilot. For each of the 
MIREG, the compound‘s smiles were extracted from WOMBAT.  MIREG were separated into 
active and inactive classes using thresholds of <= 100nM and >=10000nM respectively yielding 
252 active MIREG and 48 inactive MIREG. After removing salts, standardizing charges, and 
normalizing stereo information, 4 active and 1 inactive compounds were found to occur more 
than once in the dataset. Activities were analyzed for each of these compounds.  All duplicates 
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were found to fall in the same activity class, so one example was retained while the others were 
deleted.  This resulted in a dataset of 295 compounds (248 active and 47 inactive).  A total of 2 
MIREG occurred in both the active and inactive classes leaving a final dataset of 293 compounds 
(247 active and 46 inactive).  
PDE5 (Phosphodiesterase 5A) 
Modeling/Validation Set 
All activities with a standard_type of IC50 were extracted from ChEMBLdb using assay_ids 
that corresponded to tid 3.  These activities were then filtered into active and inactive classes 
using thresholds of <= 10nM and >=1000nM respectively yielding 327 active molregnos and 363 
inactive molregnos.  No molregnos occurred in both the active and inactive classes.   For each 
molregno, the compound‘s smiles were extracted from ChEMBLdb.  After removing salts, 
standardizing charges, and normalizing stereo information, 3 compounds were found to occur 
more than once in the dataset.  Activities were analyzed for each of these compounds.  All 
duplicates were found to fall in the same activity class, so one example was retained while the 
others were deleted.  This resulted in a final dataset of 687 compounds (324 active and 363 
inactive). 
When preparing the dataset for QSAR modeling, chirality of compounds was removed.  This 
caused the identification of several more ―duplicates‖.  When the activity class of each 
representative of these ―duplicates‖ was investigated, one replicate was kept for each duplicate 
where the activity classes were in agreement (removed 5 structures) and no duplicates were 
found where the activity classes were in disagreement.  
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External Set 
From WOMBAT, all activities with an act_type of IC50 and Ki were extracted using 
target_fullname ‗%PDE5%‘.  The activities were filtered using Pipeline Pilot. For each of the 
MIREG, the compound‘s smiles were extracted from WOMBAT.  MIREG were separated into 
active and inactive classes using thresholds of <= 100nM and >=10000nM respectively yielding 
470 active MIREG and 72 inactive MIREG. After removing salts, standardizing charges, and 
normalizing stereo information, 42 active and 1 inactive compounds were found to occur more 
than once in the dataset. Activities were analyzed for each of these compounds.  All duplicates 
were found to fall in the same activity class, so one example was retained while the others were 
deleted.  This resulted in a final dataset of 499 compounds (428 active and 71 inactive).   
 
PNP (Purine Nucleoside Phosphorylase) 
Modeling/Validation Set 
All activities with a standard_type of IC50 or Ki were extracted from ChEMBLdb using 
assay_ids that corresponded to tid 12690.  These activities were then filtered into active and 
inactive classes using thresholds of <= 10nM and >=1000nM respectively yielding 89 active 
molregnos and 86 inactive molregnos.  A total of 1 molregno occurred in both the active and 
inactive classes.  This was excluded from the set leaving 173 (88 active and 85 inactive) 
molregnos.  For each of these molregnos, the compound‘s smiles were extracted from 
ChEMBLdb.  After removing salts, standardizing charges, and normalizing stereo information, 
no compounds were found to occur more than once in the dataset.  Therefore the final dataset 
consists of 173 compounds (88 active and 85 inactive).   
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When preparing the dataset for QSAR modeling, chirality of compounds was removed.  This 
caused the identification of several more ―duplicates‖.  When the activity class of each 
representative of these ―duplicates‖ was investigated, one replicate was kept for each duplicate 
where the activity classes were in agreement (removed 14 structures) and no duplicates were 
found where the activity classes were in disagreement.  
External Set 
From WOMBAT all activities with an act_type of IC50 and Ki were extracted using 
target_fullname ‗%PNP%‘.  The activities were filtered using Pipeline Pilot. For each of the 
MIREG, the compound‘s smiles were extracted from WOMBAT.  MIREG were separated into 
active and inactive classes using thresholds of <= 100nM and >=10000nM respectively yielding 
57 active MIREG and 40 inactive MIREG. After removing salts, standardizing charges, and 
normalizing stereo information, 15 active and 1 inactive compounds were found to occur more 
than once in the dataset. Activities were analyzed for each of these compounds.  All duplicates 
were found to fall in the same activity class, so one example was retained while the others were 
deleted.  This resulted in a final dataset of 81 compounds (42 active and 39 inactive).     
PPARG (Peroxisome Proliferator-Activated Receptor Gamma) 
Modeling/Validation Set 
All activities with a standard_type of IC50 were extracted from ChEMBLdb using assay_ids 
that corresponded to tid 133.  These activities were then filtered into active and inactive classes 
using thresholds of <= 100nM and >=10000nM respectively yielding 250 active molregnos and 
131 inactive molregnos.  A total of 1 molregno occurred in both the active and inactive classes.  
This was excluded from the set leaving 379 (249 active and 130 inactive) molregnos.  For each 
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of these molregnos, the compound‘s smiles were extracted from ChEMBLdb.  After removing 
salts, standardizing charges, and normalizing stereo information, 3 compounds were found to 
occur more than once in the dataset.  Activities were analyzed for each of these compounds.  All 
duplicates were found to fall in the same activity class, so one example was retained while the 
others were deleted.  This resulted in a final dataset of 376 compounds (246 active and 130 
inactive). 
When preparing the dataset for QSAR modeling, chirality of compounds was removed.  This 
caused the identification of several more ―duplicates‖.  When the activity class of each 
representative of these ―duplicates‖ was investigated, one replicate was kept for each duplicate 
where the activity classes were in agreement (removed 20 structures) and all replicates were 
removed for duplicates where the activity classes were in disagreement (removed 5 structures). 
External Set 
From WOMBAT, all activities with an act_type of IC50 and Ki were extracted from using 
swissp_id ‗%PARG%‘.  The activities were filtered using Pipeline Pilot. For each of the 
MIREG, the compound‘s smiles were extracted from WOMBAT.  MIREG were separated into 
active and inactive classes using thresholds of <= 100nM and >=10000nM respectively yielding 
224 active MIREG and 155 inactive MIREG. After removing salts, standardizing charges, and 
normalizing stereo information, 29 active and 8 inactive compounds were found to occur more 
than once in the dataset. Activities were analyzed for each of these compounds.  All duplicates 
were found to fall in the same activity class, so one example was retained while the others were 
deleted.  This resulted in a dataset of 342 compounds (195 active and 147 inactive).  A total of 2 
MIREG occurred in both the active and inactive classes leaving a final dataset of 340 compounds 
(194 active and 146 inactive).  
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REN (Renin) 
Modeling/Validation Set 
All activities with a standard_type of IC50 were extracted from ChEMBLdb using assay_ids 
that corresponded to tid 11225.  These activities were then filtered into active and inactive 
classes using thresholds of <= 10nM and >=1000nM respectively yielding 801 active molregnos 
and 468 inactive molregnos.  A total of 16 molregnos occurred in both the active and inactive 
classes.  These were excluded from the set leaving 1237 (785 active and 452 inactive) 
molregnos.  For each of these molregnos, the compound‘s smiles were extracted from 
ChEMBLdb.  After removing salts, standardizing charges, and normalizing stereo information, 2 
compounds were found to occur more than once in the dataset.  Activities were analyzed for each 
of these compounds.  All duplicates were found to fall in the same activity class, so one example 
was retained while the others were deleted.  This resulted in a final dataset of 1235 compounds 
(783 active and 452 inactive). 
When preparing the dataset for QSAR modeling, chirality of compounds was removed.  This 
caused the identification of several more ―duplicates‖.  When the activity class of each 
representative of these ―duplicates‖ was investigated, one replicate was kept for each duplicate 
where the activity classes were in agreement (removed 69 structures) and all replicates were 
removed for duplicates where the activity classes were in disagreement (removed 11 structures). 
External Set 
From WOMBAT, all activities with an act_type of IC50 and Ki were extracted using 
target_fullname ‗%renin%‘.  The activities were filtered using Pipeline Pilot. For each of the 
MIREG, the compound‘s smiles were extracted from WOMBAT.  17 of the MIREG could not 
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be converted from SMILES. The remaining MIREG were separated into active and inactive 
classes using thresholds of <= 100nM and >=10000nM respectively yielding 676 active MIREG 
and 52 inactive MIREG. After removing salts, standardizing charges, and normalizing stereo 
information, 174 active and 3 inactive compounds were found to occur more than once in the 
dataset. Activities were analyzed for each of these compounds.  All duplicates were found to fall 
in the same activity class, so one example was retained while the others were deleted.  This 
resulted in a dataset of 551 compounds (502 active and 49 inactive).  A total of 6 MIREG 
occurred in both the active and inactive classes leaving a final dataset of 545 compounds (499 
active and 46 inactive). 9 compounds overlap with ChemBl, leaving a final dataset of 536 
compounds (498 active and 38 inactive). 
SRC (Tyrosine Protein Kinase SRC) 
Modeling/Validation Set 
All activities with a standard_type of IC50 were extracted from ChEMBLdb using assay_ids 
that corresponded to tid 10434.  These activities were then filtered into active and inactive 
classes using thresholds of <= 100 and >=10000 respectively yielding 632 active molregnos and 
831 inactive molregnos.  A total of 8 molregnos occurred in both the active and inactive classes.  
These were excluded from the modeling set leaving 1447 (624 active and 823 inactive) 
molregnos.  For each of these molregnos, the compounds smiles were extracted from 
ChEMBLdb.  After removing salts, standardizing charges, and normalizing stereo information, 4 
compounds were found to occur more than once in the dataset.  For each of these compounds 
activities were analyzed.  All duplicates were found to fall in the same activity class, so one 
example was retained while the others were deleted.  This resulted in a final dataset of 1443 (623 
active and 820 inactive).   
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When preparing the dataset for QSAR modeling, chirality of compounds was removed.  This 
caused the identification of several more ―duplicates‖.  When the activity class of each 
representative of these ―duplicates‖ was investigated, one replicate was kept for each duplicate 
where the activity classes were in agreement (removed 16 structures) and no duplicates were 
found where the activity classes were in disagreement.  
External Set 
From WOMBAT, all activities with an act_type of IC50 and Ki were extracted using 
target_fullname ‗%SRC%‘.  The activities were filtered using Pipeline Pilot. For each of the 
MIREG, the compound‘s smiles were extracted from WOMBAT.  MIREG were separated into 
active and inactive classes using thresholds of <= 100nM and >=10000nM respectively yielding 
402 active MIREG and 383 inactive MIREG. After removing salts, standardizing charges, and 
normalizing stereo information, 56 active and 32 inactive compounds were found to occur more 
than once in the dataset. Activities were analyzed for each of these compounds.  All duplicates 
were found to fall in the same activity class, so one example was retained while the others were 
deleted.  This resulted in a dataset of 697 compounds (346 active and 351 inactive).  A total of 4 
MIREG occurred in both the active and inactive classes leaving a final dataset of 693 compounds 
(344 active and 349 inactive). 4 compounds overlap with ChemBl, leaving a final dataset of 689 
compounds (344 active and 345 inactive). 
F2 (Thrombin) 
Modeling/Validation Set 
All activities with a standard_type of IC50 were extracted from ChEMBLdb using assay_ids 
that corresponded to tid 11.  These activities were then filtered into active and inactive classes 
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using thresholds of <= 100nM and >=10000nM respectively yielding 373 active molregnos and 
787 inactive molregnos.  A total of 1 molregno occurred in both the active and inactive classes.  
This was excluded from the set leaving 1158 (372 active and 786 inactive) molregnos.  For each 
of these molregnos, the compound‘s smiles were extracted from ChEMBLdb.  After removing 
salts, standardizing charges, and normalizing stereo information, 8 compounds were found to 
occur more than once in the dataset.  For each of these compounds activities were analyzed.  All 
duplicates were found to fall in the same activity class, so one example was retained while the 
others were deleted.  This resulted in a final dataset of 1150 (368 active and 782 inactive).   
External Set 
From WOMBAT, all activities with an act_type of IC50 and Ki were extracted using 
target_fullname ‗%factor II%‘.  The activities were filtered using Pipeline Pilot. For each of the 
MIREG, the compound‘s smiles were extracted from WOMBAT.  1 of the MIREG was not able 
to be converted from SMILES. The remaining MIREG were separated into active and inactive 
classes using thresholds of <= 100nM and >=10000nM respectively yielding 1194 active 
MIREG and 973 inactive MIREG. After removing salts, standardizing charges, and normalizing 
stereo information, 162 active and 63 inactive compounds were found to occur more than once in 
the dataset. Activities were analyzed for each of these compounds.  All duplicates were found to 
fall in the same activity class, so one example was retained while the others were deleted.  This 
resulted in a dataset of 1942 compounds (1032 active and 910 inactive).  A total of 2 MIREG 
occurred in both the active and inactive classes leaving a final dataset of 1940 compounds (1031 
active and 909 inactive). 7 compounds overlap with ChemBl, leaving a final dataset of 1933 
compounds (1028 active and 905 inactive). 
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Appendix V: ROC Curves from Benchmark Screening 
Contained within this appendix are the ROC curves generated when applying different 
methods to rank the screening sets.  The ROC curves are organized by both the applied method 
and by whether the ROC curve was generated considering the whole screening set or just the 
compounds with tested activity for the target of interest.  More detailed discussion of the results 
are contained in each subsection of this appendix. 
Docking 
Docking with eHiTS proves to be fairly useful when applied to virtual screening of the full 
screening library.  However, this is only the case when eHiTS was able to identify the protein 
family and use a family scoring function.  In the absence of a family scoring function (see 
B2AR, HIV-Int, PARP1, PDE5, REN, and PNP), the ranking of compounds is little better than 
random.  The same trend can be seen when looking at the ROC curves for compounds with 
known activity.  Generally, curves are poor when a family scoring function is unavailable.  
Additionally, docking accuracy is generally lower when looking at only the known compounds 
indicating that docking performs a better coarse refinement than a fine refinement of a compound 
library.    
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Similarity Searching 
ROC curves were generated for similarity search when done by two different probe sets, the 
ligand contained within the PDB entry that was used for docking and the full modeling set.  
When using only the pdb ligand as a probe, the accuracy of ranking is very uncertain.  
Occasionally the ranking is excellent as in the cases of B2AR, ESR2, and DHFR.  However, it is 
just as frequently terrible as in the cases of GR, HIV-Int, and PNP.  This is mirrored in the 
tanking of compounds with known activities, but accuracy is always lower than that obtained on 
the entire dataset.  Using the entire modeling set as probes, similarity searching provides nearly 
excellent ranking of the full database for every target.  Its ranking of compounds with known 
activity is not quite as good, but is still very acceptable.  
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Full Screening Sets-PDB ligand 
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Compounds with Known Activities – PDB Ligand 
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QSAR 
QSAR modeling yielded excellent results when ranking the entire screening library; 
however, these results were often slightly less exciting than those obtained with similarity 
searching.  On the other hand, the results of ranking compounds with known activities is often as 
good or better than the ranking of the entire library and usually provides better ranking than 
similarity searching with the same dataset.  
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Appendix VI: QSAR Validation Set Statistics 
Contained within this appendix are the plots demonstrating how QSAR statistics are effected 
by the size of the modeling set used to build the QSAR models.  The average predictive accuracy 
of models increases or stays constant as the modeling set size increases.  Generally, the stability 
(i.e. the inverse of the variation in predictive power for multiple samples of the same size) also 
increases as the modeling set size increases.  These results corroborate the expected results that 
more compounds lead to more predictive models.  
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Appendix VII: Enrichment Plots 
Contained within this appendix are the summary plots of enrichment at different cutoffs in 
the screening library.  Easily compared in these plots are the different methodologies and the 
effects of the amount of available data on ability to enrich highly ranked compounds.  It is clear 
that using more ligand data provides better enrichment with docking generally yielding 
enrichments that are significantly less than the best enrichments obtained by ligand-based 
methods.  In every case, similarity searching yielded enrichments much better than QSAR for the 
same level of input.
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Appendix VIII: CCR vs. Enrichment Plots 
Contained within this appendix are plots allow comparison of enrichment and CCR.  
Typically CCR is statistic used to determine the usefulness of a model; however, these figure 
seem to indicate that if the goal is to identify models that will provide superior enrichment in 
virtual screening applications, optimizing CCR may provide little benefit.  Generally, enrichment 
correlates only weakly with CCR.  
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Appendix IX: Gene Expression Markers for Multidrug 
Resistance 
Contained within this appendix are the hypothetical multidrug biomarkers identified in 
Section 4.3.1.  These biomarkers await experimental validation. 
Probe Name 
Gene 
Array 
Gene Name Gene Symbol RefSeq Protein ID 
222608_s_at B anillin, actin binding protein ANLN NP_061155 
222433_at B 
enabled homolog 
(Drosophila) 
ENAH 
NP_001008493  
 NP_060682 
222449_at B 
prostate transmembrane 
protein, androgen induced 1 
PMEPA1 
NP_064567  
 NP_954638  
 NP_954639  
 NP_954640 
222810_s_at B RAS protein activator like 2 RASAL2 
NP_004832  
 NP_733793 
222834_s_at B 
guanine nucleotide binding 
protein (G protein), gamma 
12 
GNG12 NP_061329 
222692_s_at B 
fibronectin type III domain 
containing 3B 
FNDC3B 
NP_001128567  
 NP_073600 
223019_at B 
family with sequence 
similarity 129, member B 
FAM129B 
NP_001030611  
 NP_073744 
223279_s_at B 
uveal autoantigen with 
coiled-coil domains and 
ankyrin repeats 
UACA 
NP_001008225  
 NP_060473 
223303_at B 
fermitin family homolog 3 
(Drosophila) 
FERMT3 
NP_113659  
 NP_848537 
223315_at B netrin 4 NTN4 NP_067052 
223322_at B 
Ras association (RalGDS/AF-6) 
domain family member 5 
RASSF5 
NP_872604  
 NP_872605  
 NP_872606 
223639_s_at B 
zinc ribbon domain containing 
1 
ZNRD1 
NP_055411  
 NP_740753 
223640_at B 
hematopoietic cell signal 
transducer 
HCST 
NP_001007470  
 NP_055081 
224352_s_at B cofilin 2 (muscle) CFL2 
NP_068733  
 NP_619579 
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Probe Name 
Gene 
Array 
Gene Name Gene Symbol RefSeq Protein ID 
224450_s_at B RIO kinase 1 (yeast) RIOK1 
NP_113668  
 NP_694550 
224407_s_at B 
serine/threonine protein 
kinase MST4 
RP6-213H19.1 
NP_001035917  
 NP_001035918  
 NP_057626 
224791_at B 
ArfGAP with SH3 domain, 
ankyrin repeat and PH 
domain 1 
ASAP1 NP_060952 
224583_at B 
coactosin-like 1 
(Dictyostelium) 
COTL1 NP_066972 
224663_s_at B cofilin 2 (muscle) CFL2 
NP_068733  
 NP_619579 
224895_at B 
Yes-associated protein 1, 
65kDa 
YAP1 
NP_001123617  
 NP_006097 
224911_s_at B 
discoidin, CUB and LCCL 
domain containing 2 
DCBLD2 NP_563615 
224917_at B microRNA 21 MIR21 --- 
224955_at B 
TEA domain family member 1 
(SV40 transcriptional 
enhancer factor) 
TEAD1 NP_068780 
224983_at B 
scavenger receptor class B, 
member 2 
SCARB2 NP_005497 
224811_at B --- --- --- 
224840_at B FK506 binding protein 5 FKBP5 
NP_001139247  
 NP_001139248  
 NP_001139249  
 NP_004108 
224856_at B FK506 binding protein 5 FKBP5 
NP_001139247  
 NP_001139248  
 NP_001139249  
 NP_004108 
224996_at B aspartate beta-hydroxylase ASPH 
NP_004309  
 NP_064549  
 NP_115855  
 NP_115856  
 NP_115857 
224999_at B --- --- --- 
225080_at B myosin IC MYO1C 
NP_001074248  
 NP_001074419  
 NP_203693 
225091_at B 
zinc finger, CCHC domain 
containing 3 
ZCCHC3 NP_149080 
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Probe Name 
Gene 
Array 
Gene Name Gene Symbol RefSeq Protein ID 
225272_at B 
spermidine/spermine N1-
acetyltransferase family 
member 2 
SAT2 NP_597998 
225502_at B dedicator of cytokinesis 8 DOCK8 NP_982272 
226425_at B 
CAP-GLY domain containing 
linker protein family, member 
4 
CLIP4 NP_078968 
227344_at B 
IKAROS family zinc finger 1 
(Ikaros) 
IKZF1 NP_006051 
227346_at B 
IKAROS family zinc finger 1 
(Ikaros) 
IKZF1 NP_006051 
226934_at B 
cleavage and polyadenylation 
specific factor 6, 68kDa 
CPSF6 NP_008938 
225701_at B AT-hook transcription factor AKNA NP_110394 
226659_at B 
differentially expressed in 
FDCP 6 homolog (mouse) 
DEF6 NP_071330 
226215_s_at B 
lysine (K)-specific 
demethylase 2B 
KDM2B 
NP_001005366  
 NP_115979 
226219_at B 
Rho GTPase activating protein 
30 
ARHGAP30 
NP_001020769  
 NP_859071 
226680_at B 
IKAROS family zinc finger 5 
(Pegasus) 
IKZF5 NP_071911 
225802_at B 
topoisomerase (DNA) I, 
mitochondrial 
TOP1MT NP_443195 
225806_at B 
jub, ajuba homolog (Xenopus 
laevis) 
JUB 
NP_116265  
 NP_932352 
226245_at B 
potassium channel 
tetramerisation domain 
containing 1 
KCTD1 
NP_001129677  
 NP_001136202  
 NP_945342 
225842_at B 
pleckstrin homology-like 
domain, family A, member 1 
PHLDA1 NP_031376 
226282_at B --- --- --- 
227213_at B 
adenosine deaminase, tRNA-
specific 2, TAD2 homolog (S. 
cerevisiae) 
ADAT2 NP_872309 
226366_at B 
SNF2 histone linker PHD RING 
helicase 
SHPRH 
NP_001036148  
 NP_775105 
227272_at B 
chromosome 15 open reading 
frame 52 
C15orf52 NP_997263 
225962_at B zinc and ring finger 1 ZNRF1 NP_115644 
227811_at B 
FYVE, RhoGEF and PH domain 
containing 3 
FGD3 
NP_001077005  
 NP_149077 
228297_at B --- --- --- 
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Probe Name 
Gene 
Array 
Gene Name Gene Symbol RefSeq Protein ID 
228824_s_at B prostaglandin reductase 1 PTGR1 
NP_001139580  
 NP_001139581  
 NP_036344 
227473_at B --- --- --- 
227484_at B 
SLIT-ROBO Rho GTPase 
activating protein 1 
SRGAP1 NP_065813 
227514_at B 
inositol 1,4,5-triphosphate 
receptor interacting protein-
like 2 
ITPRIPL2 NP_001030013 
227998_at B 
S100 calcium binding protein 
A16 
S100A16 NP_525127 
228009_x_at B 
zinc ribbon domain containing 
1 
ZNRD1 
NP_055411  
 NP_740753 
228496_s_at B 
Cysteine rich transmembrane 
BMP regulator 1 (chordin-like) 
CRIM1 NP_057525 
227556_at B 
non-metastatic cells 7, 
protein expressed in 
(nucleoside-diphosphate 
kinase) 
NME7 
NP_037462  
 NP_932076 
227628_at B 
glutathione peroxidase 8 
(putative) 
GPX8 NP_001008398 
228121_at B 
transforming growth factor, 
beta 2 
TGFB2 
NP_001129071  
 NP_003229 
227792_at B 
inositol 1,4,5-triphosphate 
receptor interacting protein-
like 2 
ITPRIPL2 NP_001030013 
227799_at B myosin IG MYO1G NP_149043 
229670_at B --- --- --- 
229686_at B 
purinergic receptor P2Y, G-
protein coupled, 8 
P2RY8 NP_835230 
230175_s_at B --- --- --- 
230805_at B --- --- --- 
230836_at B 
ST8 alpha-N-acetyl-
neuraminide alpha-2,8-
sialyltransferase 4 
ST8SIA4 
NP_005659  
 NP_778222 
229538_s_at B 
IQ motif containing GTPase 
activating protein 3 
IQGAP3 NP_839943 
232541_at B --- --- --- 
232843_s_at B dedicator of cytokinesis 8 DOCK8 NP_982272 
231897_at B prostaglandin reductase 1 PTGR1 
NP_001139580  
 NP_001139581  
 NP_036344 
232994_s_at B 
Rho-guanine nucleotide 
exchange factor 
RGNEF NP_001073948 
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Probe Name 
Gene 
Array 
Gene Name Gene Symbol RefSeq Protein ID 
235020_at B 
TAF4b RNA polymerase II, 
TATA box binding protein 
(TBP)-associated factor, 
105kDa 
TAF4B NP_005631 
235072_s_at B --- --- --- 
234339_s_at B 
glioma tumor suppressor 
candidate region gene 2 
GLTSCR2 NP_056525 
233496_s_at B cofilin 2 (muscle) CFL2 
NP_068733  
 NP_619579 
236565_s_at B 
La ribonucleoprotein domain 
family, member 6 
LARP6 
NP_060827  
 NP_932062 
236198_at B --- --- --- 
239294_at B --- --- --- 
242520_s_at B 
chromosome 1 open reading 
frame 228 
C1orf228 NP_001139108 
242521_at B --- --- --- 
241879_at B --- --- --- 
244533_at B --- --- --- 
200601_at A actinin, alpha 4 ACTN4 NP_004915 
200782_at A annexin A5 ANXA5 NP_001145 
200787_s_at A 
phosphoprotein enriched in 
astrocytes 15 
PEA15 NP_003759 
200788_s_at A 
phosphoprotein enriched in 
astrocytes 15 
PEA15 NP_003759 
243601_at B 
hypothetical protein 
LOC285957 
LOC285957 --- 
244654_at B myosin IG MYO1G NP_149043 
200859_x_at A filamin A, alpha FLNA 
NP_001104026  
 NP_001447 
200872_at A 
S100 calcium binding protein 
A10 
S100A10 NP_002957 
201681_s_at A 
discs, large homolog 5 
(Drosophila) 
DLG5 NP_004738 
202133_at A 
WW domain containing 
transcription regulator 1 
WWTR1 NP_056287 
201021_s_at A 
destrin (actin depolymerizing 
factor) 
DSTN 
NP_001011546  
 NP_006861 
201022_s_at A 
destrin (actin depolymerizing 
factor) 
DSTN 
NP_001011546  
 NP_006861 
201289_at A 
cysteine-rich, angiogenic 
inducer, 61 
CYR61 NP_001545 
202431_s_at A 
v-myc myelocytomatosis viral 
oncogene homolog (avian) 
MYC NP_002458 
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Probe Name 
Gene 
Array 
Gene Name Gene Symbol RefSeq Protein ID 
200885_at A 
ras homolog gene family, 
member C 
RHOC 
NP_001036143  
 NP_001036144  
 NP_786886 
202458_at A protease, serine, 23 PRSS23 NP_009104 
202052_s_at A retinoic acid induced 14 RAI14 
NP_001138992  
 NP_001138993  
 NP_001138994  
 NP_001138995  
 NP_001138997  
 NP_056392 
202470_s_at A 
cleavage and polyadenylation 
specific factor 6, 68kDa 
CPSF6 NP_008938 
201215_at A plastin 3 (T isoform) PLS3 
NP_001129497  
 NP_005023 
201220_x_at A C-terminal binding protein 2 CTBP2 
NP_001077383  
 NP_001320  
 NP_073713 
201445_at A calponin 3, acidic CNN3 NP_001830 
202071_at A syndecan 4 SDC4 NP_002990 
201462_at A secernin 1 SCRN1 
NP_001138985  
 NP_001138986  
 NP_001138987  
 NP_055581 
201467_s_at A 
NAD(P)H dehydrogenase, 
quinone 1 
NQO1 
NP_000894  
 NP_001020604  
 NP_001020605 
201468_s_at A 
NAD(P)H dehydrogenase, 
quinone 1 
NQO1 
NP_000894  
 NP_001020604  
 NP_001020605 
201471_s_at A sequestosome 1 SQSTM1 
NP_001135770  
 NP_001135771  
 NP_003891 
201059_at A cortactin CTTN 
NP_005222  
 NP_612632 
200636_s_at A 
protein tyrosine phosphatase, 
receptor type, F 
PTPRF 
NP_002831  
 NP_569707 
200660_at A 
S100 calcium binding protein 
A11 
S100A11 NP_005611 
201073_s_at A 
SWI/SNF related, matrix 
associated, actin dependent 
regulator of chromatin, 
subfamily c, member 1 
SMARCC1 NP_003065 
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Probe Name 
Gene 
Array 
Gene Name Gene Symbol RefSeq Protein ID 
201087_at A paxillin PXN 
NP_001074324  
 NP_002850  
 NP_079433 
201505_at A laminin, beta 1 LAMB1 NP_002282 
201939_at A polo-like kinase 2 (Drosophila) PLK2 NP_006613 
200698_at A 
KDEL (Lys-Asp-Glu-Leu) 
endoplasmic reticulum 
protein retention receptor 2 
KDELR2 
NP_001094073  
 NP_006845 
201969_at A 
nuclear autoantigenic sperm 
protein (histone-binding) 
NASP 
NP_002473  
 NP_689511  
 NP_751896 
200663_at A CD63 molecule CD63 
NP_001035123  
 NP_001771 
200673_at A 
lysosomal protein 
transmembrane 4 alpha 
LAPTM4A NP_055528 
201125_s_at A integrin, beta 5 ITGB5 NP_002204 
201585_s_at A 
splicing factor 
proline/glutamine-rich 
(polypyrimidine tract binding 
protein associated) 
SFPQ NP_005057 
201976_s_at A myosin X MYO10 NP_036466 
201983_s_at A 
epidermal growth factor 
receptor (erythroblastic 
leukemia viral (v-erb-b) 
oncogene homolog, avian) 
EGFR 
NP_005219  
 NP_958439  
 NP_958440  
 NP_958441 
201984_s_at A 
epidermal growth factor 
receptor (erythroblastic 
leukemia viral (v-erb-b) 
oncogene homolog, avian) 
EGFR 
NP_005219  
 NP_958439  
 NP_958440  
 NP_958441 
201995_at A exostoses (multiple) 1 EXT1 NP_000118 
201590_x_at A annexin A2 ANXA2 
NP_001002857  
 NP_001002858  
 NP_001129487  
 NP_004030 
202011_at A 
tight junction protein 1 (zona 
occludens 1) 
TJP1 
NP_003248  
 NP_783297 
201172_x_at A 
ATPase, H+ transporting, 
lysosomal 9kDa, V0 subunit 
e1 
ATP6V0E1 NP_003936 
201360_at A cystatin C CST3 NP_000090 
201798_s_at A myoferlin MYOF 
NP_038479  
 NP_579899 
200770_s_at A 
laminin, gamma 1 (formerly 
LAMB2) 
LAMC1 NP_002284 
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Probe Name 
Gene 
Array 
Gene Name Gene Symbol RefSeq Protein ID 
200771_at A 
laminin, gamma 1 (formerly 
LAMB2) 
LAMC1 NP_002284 
200931_s_at A vinculin VCL 
NP_003364  
 NP_054706 
201373_at A 
plectin 1, intermediate 
filament binding protein 
500kDa 
PLEC1 
NP_000436  
 NP_958780  
 NP_958781  
 NP_958782  
 NP_958783  
 NP_958784  
 NP_958785  
 NP_958786 
202237_at A 
nicotinamide N-
methyltransferase 
NNMT NP_006160 
202238_s_at A 
nicotinamide N-
methyltransferase 
NNMT NP_006160 
202252_at A 
RAB13, member RAS 
oncogene family 
RAB13 NP_002861 
200998_s_at A 
cytoskeleton-associated 
protein 4 
CKAP4 NP_006816 
200999_s_at A 
cytoskeleton-associated 
protein 4 
CKAP4 NP_006816 
201242_s_at A 
ATPase, Na+/K+ transporting, 
beta 1 polypeptide 
ATP1B1 
NP_001001787  
 NP_001668 
201243_s_at A 
ATPase, Na+/K+ transporting, 
beta 1 polypeptide 
ATP1B1 
NP_001001787  
 NP_001668 
201251_at A pyruvate kinase, muscle PKM2 
NP_002645  
 NP_872270  
 NP_872271 
202551_s_at A 
cysteine rich transmembrane 
BMP regulator 1 (chordin-like) 
CRIM1 NP_057525 
202552_s_at A 
cysteine rich transmembrane 
BMP regulator 1 (chordin-like) 
CRIM1 NP_057525 
203705_s_at A 
frizzled homolog 7 
(Drosophila) 
FZD7 NP_003498 
203706_s_at A 
frizzled homolog 7 
(Drosophila) 
FZD7 NP_003498 
204992_s_at A profilin 2 PFN2 
NP_002619  
 NP_444252 
205417_s_at A 
dystroglycan 1 (dystrophin-
associated glycoprotein 1) 
DAG1 NP_004384 
203323_at A caveolin 2 CAV2 
NP_001224  
 NP_937855 
203324_s_at A caveolin 2 CAV2 
NP_001224  
 NP_937855 
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Probe Name 
Gene 
Array 
Gene Name Gene Symbol RefSeq Protein ID 
204116_at A 
interleukin 2 receptor, 
gamma (severe combined 
immunodeficiency) 
IL2RG NP_000197 
204560_at A FK506 binding protein 5 FKBP5 
NP_001139247  
 NP_001139248  
 NP_001139249  
 NP_004108 
202733_at A 
prolyl 4-hydroxylase, alpha 
polypeptide II 
P4HA2 
NP_001017973  
 NP_001017974  
 NP_001136070  
 NP_001136071  
 NP_004190 
202756_s_at A glypican 1 GPC1 NP_002072 
202822_at A 
LIM domain containing 
preferred translocation 
partner in lipoma 
LPP NP_005569 
203262_s_at A 
family with sequence 
similarity 50, member A 
FAM50A NP_004690 
204489_s_at A 
CD44 molecule (Indian blood 
group) 
CD44 
NP_000601  
 NP_001001389  
 NP_001001390  
 NP_001001391  
 NP_001001392 
202377_at A --- --- --- 
202381_at A 
ADAM metallopeptidase 
domain 9 (meltrin gamma) 
ADAM9 
NP_001005845  
 NP_003807 
203411_s_at A lamin A/C LMNA 
NP_005563  
 NP_733821  
 NP_733822 
203416_at A CD53 molecule CD53 
NP_000551  
 NP_001035122 
204490_s_at A 
CD44 molecule (Indian blood 
group) 
CD44 
NP_000601  
 NP_001001389  
 NP_001001390  
 NP_001001391  
 NP_001001392 
203002_at A angiomotin like 2 AMOTL2 NP_057285 
202587_s_at A adenylate kinase 1 AK1 NP_000467 
203038_at A 
protein tyrosine phosphatase, 
receptor type, K 
PTPRK 
NP_001129120  
 NP_002835 
204066_s_at A 
ArfGAP with GTPase domain, 
ankyrin repeat and PH 
domain 1 
AGAP1 
NP_001032208  
 NP_055729 
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Probe Name 
Gene 
Array 
Gene Name Gene Symbol RefSeq Protein ID 
203065_s_at A 
caveolin 1, caveolae protein, 
22kDa 
CAV1 NP_001744 
203499_at A EPH receptor A2 EPHA2 NP_004422 
203510_at A 
met proto-oncogene 
(hepatocyte growth factor 
receptor) 
MET 
NP_000236  
 NP_001120972 
204513_s_at A engulfment and cell motility 1 ELMO1 
NP_001034548  
 NP_055615  
 NP_569709 
202598_at A 
S100 calcium binding protein 
A13 
S100A13 
NP_001019381  
 NP_001019382  
 NP_001019383  
 NP_001019384  
 NP_005970 
202609_at A 
epidermal growth factor 
receptor pathway substrate 8 
EPS8 NP_004438 
204517_at A 
peptidylprolyl isomerase C 
(cyclophilin C) 
PPIC NP_000934 
204951_at A 
ras homolog gene family, 
member H 
RHOH NP_004301 
204960_at A 
protein tyrosine phosphatase, 
receptor type, C-associated 
protein 
PTPRCAP NP_005599 
202949_s_at A four and a half LIM domains 2 FHL2 
NP_001034581  
 NP_001441  
 NP_963849  
 NP_963851 
202957_at A 
hematopoietic cell-specific 
Lyn substrate 1 
HCLS1 NP_005326 
204657_s_at A 
Src homology 2 domain 
containing adaptor protein B 
SHB NP_003019 
204411_at A kinesin family member 21B KIF21B NP_060066 
204425_at A 
Rho GTPase activating protein 
4 
ARHGAP4 NP_001657 
206752_s_at A 
DNA fragmentation factor, 
40kDa, beta polypeptide 
(caspase-activated DNase) 
DFFB NP_004393 
204852_s_at A 
protein tyrosine phosphatase, 
non-receptor type 7 
PTPN7 
NP_002823  
 NP_542155 
205213_at A 
ArfGAP with coiled-coil, 
ankyrin repeat and PH 
domains 1 
ACAP1 NP_055531 
204220_at A 
glia maturation factor, 
gamma 
GMFG NP_004868 
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Probe Name 
Gene 
Array 
Gene Name Gene Symbol RefSeq Protein ID 
204237_at A 
GULP, engulfment adaptor 
PTB domain containing 1 
GULP1 NP_057399 
204341_at A tripartite motif-containing 16 TRIM16 NP_006461 
204248_at A 
guanine nucleotide binding 
protein (G protein), alpha 11 
(Gq class) 
GNA11 NP_002058 
203965_at A 
ubiquitin specific peptidase 
20 
USP20 
NP_001008563  
 NP_001103773  
 NP_006667 
205038_at A 
IKAROS family zinc finger 1 
(Ikaros) 
IKZF1 NP_006051 
204688_at A sarcoglycan, epsilon SGCE 
NP_001092870  
 NP_001092871  
 NP_003910 
204798_at A 
v-myb myeloblastosis viral 
oncogene homolog (avian) 
MYB 
NP_001123644  
 NP_001123645  
 NP_001155128  
 NP_001155129  
 NP_001155130  
 NP_001155131  
 NP_001155132  
 NP_005366 
204152_s_at A 
MFNG O-fucosylpeptide 3-
beta-N-
acetylglucosaminyltransferase 
MFNG NP_002396 
204153_s_at A 
MFNG O-fucosylpeptide 3-
beta-N-
acetylglucosaminyltransferase 
MFNG NP_002396 
203760_s_at A Src-like-adaptor SLA 
NP_001039021  
 NP_001039022  
 NP_006739 
203761_at A Src-like-adaptor SLA 
NP_001039021  
 NP_001039022  
 NP_006739 
205266_at A 
leukemia inhibitory factor 
(cholinergic differentiation 
factor) 
LIF NP_002300 
205269_at A 
lymphocyte cytosolic protein 
2 (SH2 domain containing 
leukocyte protein of 76kDa) 
LCP2 NP_005556 
205270_s_at A 
lymphocyte cytosolic protein 
2 (SH2 domain containing 
leukocyte protein of 76kDa) 
LCP2 NP_005556 
203910_at A 
Rho GTPase activating protein 
29 
ARHGAP29 NP_004806 
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Gene 
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Gene Name Gene Symbol RefSeq Protein ID 
204306_s_at A 
CD151 molecule (Raph blood 
group) 
CD151 
NP_001034579  
 NP_004348  
 NP_620598  
 NP_620599 
206414_s_at A 
ArfGAP with SH3 domain, 
ankyrin repeat and PH 
domain 2 
ASAP2 
NP_001128663  
 NP_003878 
206660_at A 
immunoglobulin lambda-like 
polypeptide 1 
IGLL1 
NP_064455  
 NP_690594 
208862_s_at A 
catenin (cadherin-associated 
protein), delta 1 
CTNND1 
NP_001078927  
 NP_001078928  
 NP_001078929  
 NP_001078930  
 NP_001078931  
 NP_001078932  
 NP_001078933  
 NP_001078934  
 NP_001078935  
 NP_001078936  
 NP_001078937  
 NP_001078938  
 NP_001322 
205739_x_at A zinc finger protein 107 ZNF107 
NP_001013768  
 NP_057304 
207238_s_at A 
protein tyrosine phosphatase, 
receptor type, C 
PTPRC 
NP_002829  
 NP_563578  
 NP_563579  
 NP_563580 
205884_at A 
integrin, alpha 4 (antigen 
CD49D, alpha 4 subunit of 
VLA-4 receptor) 
ITGA4 NP_000876 
205885_s_at A 
integrin, alpha 4 (antigen 
CD49D, alpha 4 subunit of 
VLA-4 receptor) 
ITGA4 NP_000876 
205573_s_at A sorting nexin 7 SNX7 
NP_057060  
 NP_689424 
206116_s_at A tropomyosin 1 (alpha) TPM1 
NP_000357  
 NP_001018004  
 NP_001018005  
 NP_001018006  
 NP_001018007  
 NP_001018008  
 NP_001018020 
208816_x_at A annexin A2 pseudogene 2 ANXA2P2 --- 
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Probe Name 
Gene 
Array 
Gene Name Gene Symbol RefSeq Protein ID 
208820_at A 
PTK2 protein tyrosine kinase 
2 
PTK2 
NP_005598  
 NP_722560 
206039_at A 
RAB33A, member RAS 
oncogene family 
RAB33A NP_004785 
209263_x_at A tetraspanin 4 TSPAN4 
NP_001020405  
 NP_001020406  
 NP_001020407  
 NP_001020408  
 NP_001020409  
 NP_001020410  
 NP_003262 
209264_s_at A tetraspanin 4 TSPAN4 
NP_001020405  
 NP_001020406  
 NP_001020407  
 NP_001020408  
 NP_001020409  
 NP_001020410  
 NP_003262 
207522_s_at A 
ATPase, Ca++ transporting, 
ubiquitous 
ATP2A3 
NP_005164  
 NP_777613  
 NP_777614  
 NP_777615  
 NP_777616  
 NP_777617  
 NP_777618 
209734_at A NCK-associated protein 1-like NCKAP1L NP_005328 
208540_x_at A 
S100 calcium binding protein 
A11 
S100A11 NP_005611 
209289_at A nuclear factor I/B NFIB NP_005587 
209290_s_at A nuclear factor I/B NFIB NP_005587 
208770_s_at A 
eukaryotic translation 
initiation factor 4E binding 
protein 2 
EIF4EBP2 NP_004087 
207525_s_at A 
GIPC PDZ domain containing 
family, member 1 
GIPC1 
NP_005707  
 NP_974196  
 NP_974197  
 NP_974198  
 NP_974199  
 NP_974223 
208056_s_at A 
core-binding factor, runt 
domain, alpha subunit 2; 
translocated to, 3 
CBFA2T3 
NP_005178  
 NP_787127 
207738_s_at A NCK-associated protein 1 NCKAP1 
NP_038464  
 NP_995314 
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208456_s_at A 
related RAS viral (r-ras) 
oncogene homolog 2 
RRAS2 
NP_001096139  
 NP_036382 
208683_at A calpain 2, (m/II) large subunit CAPN2 
NP_001139540  
 NP_001739 
207957_s_at A protein kinase C, beta PRKCB 
NP_002729  
 NP_997700 
208885_at A 
lymphocyte cytosolic protein 
1 (L-plastin) 
LCP1 NP_002289 
208898_at A 
ATPase, H+ transporting, 
lysosomal 34kDa, V1 subunit 
D 
ATP6V1D NP_057078 
207467_x_at A calpastatin CAST 
NP_001035905  
 NP_001035906  
 NP_001035907  
 NP_001035908  
 NP_001035909  
 NP_001035910  
 NP_001035911  
 NP_001741  
 NP_775083  
 NP_775084  
 NP_775086 
208908_s_at A calpastatin CAST 
NP_001035905  
 NP_001035906  
 NP_001035907  
 NP_001035908  
 NP_001035909  
 NP_001035910  
 NP_001035911  
 NP_001741  
 NP_775083  
 NP_775084  
 NP_775086 
209684_at A Ras and Rab interactor 2 RIN2 NP_061866 
209685_s_at A protein kinase C, beta PRKCB 
NP_002729  
 NP_997700 
208711_s_at A cyclin D1 CCND1 NP_444284 
208712_at A cyclin D1 CCND1 NP_444284 
208613_s_at A filamin B, beta FLNB 
NP_001157789  
 NP_001157790  
 NP_001157791  
 NP_001448 
208206_s_at A 
RAS guanyl releasing protein 
2 (calcium and DAG-
regulated) 
RASGRP2 
NP_001092140  
 NP_001092141  
 NP_722541 
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208636_at A actinin, alpha 1 ACTN1 
NP_001093  
 NP_001123476  
 NP_001123477 
208637_x_at A actinin, alpha 1 ACTN1 
NP_001093  
 NP_001123476  
 NP_001123477 
212185_x_at A metallothionein 2A MT2A NP_005944 
209386_at A 
transmembrane 4 L six family 
member 1 
TM4SF1 NP_055035 
209834_at A 
carbohydrate (chondroitin 6) 
sulfotransferase 3 
CHST3 NP_004264 
209835_x_at A 
CD44 molecule (Indian blood 
group) 
CD44 
NP_000601  
 NP_001001389  
 NP_001001390  
 NP_001001391  
 NP_001001392 
209154_at A 
Tax1 (human T-cell leukemia 
virus type I) binding protein 3 
TAX1BP3 NP_055419 
208949_s_at A 
lectin, galactoside-binding, 
soluble, 3 
LGALS3 NP_002297 
208951_at A 
aldehyde dehydrogenase 7 
family, member A1 
ALDH7A1 NP_001173 
209488_s_at A 
RNA binding protein with 
multiple splicing 
RBPMS 
NP_001008710  
 NP_001008711  
 NP_001008712  
 NP_006858 
212195_at A 
interleukin 6 signal 
transducer (gp130, oncostatin 
M receptor) 
IL6ST 
NP_002175  
 NP_786943 
209083_at A 
coronin, actin binding protein, 
1A 
CORO1A NP_009005 
209879_at A selectin P ligand SELPLG NP_002997 
210519_s_at A 
NAD(P)H dehydrogenase, 
quinone 1 
NQO1 
NP_000894  
 NP_001020604  
 NP_001020605 
209108_at A tetraspanin 6 TSPAN6 NP_003261 
209213_at A carbonyl reductase 1 CBR1 NP_001748 
209432_s_at A 
cAMP responsive element 
binding protein 3 
CREB3 NP_006359 
210427_x_at A annexin A2 ANXA2 
NP_001002857  
 NP_001002858  
 NP_001129487  
 NP_004030 
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Gene 
Array 
Gene Name Gene Symbol RefSeq Protein ID 
209135_at A aspartate beta-hydroxylase ASPH 
NP_004309  
 NP_064549  
 NP_115855  
 NP_115856  
 NP_115857 
212169_at A 
FK506 binding protein 9, 63 
kDa 
FKBP9 NP_009201 
210038_at A protein kinase C, theta PRKCQ NP_006248 
210039_s_at A protein kinase C, theta PRKCQ NP_006248 
212061_at A U2-associated SR140 protein SR140 NP_001073884 
211160_x_at A actinin, alpha 1 ACTN1 
NP_001093  
 NP_001123476  
 NP_001123477 
210876_at A annexin A2 pseudogene 1 ANXA2P1 --- 
213539_at A 
CD3d molecule, delta (CD3-
TCR complex) 
CD3D 
NP_000723  
 NP_001035741 
211986_at A AHNAK nucleoprotein AHNAK 
NP_001611  
 NP_076965 
212086_x_at A lamin A/C LMNA 
NP_005563  
 NP_733821  
 NP_733822 
212089_at A lamin A/C LMNA 
NP_005563  
 NP_733821  
 NP_733822 
212097_at A 
caveolin 1, caveolae protein, 
22kDa 
CAV1 NP_001744 
212104_s_at A RNA binding motif protein 9 RBM9 
NP_001026865  
 NP_001076045  
 NP_001076046  
 NP_001076047  
 NP_001076048  
 NP_055124 
210986_s_at A tropomyosin 1 (alpha) TPM1 
NP_000357  
 NP_001018004  
 NP_001018005  
 NP_001018006  
 NP_001018007  
 NP_001018008  
 NP_001018020 
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Gene 
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210987_x_at A tropomyosin 1 (alpha) TPM1 
NP_000357  
 NP_001018004  
 NP_001018005  
 NP_001018006  
 NP_001018007  
 NP_001018008  
 NP_001018020 
210896_s_at A aspartate beta-hydroxylase ASPH 
NP_004309  
 NP_064549  
 NP_115855  
 NP_115856  
 NP_115857 
212014_x_at A 
CD44 molecule (Indian blood 
group) 
CD44 
NP_000601  
 NP_001001389  
 NP_001001390  
 NP_001001391  
 NP_001001392 
210835_s_at A C-terminal binding protein 2 CTBP2 
NP_001077383  
 NP_001320  
 NP_073713 
213036_x_at A 
ATPase, Ca++ transporting, 
ubiquitous 
ATP2A3 
NP_005164  
 NP_777613  
 NP_777614  
 NP_777615  
 NP_777616  
 NP_777617  
 NP_777618 
211919_s_at A 
chemokine (C-X-C motif) 
receptor 4 
CXCR4 
NP_001008540  
 NP_003458 
211938_at A 
eukaryotic translation 
initiation factor 4B 
EIF4B NP_001408 
213944_x_at A 
guanine nucleotide binding 
protein (G protein), alpha 11 
(Gq class) 
GNA11 NP_002058 
212587_s_at A 
protein tyrosine phosphatase, 
receptor type, C 
PTPRC 
NP_002829  
 NP_563578  
 NP_563579  
 NP_563580 
212588_at A 
protein tyrosine phosphatase, 
receptor type, C 
PTPRC 
NP_002829  
 NP_563578  
 NP_563579  
 NP_563580 
212589_at A 
related RAS viral (r-ras) 
oncogene homolog 2 
RRAS2 
NP_001096139  
 NP_036382 
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Gene Name Gene Symbol RefSeq Protein ID 
212590_at A 
related RAS viral (r-ras) 
oncogene homolog 2 
RRAS2 
NP_001096139  
 NP_036382 
210644_s_at A 
leukocyte-associated 
immunoglobulin-like receptor 
1 
LAIR1 
NP_002278  
 NP_068352 
211240_x_at A 
catenin (cadherin-associated 
protein), delta 1 
CTNND1 
NP_001078927  
 NP_001078928  
 NP_001078929  
 NP_001078930  
 NP_001078931  
 NP_001078932  
 NP_001078933  
 NP_001078934  
 NP_001078935  
 NP_001078936  
 NP_001078937  
 NP_001078938  
 NP_001322 
211651_s_at A laminin, beta 1 LAMB1 NP_002282 
213503_x_at A annexin A2 ANXA2 
NP_001002857  
 NP_001002858  
 NP_001129487  
 NP_004030 
211864_s_at A myoferlin MYOF 
NP_038479  
 NP_579899 
211945_s_at A 
integrin, beta 1 (fibronectin 
receptor, beta polypeptide, 
antigen CD29 includes MDF2, 
MSK12) 
ITGB1 
NP_002202  
 NP_389647  
 NP_391987  
 NP_391988  
 NP_391989  
 NP_596867 
212294_at A 
guanine nucleotide binding 
protein (G protein), gamma 
12 
GNG12 NP_061329 
212724_at A Rho family GTPase 3 RND3 NP_005159 
213746_s_at A filamin A, alpha FLNA 
NP_001104026  
 NP_001447 
212285_s_at A agrin AGRN NP_940978 
212413_at A septin 6 6-Sep 
NP_055944  
 NP_665798  
 NP_665799  
 NP_665801 
212738_at A 
Rho GTPase activating protein 
19 
ARHGAP19 NP_116289 
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212973_at A 
ribose 5-phosphate isomerase 
A 
RPIA NP_653164 
213666_at A septin 6 6-Sep 
NP_055944  
 NP_665798  
 NP_665799  
 NP_665801 
213766_x_at A 
guanine nucleotide binding 
protein (G protein), alpha 11 
(Gq class) 
GNA11 NP_002058 
212415_at A septin 6 6-Sep 
NP_055944  
 NP_665798  
 NP_665799  
 NP_665801 
212420_at A 
E74-like factor 1 (ets domain 
transcription factor) 
ELF1 
NP_001138825  
 NP_758961 
213888_s_at A TRAF3 interacting protein 3 TRAF3IP3 NP_079504 
212658_at A 
lipoma HMGIC fusion partner-
like 2 
LHFPL2 NP_005770 
212662_at A poliovirus receptor PVR 
NP_001129240  
 NP_001129241  
 NP_001129242  
 NP_006496 
212765_at A 
calmodulin regulated 
spectrin-associated protein 1-
like 1 
CAMSAP1L1 NP_982284 
212873_at A 
histocompatibility (minor) 
HA-1 
HMHA1 NP_036424 
212885_at A 
M-phase phosphoprotein 10 
(U3 small nucleolar 
ribonucleoprotein) 
MPHOSPH10 NP_005782 
212992_at A AHNAK nucleoprotein 2 AHNAK2 NP_612429 
213358_at A KIAA0802 KIAA0802 NP_056025 
213455_at A 
family with sequence 
similarity 114, member A1 
FAM114A1 NP_612398 
213901_x_at A RNA binding motif protein 9 RBM9 
NP_001026865  
 NP_001076045  
 NP_001076046  
 NP_001076047  
 NP_001076048  
 NP_055124 
213915_at A 
natural killer cell group 7 
sequence 
NKG7 NP_005592 
213160_at A dedicator of cytokinesis 2 DOCK2 NP_004937 
213029_at A nuclear factor I/B NFIB NP_005587 
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214752_x_at A filamin A, alpha FLNA 
NP_001104026  
 NP_001447 
212698_s_at A septin 10 10-Sep 
NP_653311  
 NP_848699 
212364_at A myosin IB MYO1B 
NP_001123630  
 NP_001155291  
 NP_036355 
212254_s_at A dystonin DST 
NP_001138241  
 NP_001138242  
 NP_001138243  
 NP_001714  
 NP_056363  
 NP_065121  
 NP_899236 
212919_at A 
DCP2 decapping enzyme 
homolog (S. cerevisiae) 
DCP2 NP_689837 
212825_at A 
PAX interacting (with 
transcription-activation 
domain) protein 1 
PAXIP1 NP_031375 
217028_at A 
chemokine (C-X-C motif) 
receptor 4 
CXCR4 
NP_001008540  
 NP_003458 
215464_s_at A 
Tax1 (human T-cell leukemia 
virus type I) binding protein 3 
TAX1BP3 NP_055419 
215016_x_at A dystonin DST 
NP_001138241  
 NP_001138242  
 NP_001138243  
 NP_001714  
 NP_056363  
 NP_065121  
 NP_899236 
214039_s_at A 
lysosomal protein 
transmembrane 4 beta 
LAPTM4B NP_060877 
215091_s_at A 
general transcription factor 
IIIA 
GTF3A NP_002088 
217419_x_at A agrin AGRN NP_940978 
214882_s_at A 
splicing factor, 
arginine/serine-rich 2 
SFRS2 NP_003007 
214679_x_at A 
guanine nucleotide binding 
protein (G protein), alpha 11 
(Gq class) 
GNA11 NP_002058 
217892_s_at A 
LIM domain and actin binding 
1 
LIMA1 
NP_001107018  
 NP_001107019  
 NP_057441 
216264_s_at A laminin, beta 2 (laminin S) LAMB2 NP_002283 
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218733_at A 
male-specific lethal 2 
homolog (Drosophila) 
MSL2 
NP_001138889  
 NP_060603 
218738_s_at A ring finger protein 138 RNF138 
NP_057355  
 NP_937761 
216215_s_at A RNA binding motif protein 9 RBM9 
NP_001026865  
 NP_001076045  
 NP_001076046  
 NP_001076047  
 NP_001076048  
 NP_055124 
219191_s_at A bridging integrator 2 BIN2 NP_057377 
216226_at A 
TAF4b RNA polymerase II, 
TATA box binding protein 
(TBP)-associated factor, 
105kDa 
TAF4B NP_005631 
217849_s_at A 
CDC42 binding protein kinase 
beta (DMPK-like) 
CDC42BPB NP_006026 
218870_at A 
Rho GTPase activating protein 
15 
ARHGAP15 NP_060930 
218418_s_at A 
KN motif and ankyrin repeat 
domains 2 
KANK2 
NP_001129663  
 NP_056308 
218656_s_at A lipoma HMGIC fusion partner LHFP NP_005771 
221059_s_at A 
coactosin-like 1 
(Dictyostelium) 
COTL1 NP_066972 
217996_at A 
pleckstrin homology-like 
domain, family A, member 1 
PHLDA1 NP_031376 
218793_s_at A 
sex comb on midleg-like 1 
(Drosophila) 
SCML1 
NP_001032624  
 NP_001032625  
 NP_001032629  
 NP_006737 
218028_at A 
elongation of very long chain 
fatty acids (FEN1/Elo2, 
SUR4/Elo3, yeast)-like 1 
ELOVL1 NP_073732 
218368_s_at A 
tumor necrosis factor 
receptor superfamily, 
member 12A 
TNFRSF12A NP_057723 
218581_at A 
abhydrolase domain 
containing 4 
ABHD4 NP_071343 
218168_s_at A 
chaperone, ABC1 activity of 
bc1 complex homolog (S. 
pombe) 
CABC1 NP_064632 
220704_at A 
IKAROS family zinc finger 1 
(Ikaros) 
IKZF1 NP_006051 
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220865_s_at A 
prenyl (decaprenyl) 
diphosphate synthase, 
subunit 1 
PDSS1 NP_055132 
219944_at A 
CAP-GLY domain containing 
linker protein family, member 
4 
CLIP4 NP_078968 
221007_s_at A FIP1 like 1 (S. cerevisiae) FIP1L1 
NP_001128409  
 NP_001128410  
 NP_112179 
219862_s_at A 
nuclear prelamin A 
recognition factor 
NARF 
NP_001033707  
 NP_001077077  
 NP_036468  
 NP_114174 
220330_s_at A 
SAM domain, SH3 domain 
and nuclear localization 
signals 1 
SAMSN1 NP_071419 
221676_s_at A 
coronin, actin binding protein, 
1C 
CORO1C NP_055140 
35974_at A 
lymphoid-restricted 
membrane protein 
LRMP NP_006143 
40562_at A 
guanine nucleotide binding 
protein (G protein), alpha 11 
(Gq class) 
GNA11 NP_002058 
221293_s_at A 
differentially expressed in 
FDCP 6 homolog (mouse) 
DEF6 NP_071330 
222258_s_at A SH3-domain binding protein 4 SH3BP4 NP_055336 
221606_s_at A 
nucleosomal binding protein 
1 
NSBP1 NP_110390 
222154_s_at A 
spermatogenesis associated, 
serine-rich 2-like 
SPATS2L 
NP_001093892  
 NP_001093893  
 NP_001093894  
 NP_056350 
564_at A 
guanine nucleotide binding 
protein (G protein), alpha 11 
(Gq class) 
GNA11 NP_002058 
57163_at A 
elongation of very long chain 
fatty acids (FEN1/Elo2, 
SUR4/Elo3, yeast)-like 1 
ELOVL1 NP_073732 
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Appendix X: Networks of Gene Expression Markers 
Listed below are the networks identified by ingenuity pathway analysis of hypothetical 
biomarkers of multidrug resistance.  For each network, a figure elucidating the connectivity of 
the network‘s proteins is provided. 
ID Molecules in Network Score 
Focus 
Molecules 
Top Functions 
1 
ACAP1, AGRN, Akt, ANXA2, ASAP1, ASAP2, 
Calmodulin, CaMKII, CAPN2, CAST, CAV1, CAV2, 
CKAP4, Collagen Alpha1, DAG1, Dynamin, Ecm, 
Filamin, FLNB, LAIR1, Lamin b, LMNA, NARF, PEA15, 
PLEC, PTK2, PTPRF, PXN, RGNEF, SH3BP4, 
sphingomyelinase, TEAD1, Tgf beta, WWTR1, YAP1 
43 25 
Cellular Assembly 
and Organization, 
Cellular Function 
and Maintenance, 
Cellular Movement 
2 
AMOTL2, CPSF6, Creb, CRIM1, EGFR, EIF4EBP2, 
ELF1, EPHA2, ERK, FKBP5, FKBP9, FSH, FZD7, 
GTF3A, Hsp90, LAMB2, LDL, Lh, MIR21 (includes 
EG:406991), MPHOSPH10, MST4, NFIB, 
oxidoreductase, P4HA2, peptidylprolyl isomerase, Pi3-
kinase, PKM2, PPIC, PTPRK, RAB13, RASAL2, SFPQ, 
TJP1, VCL, Vegf 
43 25 
Cell-To-Cell 
Signaling and 
Interaction, 
Cellular Assembly 
and Organization, 
Nervous System 
Development and 
Function 
3 
Actin, Actin-Actn-Ptk2-Pxn-Vcl, ACTN1, ACTN4, Alpha 
actin, Alpha Actinin, Alpha catenin, Arp2/3, Bcl9-
Cbp/p300-Ctnnb1-Lef/Tcf, CFL2, Cofilin, DFFB, DSTN, 
ENAH, EPS8, Erm, F Actin, G-Actin, GIPC1, GPC1, 
IQGAP3, JUB, LIMA1, MYC, MYO1B, MYO1C, 
NCKAP1, PFN2, PLS3, Profilin, Rock, S100A11, 
SR140, TPM1, Vla-4 
34 21 
Cellular Assembly 
and Organization, 
Cell Morphology, 
Cellular 
Compromise 
4 
ALDH7A1, CD3, CD3D, CORO1A, CREB3, Gap, 
HCLS1, IGLL1, IKZF1, IKZF5, IL2RG, LCP2, Mek, Nfat 
(family), NFkB (complex), PLK2, Ptk, PTPRC, 
PTPRCAP, PVR, Rap1, Ras, RASGRP2, RASSF5, 
RHOH, RIN2, RRAS2, SDC4, Sfk, SHB, SLA, Sos, 
TCR, TNFRSF12A, VAV 
34 23 
Hematological 
System 
Development and 
Function, Tissue 
Morphology, 
Cellular 
Development 
5 
AHNAK, Alpha tubulin, ANXA5, ARHGAP29, CBR1, 
CD44, Collagen type I, Collagen type IV, CTNND1, 
CTTN, CXCR4, CYR61, DCBLD2, DOCK2, ELMO1, 
Fgf, hCG, MAP2K1/2, MET, Mmp, P38 MAPK, Pak, 
PAXIP1, Pdgf, PDGF BB, PHLDA1, PLC gamma, 
PP2A, PTPN7, Rac, RND3, S100A10, SELPLG, Shc, 
TM4SF1 
32 20 
Cellular 
Movement, 
Cancer, 
Cardiovascular 
System 
Development and 
Function 
6 
AHNAK, ALOX5, AMOTL2, ARHGAP19, ATXN2, 
CHI3L1, CHST3, CNN3, CORO1C, COTL1, CYFIP1, 
CYFIP2 (includes EG:26999), DAZAP2 (includes 
EG:9802), FAM50A, FNDC3B, FXR2, GAS7, KDELR2, 
KIAA0182, KIAA1217, LCP1, MYOF, NCKAP1, 
NCKAP1L, NNMT, PDLIM4, QKI, RBM9, RBPMS, 
RERE, RHOXF2, RPIA, SF1, STK16, TGFB1 
28 18 
Lipid Metabolism, 
Small Molecule 
Biochemistry, 
Cellular Assembly 
and Organization 
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ID Molecules in Network Score 
Focus 
Molecules 
Top Functions 
7 
AHNAK, AK1, AKNA, ATP6V0E1, BTG3, CCDC80, 
CD40LG, CDCA7L, CDKN2A, CHEMOKINE, CSF1, 
ELOVL1, ERBB2, FAM129B, GULP1, HRAS, IL1A, 
ITGB1, JAM2, KANK2, LAMB1, LRMP, LXN, MFNG, 
MGAT5, MIR124, MYO10, MYO1G, NPNT, P4HA2, 
PMEPA1, PTRF, RIN2, S100A13, SLC29A1 
28 18 
Cell Cycle, 
Cellular Growth 
and Proliferation, 
Cell-To-Cell 
Signaling and 
Interaction 
8 
ADAM9, Calpain, Caveolin, CD53, CD63, CD151, 
Collagen(s), ERK1/2, FERMT3, FHL2, Fibrinogen, 
Focal adhesion kinase, Integrin, Integrin alpha 3 beta 1, 
Integrin alpha 6 beta 1, Integrin alpha V beta 3, 
Integrinα, Integrinβ, ITGA4, ITGB1, ITGB5, LAMB1, 
LAMC1, Laminin, Laminin1, Laminin2, LPP, 
Metalloprotease, MYO10, NTN4, SHPRH, Talin, 
TSPAN, TSPAN4, TSPAN6 
26 17 
Nervous System 
Development and 
Function, Tissue 
Development, 
Cell-To-Cell 
Signaling and 
Interaction 
9 
amino acids, ANLN, ARHGAP4, ARHGAP8, 
ARHGAP15, CAMSAP1L1, CDC42, CDC42BPA, 
CDC42BPB, DCP2, DEF6, DST, E2F1, EZR, FGD1, 
FGD3, FGD1/3, FIP1L1, GMFG, GNG12, GSK3B, 
HDAC4, MIR1, MIRLET7A1, MYO18A, RAC1, RHOA, 
RNF138, RNPS1, RUVBL2, SEPT6, SFRS2, 
TRAF3IP3, YWHAZ, ZCCHC3 
25 17 
Cellular Assembly 
and Organization, 
Cell Morphology, 
Cell Signaling 
10 
Ap1, ATP2A3, Caspase, CCND1, CTBP2, Cyclin A, 
Cyclin E, E2f, EIF4B, Estrogen Receptor, FLNA, Growth 
hormone, Gsk3, HCST, Hsp70, Ifn gamma, IL1, IL6ST, 
Insulin, Interferon alpha, JAK, Jnk, LGALS3, LIF, MT2A, 
MYB (includes EG:4602), NASP, NQO1, p85 (pik3r), 
PI3K, PI3K p85, PRKCQ, SMARCC1, STAT, STAT5a/b 
22 15 
Cellular 
Development, 
Cellular Growth 
and Proliferation, 
Cell Morphology 
11 
ANKS1B, beta-estradiol, CXCR7, DLG4, DLGAP4, 
EIF3D, FLT4, FN1, GLUL, GRB2, HTRA1, KIF21B, 
KRT17, LHFPL2, LIMA1, LMO7, MATN2, MIR23B 
(includes EG:407011), MSL2, MYO1B, PKM2, PRSS23, 
RAI14, RAPSN, RPS13, SCRN1, SHANK3, SLC25A3, 
SLC25A12, SMAD7, SNX7, TAF4B, UACA, ZNF107, 
ZNRF1 
20 14 
Cellular Assembly 
and Organization, 
Embryonic 
Development, 
Organ 
Development 
12 
BRF1, C16ORF53, CABC1, CLTCL1, CTNNB1, 
CTNNβ-TCF/LEF, DLG5, GART, GAS1, GLTSCR2, 
HNF4A, IFNA2, IPO13, KCTD1, KDM2B, KIF20A, 
LAPTM4A, LAPTM4B, NBR1, NFE2L3, NFYB, NME3, 
NME7, NOSIP, PERP, PRRG2, RFC3, RIOK1, RPL41, 
SAMSN1, SAT2, SGCE, TAX1BP3, TP53, ZNRD1 
18 14 
Cell Cycle, Gene 
Expression, 
Cancer 
13 
ABHD4, AGAP1, ASPH, ATP6V1D, ATP6V1E1, CD48, 
CDH13, CHP, DEFB103A, FABP7, Focal adhesion 
kinase, FUCA1, GNA11, HIF1A, HTRA1, HTT, IL13, 
LDHA, LONP1, MTSS1, NFkB (complex), oleic acid, 
P4HA1, PKM2, PRDX3, RAB33A, RTN3, SCARB2, 
SEPT9, SLC25A3, SLC25A11, SLC2A4, SRGAP1, 
ST8SIA4, USP20 
13 11 
Energy 
Production, 
Molecular 
Transport, Nucleic 
Acid Metabolism 
14 
2' 5' oas, Androgen-AR, ARHGAP24, ARHGAP26, 
ATP1B1, Bcl10-Card10-Malt1, CACNB2, CBFA2T3, 
Ck2, CST3, EXT1, Histone h3, Histone h4, IgG, IKK 
(complex), IL12 (complex), Immunoglobulin, 
MAP1LC3A, Mapk, MHC Class II (complex), MYO9B, 
NGF, PARP10, Pka, Pkc(s), PRKCB, Ras homolog, 
RHOC, RHPN1, RNA polymerase II, SPATS2L, 
SQSTM1, TGFB2, TRIM16, Ubiquitin 
12 10 
Cardiac 
Necrosis/Cell 
Death, Cell Death, 
Cellular Assembly 
and Organization 
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